Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
METHODS AND COMPOSITIONS USING FGF23 FUSION POLYPEPTIDES
This application claims priority to U.S. Application Serial No. 12/696693,
filed
January 29, 2010, the contents of which are incorporated herein by reference
in their
entirety.
1. BACKGROUND
Fibroblast growth factors (FGFs) constitute a family of homologous polypeptide
growth factors expressed in many organisms (Ornitz and Itoh, Genome Biol. 2:
reviews,
3005.1-3005.12 (2001)). Among vertebrate species, FGFs are highly conserved in
both
gene structure and amino-acid sequence, having between 13-71% amino acid
identity
with one another. In humans, there are 22 known members of the FGF family (FGF
15 is
the mouse ortholog of human FGF19, hence there is no human FGF15). During
early
development, FGFs regulate cell proliferation, migration, and differentiation,
but in the
adult organism, FGFs maintain homeostasis, function in tissue repair, and
respond to
injury.
FGFs function as growth factors by binding and thereby activating cell-surface
FGF receptors. FGF receptors (FGFRs) are tyrosine kinase receptors that
activate signal
transduction through autophosphorylation of FGFR, phosphorylation of FRS2 (FGF
receptor substrate 2) and ERKl/2 (extracellular signal-regulated protein
kinase 1/2), and
activating Egr-1 (early growth response-1). FGFs also have a high affinity for
heparin
sulfate proteoglycans. When bound to FGFs, heparin sulfate enhances the
activation of
FGFRs.
The alpha-Klotho gene encodes a 130 kDa single pass type I transmembrane
protein with an extracellular domain and a short cytoplasmic domain. The
extracellular
domain of alpha-Klotho protein comprises two subdomains termed, KL-D1 and KL-
D2.
These two subdomains share sequence homology to (3-glucosidase of bacteria and
plants.
The extracellular domain of the alpha-Klotho protein may be bound to the cell
surface by
the transmembrane domain or may be cleaved and released into the extracellular
milieu.
Cleavage of the extracellular domain appears to be facilitated by local low
extracellular
Cat concentrations.
In addition to alpha-Klotho, a homolog of alpha-Klotho, beta-Klotho, has been
identified (Ito et al., Mech. Dev. 98:115-9 (2000)). Beta-Klotho is also a
single pass type
I transmembrane protein with extracellular KL-D1 and KL-D2 subdomains.
1
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
Modulation of alpha-Klotho expression has been demonstrated to produce aging
related characteristics in mammals. Mice homozygous for a loss of function
mutation in
the alpha-Klotho gene develop characteristics resembling human aging,
including
shortened lifespan, skin atrophy, muscle wasting, arteriosclerosis, pulmonary
emphysema
and osteoporosis (Kuro-o et al., Nature, 390:45-51 (1997)). In contrast,
overexpression of
the alpha-Klotho gene in mice extends lifespan and increases resistance to
oxidative stress
relative to wild-type mice (Kurosu et al., Science 309:1829-1833 (2005);
Yamamoto et
al., J. Biol. Chem. 280:38029-38034 (2005)).
Recent studies have demonstrated strikingly similar biological characteristics
between FGF23-deficient mice and alpha-Klotho-deficient mice (Shimada et al.,
J. Clin.
Invest. 113:561-568 (2004); Yoshida et al. Endocrinology 143:683-689 (2002)),
indicating functional crosstalk between FGF23 and alpha-Klotho. These studies
led to the
identification of alpha-Klotho as an obligatory partner of FGF23, in terms of
both binding
and signaling through its cognate FGF receptors (Urakawa et al., Nature
22:1524-6
(2007)). The alpha-Klotho gene is mainly expressed in kidney, parathyroid
gland and
choroid plexus. It is hypothesized that the tissue-specific expression of
alpha-Klotho
restricts activation of FGF23 signaling to those tissues.
Similar to FGF23/alpha-Klotho, beta-Klotho is an obligatory partner of FGF19
and FGF2 1, both in binding and in signaling through their respective cognate
FGF
receptors (Ogawa et al., Proc. Natl. Acad. Sci. USA 104:7432-7 (2007); Lin et
al., J. Biol
Chem. 282:27227-84 (2007); and Wu et al., J. Biol. Chem. 282:29069-72 (2007)).
Such
studies have also demonstrated the involvement of beta-Klotho in regulating
tissue-
specific metabolic activity. Beta-Klotho was initially shown to act with FGF21
as a
cofactor for regulating carbohydrate and lipid metabolism in adipose tissue.
Beta-Klotho
in conjunction with FGF19 regulates bile acid metabolism in liver, thus
explaining
elevated bile synthesis in beta-Klotho deficient mice (Ito et al., J Clin
Invest. 2005
Aug; 115(8):2202-8).
U.S. Patent No. 6,579,850 describes polypeptides and compositions comprising
an
alpha-Klotho polypeptide. Human and mouse alpha-Klotho polypeptides are
disclosed.
The patent also disclosed that compositions comprising the polypeptides are
useful in
treating a syndrome resembling premature aging, treating adult diseases, and
suppressing
aging.
U.S. Patent No. 7,223,563 describes isolated nucleic acids encoding the FGF23
polypeptide sequence or recombinant cells comprising such an isolated nucleic
acid. The
2
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
patent further relates to methods of diagnosing and treating hypophosphatemic
and
hyperphosphatemic disorders, osteoporosis, dermatomyositis, and coronary
artery disease.
U.S. Patent No. 7,259,248 describes isolated nucleic acids encoding the FGF21
polypeptide sequence. The patent further relates to methods of diagnosing and
treating
liver disease, conditions related to thymic function, and methods of treating
conditions of
the testis.
2. SUMMARY OF THE INVENTION
The present disclosure is directed to methods, uses, kits and compositions for
preventing or treating age-related conditions or metabolic disorders with
fusion
polypeptides or soluble polypeptides. The fusion polypeptides of the present
disclosure
are formed of a FGF (e.g., FGF23); and either a Klotho protein or an active
fragment
thereof (e.g., sKlotho) and/or a Fc fragment (e.g., FcLALA); and, optionally,
a linker. In
some embodiments, the FGF23 is mutated. In some embodiments, the present
disclosure
provides a Klotho fusion polypeptide comprising a Klotho protein or an active
fragment
thereof and a fibroblast growth factor or an active fragment thereof. In some
embodiments, the fusion polypeptide comprises a Klotho polypeptide, a FGF
(such as
FGF23) and a modified Fc fragment. The Fc fragment can, for example, have
decreased
binding to Fc-gamma-receptor and increased serum half-life. Fusion proteins
comprising
sKlotho, FGF23 and FcLALA (a modified Fc fragment having decreased affinity
for Fc-
gamma-receptorand/or increased serum half-life) are described in SEQ ID NOs.
46, 47,
48, and 49. In some embodiments, the fusion polypeptide or protein comprises a
FGF
(e.g., FGF23), or a functionally active variant or derivative (e.g., a variant
comprising at
least one conservative amino acid substitution and/or one amino acid deletion)
thereof,
and a modified Fc fragment, or a functionally active variant or derivative
(e.g., a variant
comprising at least one conservative amino acid substitution and/or one amino
acid
deletion) thereof. Fusion proteins comprising FGF23 and FcLALA are described
in SEQ
ID NOs. 50, 51, 52 and 53. In some embodiments, the fusion polypeptide has one
or
more mutations in FGF23 which decrease aggregation and/or protease-mediated
cleavage.
In a first aspect, the disclosure provides a fusion polypeptide having at
least one
extracellular subdomain of a Klotho protein and a fibroblast growth factor or
an active
fragment thereof. In some embodiments, the fusion further comprises a modified
Fc
fragment having decreased affinity (e.g., decreased Ka or increased Kd) for Fc-
gamma-
receptorand/or increased serum half-life. The Klotho extracellular domain may
be derived
3
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
from either the alpha or beta Klotho isoforms. Further, although the FGF
component of
the Klotho fusion polypeptide is described primarily with reference to
fibroblast growth
factor-19, fibroblast growth factor-21 and fibroblast growth factor-23, it is
contemplated
that any of the twenty-three known FGFs can be used in practicing the
disclosure. The
reader of the instant application may assume that each of every combination of
alpha or
beta extracellular domain with each human FGF protein or an active fragment
thereof are
individually and specifically contemplated.
According to the present disclosure, the extracellular domain of the Klotho
protein
can include one or both of the KL-D1 and KL-D2 domains of a Klotho protein, or
a
functionally active variant or derivative (e.g., a variant comprising at least
one
conservative amino acid substitution and/or one amino acid deletion) thereof.
In some
embodiments, the Klotho fusion polypeptide of the disclosure has at least two
extracellular subdomains of a Klotho protein, or a functionally active variant
or derivative
(e.g., a variant comprising at least one conservative amino acid substitution
and/or one
amino acid deletion) thereof. For example, the at least two extracellular
subdomains can
be at least two KL-D1 domains in tandem repeats, at least two KL-D2 domains in
tandem
repeats, or at least one KL-D1 domain and at least one KL-D2 domain. In
various
embodiments, the fusion polypeptide of the disclosure comprises amino acids 28-
292 of
the full length alpha Klotho protein, or amino acids 28-982 (SEQ ID NO: 7). In
another
embodiment, the fusion polypeptide of the disclosure comprises amino acids 52-
997 of
the full length beta Klotho protein.
In one embodiment of the present disclosure, the components of a fusion
polypeptide comprise: (a) a polypeptide comprising fibroblast growth factor 23
(FGF23),
or a functionally active variant or derivative (e.g., a variant comprising at
least one
conservative amino acid substitution and/or one amino acid deletion) thereof,
wherein
FGF23 has a mutation at one or more of the positions Q156, C206 and C244; and
(b)
either a modified Fc fragment having decreased affinity for Fc-gamma-receptor
and/or
increased serum half-life, or a polypeptide comprising at least one
extracellular
subdomain of a Klotho protein, or a functionally active variant or derivative
(e.g., a
variant comprising at least one conservative amino acid substitution and/or
one amino
acid deletion) thereof, and, optionally (c) a linker. The components can be,
for example,
chemically linked or fused in frame by a peptide bond. They may also linked
via a linker.
Non-limiting examples of polypeptide linker are SEQ ID NOs: 11, 12, 13, 14,
15, 16, 17,
and 18. Such linkers may comprise at least one and up to about 30 repeats of
SEQ ID
4
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
NOs:11, 12, 13, 14, 15, 16, 17 and 18. In another non-limiting embodiment, the
fusion
comprises (2) a FGF or an active fragment thereof and (3) a modified Fc
fragment. The
various components of the fuion can be operatively linked in any order; the
polypeptide
(1) can be operatively linked to the N-terminus of the polypeptide for (2) or
(3); the
polypeptide for (2) can be operatively linked to the N-terminus of the
polypeptide for (1)
or (3); the polypeptide for (3) can be operatively linked to the N-terminus of
the
polypeptide for (1) or (2).
According to the present disclosure, the extracellular subdomain of a Klotho
protein, the fibroblast growth factor and the (optional) modified Fc fragment
having
decreased affinity for Fc-gamma-receptorand/or increased serum half-life can
be
operatively linked to one another in a variety of orientations and manners.
For example,
the extracellular subdomain of the Klotho protein can be operatively linked to
the N-
terminus of the fibroblast growth factor or alternatively the fibroblast
growth factor can
be operatively linked to the N-terminus of an extracellular subdomain of the
Klotho
protein.
In one embodiment, the present disclosure provides a fusion polypeptide
comprising a sKlotho of a Klotho protein and a linker. In another embodiment,
the
present disclosure provides a fusion polypeptide comprising a sKlotho of the
alpha
Klotho protein and a linker. In another embodiment, the present disclosure
provides a
fusion polypeptide comprising a sKlotho of the beta Klotho protein and a
linker. In yet
another embodiment, the present disclosure provides a human FGF protein or an
active
fragment thereof (e.g., without signal peptide) and a linker. In one
embodiment the
disclosure provides fusion proteins, nucleic acid molecules or pharmaceutical
composition for use in therapy or as medicament for use in the treatment of a
pathological
disorder. Pharmaceutical compositions comprising the fusion proteins of the
disclosure
and their uses for treating or preventing age-related conditions or metabolic
disorders are
also encompassed by the present disclosure. In some embodiments, the fusion
protein
further comprises a modified Fc fragment having decreased affinity for Fc-
gamma-
receptorand/or increased serum half-life.
In one embodiment, the present disclosure provides a fusion polypeptide
comprising a sKlotho of alpha Klotho protein with signal peptide fused
(directly or
indirectly via a linker) to FGF-23. In another embodiment, the present
disclosure
provides a fusion polypeptide comprising a sKlotho of alpha Klotho protein
without
signal peptide fused (directly or indirectly via a linker) to FGF-23. In
another
5
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
embodiment, the present disclosure provides sKlotho of alpha Klotho protein
with signal
peptide fused (directly or indirectly via a linker) to FGF-23 without signal
peptide. In
another embodiment, the present disclosure provides a fusion polypeptide
comprising
sKlotho of alpha Klotho protein without signal peptide fused (directly or
indirectly via a
linker) to FGF-23 without signal peptide. In some embodiments, the fusion
protein
further comprises a modified Fc fragment having decreased affinity for Fc-
gamma-
receptorand/or increased serum half-life.
In one embodiment, the present disclosure provides a fusion polypeptide
comprising a sKlotho of alpha Klotho protein with signal peptide fused
(directly or
indirectly via a linker) to FGF-23 (R179Q) variant. In another embodiment, the
present
disclosure provides a fusion polypeptide comprising a sKlotho of alpha Klotho
protein
without signal peptide fused (directly or indirectly via a linker) to FGF-23
(R179Q)
variant. In another embodiment, the present disclosure provides sKlotho of
alpha Klotho
protein with signal peptide fused (directly or indirectly via a linker) to FGF-
23 (R179Q)
variant without signal peptide. In another embodiment, the present disclosure
provides a
fusion polypeptide comprising sKlotho of alpha Klotho protein without signal
peptide
fused (directly or indirectly via a linker) to FGF-23 (R179Q) variant without
signal
peptide. In some embodiments, the fusion protein further comprises a modified
Fc
fragment having decreased affinity for Fc-gamma-receptorand/or increased serum
half-
life.
In one embodiment, the present disclosure provides a fusion polypeptide
comprising: (a) a polypeptide comprising fibroblast growth factor 23 (FGF23),
or a
functionally active variant or derivative (e.g., a variant comprising at least
one
conservative amino acid substitution and/or one amino acid deletion) thereof,
wherein
FGF23 has a mutation at one or more of the positions Q156, C206 and C244; and
(b)
either a modified Fc fragment having decreased affinity for Fc-gamma-receptor
and/or
increased serum half-life, or a polypeptide comprising at least one
extracellular
subdomain of a Klotho protein, or a functionally active variant or derivative
(e.g., a
variant comprising at least one conservative amino acid substitution and/or
one amino
acid deletion) thereof, and, optionally (c) a linker. Such fusion polypeptides
are disclosed
in SEQ ID NOs: 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, and 68.
In one embodiment, the present disclosure provides a fusion polypeptide
comprising (1) sKlotho of alpha Klotho protein with signal peptide, or a
functionally
active variant or derivative (e.g., a variant comprising at least one
conservative amino
6
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
acid substitution and/or one amino acid deletion) thereof; (2) a linker; and
(3) FGF-23
(R179Q) variant without signal peptide, or a functionally active variant or
derivative (e.g.,
a variant comprising at least one conservative amino acid substitution and/or
one amino
acid deletion) thereof. In another embodiment, the present disclosure provides
a fusion
polypeptide comprising (1) sKlotho of alpha Klotho protein without signal
peptide, or a
functionally active variant or derivative (e.g., a variant comprising at least
one
conservative amino acid substitution and/or one amino acid deletion) thereof;
(2) a linker;
and (3) FGF-23 (RI 79Q) variant without signal peptide, or a functionally
active variant or
derivative (e.g., a variant comprising at least one conservative amino acid
substitution
and/or one amino acid deletion) thereof. In some embodiments, the fusion
polypeptides
of the disclosure are glycosylated. In some embodiments, the fusion protein
further
comprises a modified Fc fragment having decreased affinity for Fc-gamma-
receptorand/or increased serum half-life.
In one embodiment, the present disclosure provides a fusion polypeptide
comprising (1) sKlotho of alpha Klotho protein with signal peptide (SEQ ID NO:
44 or
SEQ ID NO: 45), or a functionally active variant or derivative (e.g., a
variant comprising
at least one conservative amino acid substitution and/or one amino acid
deletion) thereof
(2) a linker comprising SEQ ID NO: 11; and (3) FGF-23 (R179Q) variant without
signal
peptide (SEQ ID NO: 43), or a functionally active variant or derivative (e.g.,
a variant
comprising at least one conservative amino acid substitution and/or one amino
acid
deletion) thereof. In another embodiment, the present disclosure provides a
fusion
polypeptide comprising (1) sKlotho of alpha Klotho protein without signal
peptide (SEQ
ID NO: 7), or a functionally active variant or derivative (e.g., a variant
comprising at least
one conservative amino acid substitution and/or one amino acid deletion)
thereof (2) a
linker comprising SEQ ID NO: 11; and (3) FGF-23 (R179Q) variant without signal
peptide (SEQ ID NO: 43), or a functionally active variant or derivative (e.g.,
a variant
comprising at least one conservative amino acid substitution and/or one amino
acid
deletion) thereof In one embodiment, the present disclosure provides a fusion
polypeptide comprising the amino acid sequence of SEQ ID NO: 19, 20, 40, or
41. In
some embodiments, the fusion polypeptides of the disclosure are glycosylated.
In one embodiment, the present disclosure provides a fusion polypeptide
comprising sKlotho of alpha Klotho protein with signal peptide (SEQ ID NO: 44
or SEQ
ID NO: 45), or a functionally active variant or derivative (e.g., a variant
comprising at
least one conservative amino acid substitution and/or one amino acid deletion)
thereof;
7
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
and a linker comprising SEQ ID NO: 11. In another embodiment, the present
disclosure
provides a fusion polypeptide comprising sKlotho of alpha Klotho protein
without signal
peptide (SEQ ID NO: 7); and a linker comprising SEQ ID NO: 11. In some
embodiments, the fusion polypeptides of the disclosure are glycosylated. In
some
embodiments, the fusion protein further comprises a modified Fc fragment
having
decreased affinity for Fc-gamma-receptorand/or increased serum half-life.
In one embodiment, the present disclosure provides a fusion polypeptide
comprising a human FGF protein or an active fragment thereof (e.g., without
the signal
peptide); and a linker comprising SEQ ID NO: 11. In some embodiments, the
fusion
polypeptides of the disclosure are glycosylated. In some embodiments, the
fusion protein
further comprises a modified Fc fragment having decreased affinity for Fc-
gamma-
receptorand/or increased serum half-life.
In one embodiment, the present disclosure provides a fusion polypeptide
comprising a human FGF protein (e.g., FGF23) or an active fragment thereof
(e.g.,
without the signal peptide); a linker (e.g., a linker comprising SEQ ID NO:
11); and
sKlotho (with or without a signal peptide), or a functionally active variant
or derivative
(e.g., a variant comprising at least one conservative amino acid substitution
and/or one
amino acid deletion) thereof) or a Fc-gramma-receptor (e.g., FcLALA); wherein
the FGF
(e.g., FGF23) has one or more mutations at these residues: R179, Q156, C206,
and/or
C244. In various embodiments, the mutations are R179Q, Q156A, C206S, and/or
C244S.
Even though these mutations are conserved in the human, rhesus, bovine, mouse
and rat
FGF23, mutating them does not prevent FGF23 activity. Rather, mutating these
amino
acids unexpectedly enhances the qualities of the proteins, by reducing
aggregation,
reducing undesired protease-induced cleavage, and increasing protein
production from
cells. In various embodiments, the fusion protein comprising one or more FGF23
mutation is glycosylated.
In one embodiment, the present disclosure provides a pharmaceutical
composition
(e.g., in an intra-muscular administering form) comprising (e.g., as a sole
pharmaceutically active ingredient) a fusion polypeptide (e.g., glycosylated
or non-
glycosylated) that comprises (1) FGF-23 (R179Q) variant without signal peptide
(SEQ ID
NO: 43), or a variant comprising additional mutations which reduce aggregation
and/or
protease-mediated cleavage, or a functionally active variant or derivative
(e.g., a variant
comprising at least one conservative amino acid substitution and/or one amino
acid
deletion) thereof (2) optionally, a linker comprising SEQ ID NO: 11; and (3)
sKlotho of
8
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
alpha Klotho protein with signal peptide (SEQ ID NO: 44 or SEQ ID NO: 45), or
a
functionally active variant or derivative (e.g., a variant comprising at least
one
conservative amino acid substitution and/or one amino acid deletion) thereof
or a
modified Fc fragment having decreased affinity for Fc-gamma-receptorand/or
increased
serum half-life; and uses of the pharmaceutical composition in therapy or as
medicament
for the treatment of a pathological disorder, for example treating and/or
preventing age-
related conditions, such as muscular atrophy. In another embodiment, the
present
disclosure provides a pharmaceutical composition (e.g., in an intra-muscular
administering form) comprising (e.g., as a sole pharmaceutically active
ingredient) a
fusion polypeptide (e.g., glycosylated or non-glycosylated) that comprises (1)
FGF-23
(R179Q) variant without signal peptide (SEQ ID NO: 43), or a variant
comprising
additional mutations which reduce aggregation and/or protease-mediated
cleavage, or a
functionally active variant or derivative (e.g., a variant comprising at least
one
conservative amino acid substitution and/or one amino acid deletion) thereof
(2) a linker
comprising SEQ ID NO: 11; and (3) sKlotho of alpha Klotho protein without
signal
peptide (SEQ ID NO: 7), or a functionally active variant or derivative (e.g.,
a variant
comprising at least one conservative amino acid substitution and/or one amino
acid
deletion) thereof, or a modified Fc fragment having decreased affinity for Fc-
gamma-
receptorand/or increased serum half-life, or a functionally active variant or
derivative
(e.g., a variant comprising at least one conservative amino acid substitution
and/or one
amino acid deletion) thereof; and uses of the pharmaceutical composition in
therapy or as
medicament for the treatment of a pathological disorder, for example treating
and/or
preventing age-related conditions, such as muscular atrophy. In one
embodiment, the
present disclosure provides a pharmaceutical composition (e.g., in an intra-
muscular
administering form) comprising (e.g., as a sole pharmaceutically active
ingredient) a
fusion polypeptide (e.g., glycosylated or non-glycosylated) comprising the
amino acid
sequence of SEQ ID NO: 19, 20, 40, or 41; and uses of the pharmaceutical
composition in
therapy or as medicament for the treatment of a pathological disorder, for
example
treating and/or preventing age-related conditions, such as muscular atrophy.
In one embodiment, the present disclosure provides a pharmaceutical
composition
(e.g., in an intra-muscular administering form) comprising (e.g., as a sole
pharmaceutically active ingredient) a fusion polypeptide (e.g., glycosylated
or non-
glycosylated) that comprises sKlotho of alpha Klotho protein with signal
peptide (SEQ ID
NO: 44 or SEQ ID NO: 45); and a linker comprising SEQ ID NO: 11; and uses of
the
9
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
pharmaceutical composition for treating and/or preventing age-related
conditions, such as
muscular atrophy. In another embodiment, the present disclosure provides a
pharmaceutical composition (e.g., in an intra-muscular administering form)
comprising
(e.g., as a sole pharmaceutically active ingredient) a fusion polypeptide
(e.g., glycosylated
or non-glycosylated) comprising sKlotho of alpha Klotho protein without signal
peptide
(SEQ ID NO: 7); and a linker comprising SEQ ID NO: 11; and uses of the
pharmaceutical
composition in therapy or as medicament for the treatment of a pathological
disorder,for
example treating and/or preventing age-related conditions, such as muscular
atrophy. In
some embodiments, the fusion protein further comprises a modified Fc fragment.
In one embodiment, the present disclosure provides a pharmaceutical
composition
comprising (e.g., as a sole pharmaceutically active ingredient) a fusion
polypeptide (e.g.,
glycosylated or non-glycosylated) that comprises a human FGF protein or an
active
fragment thereof (e.g., without the signal peptide); and a linker comprising
SEQ ID NO:
11.
Pharmaceutical compositions comprising the fusion proteins of the disclosure
and
their uses in therapy or as medicament for the treatment of a pathological
disorder
therapy, for example treating or preventing age-related conditions (e.g.,
muscle atrophy)
or metabolic disorders (e.g., diabete) are also encompassed by the present
disclosure.
In one embodiment, the present disclosure provides a fusion polypeptide that
is at
least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least
94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99%
identical to SEQ
ID NO: 19. In another embodiment, the present disclosure provides a fusion
polypeptide
that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%,
at least 94%, at
least 95%, at least 96%, at least 96%, at least 97%, at least 98%, at least
99% identical to
SEQ ID NO: 20.
In one embodiment, the present disclosure provides a fusion polypeptide that
is at
least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least
94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99%
identical to SEQ
ID NO: 40. In another embodiment, the present disclosure provides a fusion
polypeptide
that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%,
at least 94%, at
least 95%, at least 96%, at least 96%, at least 97%, at least 98%, at least
99% identical to
SEQ ID NO: 41.
In one embodiment, the present disclosure provides a fusion polypeptide that
is at
least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least
94%, at least
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 46. In another embodiment, the present disclosure provides a
fusion
polypeptide that is at least 85%, at least 90%, at least 91%, at least 92%, at
least 93%, at
least 94%, at least 95%, at least 96%, at least 96%, at least 97%, at least
98%, at least
99% or 100% identical to SEQ ID NO: 47.
In another embodiment, the present disclosure provides a fusion polypeptide
that
is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 48. In another embodiment, the present disclosure provides a
fusion
polypeptide that is at least 85%, at least 90%, at least 91%, at least 92%, at
least 93%, at
least 94%, at least 95%, at least 96%, at least 96%, at least 97%, at least
98%, at least
99% or 100% identical to SEQ ID NO: 49.
In one embodiment, the present disclosure provides a fusion polypeptide that
is at
least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least
94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 50. In another embodiment, the present disclosure provides a
fusion
polypeptide that is at least 85%, at least 90%, at least 91%, at least 92%, at
least 93%, at
least 94%, at least 95%, at least 96%, at least 96%, at least 97%, at least
98%, at least
99% or 100% identical to SEQ ID NO: 51.
In one embodiment, the present disclosure provides a fusion polypeptide that
is at
least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least
94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 52. In another embodiment, the present disclosure provides a
fusion
polypeptide that is at least 85%, at least 90%, at least 91%, at least 92%, at
least 93%, at
least 94%, at least 95%, at least 96%, at least 96%, at least 97%, at least
98%, at least
99% or 100% identical to SEQ ID NO: 53.
In another embodiment, the present disclosure provides a fusion polypeptide
that
is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 54.
In another embodiment, the present disclosure provides a fusion polypeptide
that
is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least
11
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 55.
In another embodiment, the present disclosure provides a fusion polypeptide
that
is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 56.
In another embodiment, the present disclosure provides a fusion polypeptide
that
is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQIDNO: 57.
In another embodiment, the present disclosure provides a fusion polypeptide
that
is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 58.
In another embodiment, the present disclosure provides a fusion polypeptide
that
is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 59.
In another embodiment, the present disclosure provides a fusion polypeptide
that
is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 60.
In another embodiment, the present disclosure provides a fusion polypeptide
that
is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 61.
In another embodiment, the present disclosure provides a fusion polypeptide
that
is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 62.
12
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
In another embodiment, the present disclosure provides a fusion polypeptide
that
is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 63.
In another embodiment, the present disclosure provides a fusion polypeptide
that
is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 64.
In another embodiment, the present disclosure provides a fusion polypeptide
that
is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 65.
In another embodiment, the present disclosure provides a fusion polypeptide
that
is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 66.
In another embodiment, the present disclosure provides a fusion polypeptide
that
is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 67.
In another embodiment, the present disclosure provides a fusion polypeptide
that
is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least
95%, at least 96%, at least 96%, at least 97%, at least 98%, at least 99% or
100% identical
to SEQ ID NO: 68.
In one embodiment, the present disclosure provides a fusion polypeptide
comprising a sKlotho of beta Klotho protein with signal peptide fused
(directly or
indirectly via a linker) to FGF- 19 or an active fragment thereof. In some
embodiments,
the fusion further comprises a modified Fc fragment having decreased affinity
for Fc-
gamma-receptor and/or increased serum half-life. In another embodiment, the
present
disclosure provides a fusion polypeptide comprising a sKlotho of beta Klotho
protein
without signal peptide fused (directly or indirectly via a linker) to FGF- 19
or an active
13
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
fragment thereof. In another embodiment, the present disclosure provides a
fusion
polypeptide comprising a sKlotho of beta Klotho protein with signal peptide
fused
(directly or indirectly via a linker) to FGF-21 or an active fragment thereof.
In another
embodiment, the present disclosure provides a fusion polypeptide comprising a
sKlotho
of beta Klotho protein without signal peptide fused (directly or indirectly
via a linker) to
FGF-21 or an active fragment thereof.
The disclosure provides nucleic acid sequences encoding any of the Klotho
fusion
polypeptides described herein and host cells containing the nucleic acids. In
some
embodiments, the fusion further comprises a modified Fc fragment having
decreased
affinity for Fc-gamma-receptor and/or increased serum half-life.
The disclosure also provides composition having any of the Klotho fusion
polypeptides contemplated herein. The compositions of the disclosure can
further include
heparin. In some embodiments, the fusion further comprises a modified Fc
fragment
having decreased affinity for Fc-gamma-receptor and/or increased serum half-
life.
The disclosure also provides a method for treating or preventing an age-
related
condition in an individual. An individual (e.g., human) is administered a
therapeutically
effective dose of a pharmaceutical composition containing a Klotho fusion
polypeptide,
having at least one extracellular subdomain of a Klotho protein (e.g., alpha
Klotho
protein) and a fibroblast growth factor or an active fragment thereof so as to
treat or
prevent the age-related condition. In some embodiments, the fusion further
comprises a
modified Fc fragment having decreased affinity for Fc-gamma-receptor and/or
increased
serum half-life. In particular, the disclosure provides a method of treating
or preventing
muscle wasting comprising administering to an individual (e.g., human) an
therapeutically effective amount of a fusion polypeptide having at least one
extracellular
subdomain of an alpha Klotho protein and a fibroblast growth factor (or an
active
fragment thereof).
Additionally, the disclosure provides a method for treating or preventing a
metabolic disorder in an individual. An individual is administered a
therapeutically
effective dose of a pharmaceutical composition containing a fusion polypeptide
of the
disclosure, having at least one extracellular subdomain of a Klotho protein
and a
fibroblast growth factor (or an active fragment thereof) so as to treat the
metabolic
disorder. In some embodiments, the fusion further comprises a modified Fc
fragment
having decreased affinity for Fc-gamma-receptor and/or increased serum half-
life. In
particular, a fusion polypeptide of the disclosure having at least one
extracellular
14
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
subdomain of a beta-Klotho protein and a fibroblast growth factor 21 is useful
for treating
a metabolic disorder.
Klotho-FGF23 fusion polypeptides of the disclosure can be used for treating or
preventing hyperphosphatemia or calcinosis in an individual. In some
embodiments, the
fusion further comprises a modified Fc fragment having decreased affinity for
Fc-gamma-
receptor and/or increased serum half-life. A pharmacologically effective dose
of a
pharmaceutical composition containing the Klotho fusion polypeptide of the
disclosure,
having at least one extracellular subdomain of a Klotho protein and a
fibroblast growth
factor, is administered to treat or prevent hyperphosphatemia or calcinosis.
In particular,
a Klotho fusion polypeptide of the disclosure having at least one
extracellular subdomain
of an alpha Klotho protein and a fibroblast growth factor 23 is useful for
treating
hyperphosphatemia or calcinosis.
Klotho-FGF23 fusion polypeptides of the disclosure can be used for treating or
preventing chronic renal disease or chronic renal failure in an individual. In
some
embodiments, the fusion further comprises a modified Fc fragment having
decreased
affinity for Fc-gamma-receptor and/or increased serum half-life. A
therapeutically
effective dose of a pharmaceutical composition containing the Klotho fusion
polypeptide
of the disclosure, having at least one extracellular subdomain of a Klotho
protein (e.g.,
alpha Klotho protein) and a fibroblast growth factor, is administered to treat
or prevent
chronic renal disease or chronic renal failure.
Klotho-FGF23 fusion polypeptides of the disclosure can be used for treating or
preventing cancer (e.g., breast cancer) in an individual. In some embodiments,
the fusion
further comprises a modified Fc fragment having decreased affinity for Fc-
gamma-
receptor and/or increased serum half-life. A therapeutically effective dose of
a
pharmaceutical composition containing the Klotho fusion polypeptide of the
disclosure,
having at least one extracellular subdomain of a Klotho protein (e.g., alpha
Klotho
protein) and a fibroblast growth factor, is administered to treat or prevent
cancer or breast
cancer.
The present disclosure provides fusion polypeptides comprising at least one
extracellular subdomain of Klotho protein and a FGF or an active fragment
thereof for
use in medicine. In some embodiments, the fusion further comprises a modified
Fc
fragment having decreased affinity for Fc-gamma-receptor and/or increased
serum half-
life. In one embodiment, the present disclosure provides fusion polypeptides
comprising
at least one extracellular subdomain of Klotho protein and a FGF or an active
fragment
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
thereof for use in treating or preventing muscle atrophy. The present
disclosure also
provides a method of treating or preventing an age related condition (e.g.,
muscle
atrophy) comprising administering to an individual in need thereof a
therapeutically
effective dose of a pharmaceutical composition comprising a soluble Klotho
protein.
The disclosure futhermore provides the above described peptides and fusion
polypeptides or pharmaceutical compositions comprising said peptides for use
in therapy,
as a medicament or for use in the treatment of a pathological disorder, for
example age-
related condition, metabolic disorder, hyperphosphatemia or calcinosis,
chronic renal
disease or chronic renal failure or to prevent cancer or breast cancer, in an
individual.
Additonally, the disclosure further provides use of a polypeptide, nucleic
acid or
pharmaceutical composition of the invention in the manifacture of a medicament
for the
treatment of a pathological disorder, particularly for the treatment of the
above mentioned
disorders, preferably age related conditions like muscle atrophy.
The disclosure also includes kits for treating or preventing an age-related
disorder
or metabolic disorder in an individual. The kit includes instructions for use
and a purified
Klotho fusion polypeptide having at least one extracellular subdomain of a
Klotho protein
and a fibroblast growth factor. In some embodiments, the fusion further
comprises a
modified Fc fragment having decreased affinity for Fc-gamma-receptor and/or
increased
serum half-life.
The disclosure also provides a kit for producing a Klotho fusion polypeptide
of the
disclosure. The kit of the disclosure includes instructions for use and a
nucleic acid
encoding a Klotho fusion polypeptide, having at least one extracellular
subdomain of
Klotho protein and a fibroblast growth factor. In some embodiments, the fusion
further
comprises a modified Fc fragment having decreased affinity for Fc-gamma-
receptor
and/or increased serum half-life.
In one embodiment of the disclosure, the fusion polypeptide comprises: (a) a
polypeptide comprising a fibroblast growth factor, or a functionally active
variant or
derivative (e.g., a variant comprising at least one conservative amino acid
substitution
and/or one amino acid deletion) thereof, and (b) a modified Fc fragment, or a
functionally
active variant or derivative (e.g., a variant comprising at least one
conservative amino
acid substitution and/or one amino acid deletion) thereof, having decreased
affinity for
Fc-gamma-receptor and/or increased serum half-life
16
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
In one embodiment of the disclosure, the polypeptide of (a) and the
polypeptide of
(b) are connected by a polypeptide linker. The linker can be repeated 1 to 30
times, or
more.
In one embodiment of the disclosure, the polypeptide linker comprises an amino
acid sequence selected from the group consisting of. SEQ ID NO: 11, SEQ ID NO:
12,
SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, and
SEQ ID NO: 18.
In one embodiment of the disclosure, the polypeptide of (a) is connected by a
peptide bond to the N-terminus of said polypeptide linker, and the polypeptide
of (b) is
connected by a peptide bond to the C-terminus of said polypeptide linker.
In one embodiment of the disclosure, the fusion polypeptide further comprises
a
signal peptide.
In one embodiment of the disclosure, the signal peptide is the IgG signal
peptide.
In one embodiment of the disclosure, the fibroblast growth factor is
fibroblast
growth factor-23 or a fibroblast growth factor-23 variant (R179Q).
In one embodiment of the disclosure, the fibroblast growth factor is
fibroblast
growth factor-19 or fibroblast growth factor-21.
In one embodiment of the disclosure, fusion polypeptide comprises an amino
acid
sequence which is 95% or more identical to the amino acid sequence of SEQ ID
NO: 51,
or SEQ ID NO: 53.
In one embodiment of the disclosure, fusion polypeptide comprises the amino
acid
sequence of SEQ ID NO: 51, or SEQ ID NO: 53.
In one embodiment of the disclosure, fusion polypeptide comprises FcLALA.
3. BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 illustrates several different embodiments of the Klotho fusion
polypeptides of the disclosure. The represented fusion polypeptides include
one or more
Klotho extracellular subdomains operatively linked to a fibroblast growth
factor.
Polypeptides containing one or more Klotho extracellular subdomains include,
for
example, an extracellular domain of Klotho (e.g., as 1 to 982 of human
Klotho), or an
active fragment of Klotho.
Figure 2 illustrates the amino acid and nucleic acid sequences of several
Klotho
fusion polypeptides of the disclosure and components thereof (e.g., Klotho
extracellular
17
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
domain, FGF). Fusion proteins comprising sKlotho, FGF23 and FcLALA (a modified
Fc
fragment having decreased affinity for Fc-gamma-receptor and/or increased
serum half-
life) are described in SEQ ID NOs. 46, 47, 48, and 49. Fusion proteins
comprising
FGF23 and FcLALA are described in SEQ ID NOs. 50, 51, 52 and 53.
Figures 3A-3C depict protein expression of an sKlotho-FGF23 fusion protein.
Figure 3A shows that sKlotho-FGF23 fusion protein was detected in conditioned
media
by Western blotting with anti-FGF23 antibodies. Figure 3B shows that sKlotho-
FGF23
fusion protein was detected in conditioned media by SDS-PAGE and Coomassie
blue
staining Figure 3C shows a highly purified sKlotho-FGF23-6xHis fusion protein,
analyzed by SDS-PAGE and Coomassie blue staining.
Figure 4 illustrates the results of an Egr-1 luciferase assay comparing the
activation level of Egr-1 in cells treated with conditioned media containing
either a
Klotho fusion polypeptide, a FGF 23 polypeptide only, a soluble Klotho
(sKlotho)
polypeptide only, and a soluble Klotho polypeptide in combination with a FGF
23
polypeptide in the absence or presence of heparin (20 gg/ml).
Figures 5A-5B depict the results of an Egr-1 luciferase assay comparing the
activation level of Egr-1 in cells treated with purified Klotho fusion
polypeptide, FGF 23
polypeptide, or soluble Klotho polypeptide in the absence or presence of
heparin. Figure
5A shows an the results of an experiment comparing the activation level of Egr-
1 in cells
treated with FGF 23 alone, sKlotho-His (10 nM or 20 nM) and a combination of
FGF 23
and sKlotho-His (10 nM or 20 nM) in the absence or presence of heparin (20
gg/ml).
Figure 5B shows Egr-1 luciferase reporter activity in cells treated with
sKlotho-FGF23-
His fusion (0 nM, 0.6 nM, 1.21 nM, 2.41 nM, 4.83 nM, 9.65 nM, and 19.3 nM).
Figures 6A-6B illustrate the effect of treatment with a purified sKlotho
fusion
polypeptide on C2C12 muscle cells. Figure 6A shows measurements of myotube
diameter in C2C12 muscle cells treated with either IGF-1 (10 nM), FGF2
(20ng/ml), or a
purified Klotho fusion polypeptide (20 nM), in the absence or presence of
dexamethasone
(100 M). Figure 6B shows the phosphorylation of signaling pathway proteins in
C2C12
muscle cells by IGF-1 (10 nM), FGF2 (20ng/ml), or a purified Klotho fusion
polypeptide
(20 nM), in the absence or presence of rapamycin (40 nM).
Figure 7 shows activation of EGR-1-luc reporter gene by sKlotho-
FGF23(R179Q)-FcLALA fusion proteins.
18
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
Figure 8 shows the activation of EGR-1-luc reporter gene by FGF23(R179Q)-
FcLALA proteins.
Figure 9 shows the pharmacokinetic profile of FGF23(R179Q) vs
FGF23(R179Q)-FcLALAv2.
Figures 10A and l0B show the in vivo efficacy of sKlotho-FGF23 fusion in
enhancing muscle growth after dexamethasone-induced muscle atrophy.
Figure 11. This figure shows activation of EGR-1-luc reporter gene by
FGF23(R179Q)-FcLALA and Q156A, C206S, C244S and C206S/C244S mutants.
Figure 12 shows protein qualities and dimerization of WT (wild-type), Q156A,
C206S, C244S and C206S/C244S mutants of FGF23(R179Q)-FcLaLa.
4. DETAILED DESCRIPTION
The present disclosure is directed to methods, kits and compositions for
preventing or treating age-related conditions and metabolic disorders; and to
the use of
said compostions in therapy, as a medicament or for use in the treatment of a
pathological
disorder. The fusion polypeptides of the disclosure include a Klotho protein
or active
fragment thereof. In some embodiments, the fusion polypeptides of the
disclosure
include a Klotho protein or an active fragment thereof operatively linked to a
fibroblast
growth factor polypeptide or active fragment thereof. In some embodiments, the
fusion
further comprises a modified Fc fragment with decreased ability to bind FcRn
and/or
increased stability in serum. In another embodiment, the fusion polypeptide
comprises a
FGF (e.g., FGF23) and a modified Fc fragment with decreased ability to bind
FcRn
and/or increased stability in serum.
The fusion proteins or sKlotho of the present disclosure are useful in the
treatment
and prevention of a variety of age-related conditions including sarcopenia,
skin atrophy,
muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, pulmonary
emphysema,
osteoporosis, osteoarthritis, immunologic incompetence, high blood pressure,
dementia,
Huntington's disease, Alzheimer's disease, cataracts, age-related macular
degeneration,
prostate cancer, stroke, diminished life expectancy, memory loss, wrinkles,
impaired
kidney function, and age-related hearing loss; and metabolic disorders
including Type II
Diabetes, Metabolic Syndrome, hyperglycemia, and obesity.
19
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
The present disclosure is based at least in part on the finding that despite
the
physical constraints (e.g., large size of both the Klotho and FGF
polypeptides) the
Klotho-FGF fusion polypeptides are highly effective in activating an FGF
receptor. This
finding is unexpected given that fusion of these two proteins would likely
interfere with
the heterodimerization and thus the activities of the proteins; e.g., the
binding domains of
the proteins may be perturbed by the fusion or the proteins may be mis-
oriented spatially
if put together in a "cis" formation.
The fusion polypeptides described herein are advantageous because they allow
the
administration of a single therapeutic protein that has enhanced activity
compared to
Klotho or FGF administered alone or together as separate polypeptides. The use
of
Klotho and FGF as a single fusion polypeptide rather than as two separate
polypeptides
(i.e., a Klotho polypeptide and a separate FGF polypeptide) is more effective
at activating
the FGF receptor.
Definitions
"Klotho polypeptide", "Klotho protein", or "Klotho" as used herein, includes
active fragments, derivatives, mimetics, variants and chemically modified
compounds or
hybrids thereof of wild-type "Klotho". A Klotho active fragment has the
ability to bind to
an FGF polypeptide. Generally, a Klotho active polypeptide contains at least a
Klotho
subdomain (e.g., KL-D1 and KL-D2). Wild-type Klotho has the amino acid
sequence as
is found in nature. Example Klotho polypeptides suitable for use with the
present
disclosure include alpha-Klotho (SEQ ID NO: 2) and beta-Klotho (SEQ ID NO: 4).
Nucleotide and amino acid sequences of the alpha-Klotho and beta-Klotho are
found in
the GenBank database at Accession No. NM 004795; NP 004786 and NM 175737;
NP783864, respectively. Klotho polypeptides include those described in U.S.
Patent
No. 6,579,850, the content of which is herein incorporated by reference in its
entirety.
The Klotho polypeptides include those from other species besides humans,
including
alpha-Klotho from mouse (NP_038851), rat (NP_112626), rabbit (NP_001075692)
and
beta-Klotho from mouse (NP_112457). Species predicted to have alpha-Klotho
include
chimpanzee (XP_522655), macaque (XP_001101127), horse (XP_001495662), cow
(XP001252500), platypus (XP001510981), and chicken (XP_417105). Species
predicted to have beta-Klotho include chimpanzee (XP_526550), macaque
(XP001091413), horse (XP001495248), dog (XP_536257), rat (XP001078178),
platypus (XP_001512722), and chicken (XP_423224). The Klotho polypeptides have
an
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
amino acid sequence that is substantially identical to the amino acid sequence
of SEQ ID
NO: 2 or SEQ ID NO: 4; i.e., at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%,
98%,
99% or more identical at the amino acid sequences of SEQ ID NO: 2 or SEQ ID
NO: 4,
or active fragment thereof.
"Fusion polypeptide" or "fusion protein", as used herein, shall mean a
polypeptide
comprising two or more different polypeptides or active fragments thereof that
are not
naturally present in the same polypeptide. In some embodiments, the two or
more
different polypeptides are operatively linked together covalently, e.g.,
chemically linked
or fused in frame by a peptide bond. As used herein a "Klotho fusion
polypeptide" is a
fusion polypeptide which includes an amino acid sequence from a Klotho
polypeptide or
active fragment thereof. A fusion polypeptide can comprise, as non-limiting
examples,
Klotho (e.g., sKlotho), FGF (e.g., FG23), and (optionally) a modified Fc
fragment (e.g., a
modified Fc fragment with decreased binding affinity to FC-gamma-receptor
and/or
increased serum half-life). Examples of this type of fusion polypeptide are
presented in
SEQ ID NOs. 46 to 49. In another embodiment, the fusion proteins comprise FGF
(e.g.,
FGF23) and a modified Fc (e.g., FcLALA). Fusion proteins comprising FGF23 and
FcLALA are described in SEQ ID NOs. 50, 51, 52 and 53. FcLALA is a Fc fragment
with a LALA mutation (L234A, L235A), which triggers ADCC with lowered
efficiency,
and binds and activates human complement weakly. Hessell et al. 2007 Nature
449:101-
104.
"Fibroblast growth factor" and "FGF" are used interchangeably herein and shall
refer to polypeptides that regulate cell proliferation, migration,
differentiation,
homeostasis, tissue repair and response to injury in an animal, including a
human subject.
FGFs have the ability to bind to a fibroblast growth factor receptor and
regulate its
activity, including autophosphorylation of FGFR, phosphorylation of FRS2 (FGF
receptor
substrate 2) and ERKl/2 (extracellular signal-regulated protein kinase 1/2),
and activating
Egr-1 (early growth response-1). The term "FGF" includes active fragments,
derivatives,
mimetics, variants and chemically modified compounds or hybrids thereof of
wild-type
"FGF", e.g., as known in the art and as described in U.S. Patent No. 7,223,563
and U.S.
Patent No. 7,259,248, the contents of which are incorporated by reference in
their
entirety. Wild-type FGF has an amino acid sequence as is found in nature.
Example
fibroblast growth factors suitable for use with the present disclosure include
fibroblast
growth factor-19 (FGF19; SEQ ID NO: 31), fibroblast growth factor-21 (FGF21;
SEQ ID
NO: 33), and fibroblast growth factor-23 (FGF23; SEQ ID NO: 35). The FGF
21
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
polypeptides include those from other species besides humans, including murine
FGFs.
Generally, FGF polypeptides have an amino acid sequence that is substantially
identical
to the amino acid sequence of SEQ ID NO: 31, SEQ ID NO: 33 or SEQ ID NO: 35;
i.e.,
having an amino acid sequence is which is at least 70%, 75%, 80%, 85%, 90%,
95%,
96%, 97%, 98%, 99% or more or 100% identical to the amino acid sequences of
SEQ ID
NO: 31 SEQ ID NO: 33 or SEQ ID NO: 35, or active fragments thereof. Additional
non-
limiting examples of FGF, particularly FGF23, are provided at as 1002-1228 of
SEQ ID
NO: 47; as 1002-1228 of SEQ ID NO: 49; as 1-251 of SEQ ID NO: 51, and as 1-251
of
SEQ ID NO: 53; and sequences which are at least 70%, 75%, 80%, 85%, 90%, 95%,
96%, 97%, 98%, 99% or more or 100% identical to these sequences. Nucleotides
encoding these sequences are provided in SEQ ID NOs: 46, 48, 50 and 52.
The term "FGF", includes active fragments of the full-length polypeptide.
Active
FGF fragments that are able to bind to their corresponding FGF receptors are
known in
the art and also contemplated for use in the present disclosure. One skilled
in the art
would appreciate, based on the sequences disclosed herein, that overlapping
fragments of
the FGFs can be generated using standard recombinant technology, for example,
that
described in Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual,
Cold
Spring Harbor Laboratory Press, New York) and Ausubel et al. (1997, Current
Protocols
in Molecular Biology, Green & Wiley, New York). One skilled in the art would
appreciate, based on the disclosure presented herein, that the biological
activity of FGF
fragments could be tested by methods well known in the art and described
herein,
including binding to the FGF receptor. Similarly, cell culture models which
possess the
necessary FGF signal transduction machinery (i.e. FGF receptor) may be
transfected with
FGF fragments and subsequently tested for alterations in FGF signaling,
relative to wild
type FGF.
FGFs are grouped into seven subfamilies based on the homology of the FGF core
homology domain (approximately 120 amino acids long), which is flanked by N-
and C-
terminal sequences that are highly variable in both length and primary
sequence,
particularly among different FGF subfamilies (Goetz et al., Molecular and
Cellular
Biology, 2007, Vol. 27, 3417-3428). An FGF active polypeptide generally
contains at
least an FGF core homology domain. In some embodiments, an FGF active
polypeptide
may contain, in addition to an FGF core homology domain, flanking sequences
which
may confer additional specificity in binding FGF receptors. FGF19, FGF21, and
FGF23
are grouped in the FGF19 subfamily because the core region of these ligands
share high
22
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
sequence identity relative to other FGFs (FGF19 v. FGF21: 38% identity; FGF19
v.
FGF23: 36% identity). FGF19 subfamily members act analogously to signaling
molecules of the endocrine system and regulate diverse physiological processes
uncommon to classical FGFs (e.g., FGF19: energy and bile acid homeostasis;
FGF21:
glucose and lipid metabolism; and FGF 23: phosphate and vitamin D
homeostasis).
"Fibroblast growth factor receptor" and "FGFR" as used herein refer to any one
of FGFRs 1-4 known in the art, or splice variants thereof (e.g., FGFRlc).
Example
fibroblast growth factor receptors suitable for use with the present
disclosure include
fibroblast growth factor receptor-19 (e.g., FGFR4-beta Klotho), fibroblast
growth factor
receptor-21 (e.g., FGFRlc-alpha Klotho), and fibroblast growth factor receptor-
23 (e.g.,
FGFRlc-alpha Klotho, FGFR3-alpha Klotho, FGFR4-alpha Klotho).
"Extracellular domain", as used herein, refers to the fragment of a
transmembrane
protein existing outside of a cell (e.g., not including the intracellular or
transmembrane
region). The "extracellular domain of the Klotho protein", "soluble Klotho",
or
"sKlotho" (e.g., SEQ ID NO: 7; SEQ ID NO: 39), refers to an extracellular
domain of the
Klotho polypeptide that is capable of binding a fibroblast growth factor,
and/or capable of
enabling the binding of a fibroblast growth factor to a fibroblast growth
factor receptor by
binding to the fibroblast growth factor. The Klotho extracellular domain
corresponds to
amino acid residues 28-982 of the full length alpha Klotho sequence (SEQ ID
NO: 2) and
to amino acid residues 52-997 of the full length beta Klotho sequence (SEQ ID
NO: 4).
"Extracellular subdomain of Klotho protein" and "extracellular subdomain of
Klotho protein" are used interchangeably herein and shall refer to a region in
the
extracellular domain of the Klotho polypeptide that is capable of binding a
fibroblast
growth factor, and/or is capable of enabling the binding of a fibroblast
growth factor to a
fibroblast growth factor receptor by binding to the fibroblast growth factor.
In various
embodiments, the fusion comprises a polypeptide comprising at least one
extracellular
subdomain of a Klotho protein; a polypeptide comprising a fibroblast growth
factor; and,
optionally, a modified Fc fragment having decreased affinity for Fc-gamma-
receptor
and/or increased serum half-life. The Klotho extracellular domain has two
homologous
subdomains that are repeated, i.e., KL-D1 (SEQ ID NO: 5) and KL-D2 (SEQ ID NO:
6).
KL-D1 and KL-D2 correspond respectively to amino acid residues 58-506 and 517-
953
of the full length alpha Klotho polypeptide (SEQ ID NO: 2) and respectively to
amino
acid residues 77-508 and 571-967 of the full length beta Klotho polypeptide
(SEQ ID
NO: 4) and are suitable for use with the present disclosure. Generally, a
polypeptide that
23
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
contains at least one Klotho subdomain is a Klotho active polypeptide. The
Klotho
extracellular subdomain for use with the polypeptide of the disclosure may be
an alpha
Klotho or beta Klotho KL-D1 domain with an amino acid sequence that is
substantially
identical to the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 37,
respectively.
Further, the Klotho KL-D1 domain may have an amino acid sequence that is at
least 70%,
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical to the amino
acid
sequence of SEQ ID NO: 5 or SEQ ID NO: 37. The Klotho extracellular subdomain
may
also be an alpha or beta Klotho polypeptide KL-D2 domain that is substantially
identical
to the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 38, respectively. In
a
further embodiment, the KL-D2 domain has an amino acid sequence that is at
least at
least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical to
the
amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 38. In some embodiments, the
fusion comprises at least two extracellular subdomains of the Klotho protein
(e.g., KL-D1
and KL-D2; KL-D1 and KL-D1 in tandem repeats; KL-D2 and KL-D2 in tandem
repeats,
etc.).
"Modified Fc fragment", as used herein, shall mean an Fc fragment of an
antibody
comprising a modified sequence. The Fc fragment is a portion of an antibody
comprising
the CH2, CH3 and part of the hinge region. The modified Fc fragment can be
derived
from, for example, IgGI, IgG2, IgG3, or IgG4. FcLALA is a modified Fc fragment
with a
LALA mutation (L234A, L235A), which triggers ADCC with lowered efficiency, and
binds and activates human complement weakly. Hessell et al. 2007 Nature
449:101-104.
Additional modifications to the Fc fragment are described in, for example,
U.S. Patent
No. 7,217,798. For example, in various modified Fc fragments: (a) amino acid
residue
250 is glutamic acid and amino acid residue 428 is phenylalanine; or (b) amino
acid
residue 250 is glutamine and amino acid residue 428 is phenylalanine; or (c)
amino acid
residue 250 is glutamine and amino acid residue 428 is leucine. In some
embodiments,
amino acid residues 250 and 428 differ from the residues present in an
unmodified Fc-
fusion protein by amino acid residue 250 being glutamic acid or glutamine and
amino
acid residue 428 being leucine or phenylalanine, and wherein amino acid
residues are
numbered by the EU numbering system, as described in U.S. Patent No.
7,217,798. In
some embodiments, the modified Fc-fusion protein has a higher affinity for
FcRn at pH
6.0 than at pH 8Ø Preferably, the modified Fc fragment has decreased
affinity to FcRn
and/or increased serum half-life. Non-limiting examples of modified Fc
fragments
include that at as (amino acids) 1234-1459 of SEQ ID NO: 47; as 1234 to 1450
of SEQ
24
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
ID NO: 49; as 257 to 482 of SEQ ID NO: 51; and as 257 to 473 of SEQ ID NO: 53;
and
sequences which are at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%
or
more or 100% identical to these sequences. Nucleotides encoding these
sequences are
provided in SEQ ID NOs: 46, 48, 50 and 52.
"Signal peptide", as used herein, shall mean a peptide chain (3-60 amino acids
long) that directs the post-translational transport of a protein to the
endoplasmic reticulum
and may be cleaved off. Example signal peptides suitable for use with the
present
disclosure include the Klotho signal peptide (SEQ ID NO: 19) and the IgG
signal peptide
(SEQ ID NO: 20). Note that upon secretion and cleavage by the producer cell
line, the
signal peptide (e.g., of the peptides corresponding to SEQ ID NO: 19 and SEQ
ID NO:
20) is cleaved off. Thus, after secretion and cleavage of the signal peptide
by the
producer cell lines, the peptide of SEQ ID NO: 19 would generate the peptide
of SEQ ID
NO: 41.
"Linker", as used herein, shall mean a functional group (e.g., chemical or
polypeptide) that covalently attaches two or more polypeptides or nucleic
acids so that
they are connected with one another. As used herein, a "peptide linker" refers
to one or
more amino acids used to couple two proteins together (e.g., to couple the
extracellular
domain of Klotho and fibroblast growth factor-23). Peptide linkers suitable
for use with
the present disclosure include, but are not limited to, polypeptides with
amino acid
sequences represented by SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO:
11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16,
SEQ ID NO: 17 and SEQ ID NO: 18. A polypeptide linker can comprise at least 1
and up to about 30 repeats of any of these amino acid sequences.
"Operatively linked", as used herein, shall mean the linking of two or more
biomolecules so that the biological functions, activities, and/or structure
associated with
the biomolecules are at least retained. In reference to polypeptides, the term
means that
the linking of two or more polypeptides results in a fusion polypeptide that
retains at least
some of the respective individual activities of each polypeptide component.
The two or
more polypeptides may be linked directly or via a linker. In reference to
nucleic acids,
the term means that a first polynucleotide is positioned adjacent to a second
polynucleotide that directs transcription of the first polynucleotide when
appropriate
molecules (e.g., transcriptional activator proteins) are bound to the second
polynucleotide.
"Specifically binds", as used herein, shall refer to the ability of a first
molecule to
bind to a target molecule out of many, different types of molecules to which
it may be
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
exposed because of the ability of the first molecule to adopt a particular
structure
conducive to forming non-covalent interactions between itself and the other
target
molecule. The first molecule binds to the target forming a stable complex
while there is
substantially less recognition, contact, or complex formation of the first
molecule with
any other non-specific molecules.
"Polypeptide variant" or "protein variant", as used herein, refers to
polypeptides in
which one or more amino acids have been substituted by different amino acids
from a
reference sequence. It is well understood in the art that some amino acids may
be
substituted by others with broadly similar properties without changing the
nature of the
activity of the polypeptide (conservative substitutions) as described
hereinafter. These
terms also encompass polypeptides in which one or more amino acids have been
added or
deleted, or replaced with different amino acids, e.g., protein isoforms. An
example
variant of fibroblast growth factor-23 suitable for use with the present
disclosure is the
fibroblast growth factor-23 variant (R179Q).
"Pharmaceutical composition", as used herein, shall mean a composition
containing a compound (e.g., a fusion polypeptide of the disclosure) that may
be
administered to treat or prevent a disease or disorder in an individual.
"Individual" or "subject", as used herein, shall refer to a mammal, including,
but
not limited to, a human or non-human mammal, such as a bovine, equine, canine,
ovine,
or feline.
"Treat", as used herein, shall mean decrease, suppress, attenuate, diminish,
arrest,
or stabilize the development or progression of a disease. In the context of
the disclosure,
the administration of the polypeptides of the disclosure may be used to treat
age-related
conditions, including sarcopenia, skin atrophy, muscle wasting, brain atrophy,
atherosclerosis, arteriosclerosis, pulmonary emphysema, osteoporosis,
osteoarthritis,
immunologic incompetence, high blood pressure, dementia, Huntington's disease,
Alzheimer's disease, cataracts, age-related macular degeneration, prostate
cancer, stroke,
diminished life expectancy, memory loss, wrinkles, impaired kidney function,
and age-
related hearing loss; and metabolic disorders, including Type II Diabetes,
Metabolic
Syndrome, hyperglycemia, and obesity.
"Prevent", as used herein, shall refer to a decrease in the occurrence of a
disorder
or decrease in the risk of acquiring a disorder or its associated symptoms in
a subject. In
the context of the disclosure, the administration of the polypeptides of the
disclosure may
be used to prevent age-related conditions, including sarcopenia, skin atrophy,
muscle
26
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
wasting, brain atrophy, atherosclerosis, arteriosclerosis, pulmonary
emphysema,
osteoporosis, osteoarthritis, immunologic incompetence, high blood pressure,
dementia,
Huntington's disease, Alzheimer's disease, cataracts, age-related macular
degeneration,
prostate cancer, stroke, diminished life expectancy, memory loss, wrinkles,
impaired
kidney function, and age-related hearing loss; and metabolic disorders,
including Type II
Diabetes, Metabolic Syndrome, hyperglycemia, and obesity. The prevention may
be
complete, e.g., the total absence of an age-related condition or metabolic
disorder. The
prevention may also be partial, such that the likelihood of the occurrence of
the age-
related condition or metabolic disorder in a subject is less likely to occur
than had the
subject not received the present disclosure.
"Disease", as used herein, shall mean any condition or disorder that damages
or
interferes with the normal function of a cell, tissue, or organ.
"Age-related condition", as used herein, shall mean any disease or disorder
whose
incidence in a population or severity in an individual correlates with the
progression of
age. In one embodiment, the age-related condition is a disease or disorder
whose
incidence is at least 1.5 fold higher among human individuals greater than 60
years of age
relative to human individuals between the ages of 30-40 and in a selected
population of
greater than 100,000 individuals. Age-related conditions relevant to the
present disclosure
include, but are not limited to, sarcopenia, skin atrophy, muscle wasting,
brain atrophy,
atherosclerosis, arteriosclerosis, pulmonary emphysema, osteoporosis,
osteoarthritis,
immunologic incompetence, high blood pressure, dementia, Huntington's disease,
Alzheimer's disease, cataracts, age-related macular degeneration, prostate
cancer, stroke,
diminished life expectancy, memory loss, wrinkles, impaired kidney function,
and age-
related hearing loss.
"Metabolic disorder", as used herein, shall mean any disease or disorder that
damages or interferes with normal function in a cell, tissue, or organ by
affecting the
production of energy in cells or the accumulation of toxins in a cell, tissue,
organ, or
individual. Metabolic disorders relevant to the present disclosure include,
but are not
limited to, Type II Diabetes, Metabolic Syndrome, hyperglycemia, and obesity.
An "effective dose" or "effective amount" is an amount sufficient to effect a
beneficial or desired clinical result. In the context of the disclosure, it is
an amount of a
Klotho fusion polypeptide or sKlotho effective to produce the intended
pharmacological,
therapeutic or preventive result. A therapeutically effective dose results in
the prevention
or amelioration of the disorder or one or more symptoms of the disorder,
(e.g., an age-
27
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
related condition or metabolic disorder). Therapeutically effective doses will
vary
depending upon the subject and disease condition being treated, the weight and
age of the
subject, the severity of the disease condition, the manner of administration
and the like
which can be readily be determined by one of ordinary skill in the art.
"Klotho nucleic acid molecule", as used herein is a gene encoding a Klotho
protein. An example human Klotho gene is provided at GenBank Accession No.
NM_004795 (SEQ ID NO: 1). Additional non-limiting examples of Klotho are
provided
at as 1-982 of SEQ ID NO: 47 and as 1-982 of SEQ ID NO: 49; and sequences
which are
at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more or 100%
identical to these sequences.
"Fragment", as used herein, refers to a portion of a polypeptide or nucleic
acid
molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%,
60%,
70%, 80%, 90% or more of the entire length of the reference nucleic acid
molecule or
polypeptide. A fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or
100, 200, 300,
400, 500, 600, 700, 800, 900, 1000 or up to 3000 nucleotides or amino acids.
The term "substantially identical" refers to a polypeptide or nucleic acid
molecule
exhibiting at least 50% identity to a reference amino acid sequence (for
example, any one
of the amino acid sequences described herein) or nucleic acid sequence (for
example, any
one of the nucleic acid sequences described herein). Preferably, such a
sequence is at
least 60%, 70%, 75%, 80% or 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
99% or more identical at the amino acid level or nucleic acid to the sequence
used for
comparison.
The present disclosure is directed to methods, kits and compositions for
preventing or treating age-related conditions and metabolic disorders; and to
the use of
said compostions in therapy, as a medicament or for use in the treatment of a
pathological
disorder. In some embodiments, the disclosure provides a fusion polypeptide
having at
least one extracellular subdomain of a Klotho protein. In some embodiments,
the fusion
polypeptides further comprise a fibroblast growth factor or an active fragment
thereof. In
some embodiments, the fusion further comprises a modified Fc fragment having
decreased affinity for Fc-gamma-receptorand/or increased serum half-life. In
other
embodiments, the fusion comprises an FGF (e.g., FGF19, FGF21, FGF23 or FGF23
variant R179Q) fused to a modified Fc (e.g., FcLALA). FcLALA is a Fc fragment
with a
LALA mutation (L234A, L235A), which triggers ADCC with lowered efficiency, and
binds and activates human complement weakly. The Klotho extracellular domain
may be
28
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
derived from either the alpha or beta Klotho isoforms. Further, although the
FGF
component of the Klotho fusion polypeptide is described primarily with
reference to
fibroblast growth factor-19, fibroblast growth factor-21 and fibroblast growth
factor-23, it
is contemplated that any of the twenty-three known FGFs or an active fragment
thereof
can be used in practicing the disclosure.
The extracellular domain of the Klotho protein can include one or both of the
KL-
Dl and KL-D2 domains of a Klotho protein. In some embodiments, the Klotho
fusion
polypeptide has at least two extracellular subdomains of a Klotho protein. For
example,
the at least two extracellular subdomains can be at least two KL-D1 domains in
tandem
repeats, at least two KL-D2 domains in tandem repeats, or at least one KL-D1
domain and
at least one KL-D2 domain.
The extracellular subdomain of a Klotho protein and the fibroblast growth
factor
(or an active fragment thereof) can be operatively linked to one another in a
variety of
orientations and manners. For example, the extracellular subdomain of the
Klotho protein
can be operatively linked to the N-terminus of the fibroblast growth factor or
alternatively
the fibroblast growth factor can be operatively linked to the N-terminus of
the at least one
extracellular subdomain of the Klotho protein.
The fusion polypeptide of the disclosure may include one or both of the Klotho
extracellular domains, i.e., KL-D1 (SEQ ID NO: 5) and KL-D2 (SEQ ID NO: 6). KL-
D1
and KL-D2 correspond respectively to amino acid residues 58-506 and 517-953 of
the
full length alpha Klotho polypeptide (SEQ ID NO: 2) and to amino acid residues
77-508
and 571-967 of the full length beta Klotho polypeptide (SEQ ID NO: 4) and are
suitable
for use with the present disclosure. The Klotho fusion polypeptide may have a
KL-D1
domain of an alpha Klotho polypeptide having an amino acid sequence that is
substantially identical to the amino acid sequence of SEQ ID NO: 5 or of a
beta Klotho
polypeptide having an amino acid sequence that is substantially identical to
the amino
acid sequence of SEQ ID NO: 37. Specifically, the Klotho fusion polypeptide
may have
an amino acid sequence that is at least at least 70%, 75%, 80%, 85%, 90%, 95%,
96%,
97%, 98%, 99% or more identical to SEQ ID NO: 5 or SEQ ID NO: 37. The Klotho
fusion polypeptide may have a KL-D2 domain of an alpha Klotho polypeptide with
an
amino acid sequence that is substantially identical to the amino acid sequence
of SEQ ID
NO: 6 or of a beta Klotho polypeptide having an amino acid sequence that is
substantially
identical to the amino acid sequence of SEQ ID NO: 38. Specifically,, the
Klotho fusion
29
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
polypeptide may have an amino acid sequence that is at least at least 70%,
75%, 80%,
85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO: 6 or SEQ ID
NO: 38, respectively.
In some embodiments, the Klotho fusion polypeptide of the disclosure is
soluble
and is capable of binding to an FGF receptor.
The Klotho fusion polypeptides of the disclosure can contain a polypeptide
linker
which connects the polypeptide having at least one extracellular subdomain of
a Klotho
protein and the fibroblast growth factor and the (optional) modified Fc
fragment. Suitable
linkers are well known in the art and generally contain several Gly and
several Ser
residues, e.g., (G1y4 Ser)3 (SEQ ID NO: 11), G1y4 Ser polypeptide (SEQ ID NO:
12), Gly
(SEQ ID NO: 13), Gly Gly (SEQ ID NO: 14), Gly Ser (SEQ ID NO: 15), Gly2 Ser
(SEQ
ID NO: 16), Ala (SEQ ID NO: 17), and Ala Ala (SEQ ID NO: 18). In some
embodiments, the linker will have at least 2 and up to about 30 repeats of an
amino acid
sequence represented by any one of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO:
14,
SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 18.
When a polypeptide linker is present in the Klotho fusion polypeptide of the
disclosure, the polypeptide having at least one extracellular subdomain of a
Klotho
protein may be connected by a peptide bond to the N-terminus of the linker
polypeptide
with the FGF connected by a peptide bond to the C-terminus of the polypeptide
linker.
Alternatively, the FGF may be connected by a peptide bond to the N-terminus of
the
linker polypeptide with the polypeptide having at least one extracellular
subdomain of
Klotho connected by a peptide bond to the C-terminus of the polypeptide
linker. A
chemical linker can also be used to link the two polypeptides.
The Klotho fusion polypeptide of the disclosure may include a signal peptide.
Example signal peptides for use with the Klotho fusion polypeptide include,
but are not
limited to the Klotho signal peptide (SEQ ID NO: 8) and the IgG signal peptide
(SEQ ID
NO: 9).
In some embodiments, the disclosure provides a fusion between a FGF (e.g.,
FGF19, FGF21, FGF23, or FGF23 variant R179Q) and a modified Fc (e.g., FcLALA).
The fusion can also optionally comprise linkers between the FGF and Fc
portions. The
fusion can also optionally comprise a signal peptide. In various embodiments,
the
disclosure encompasses nucleic acids encoding these fusion polypeptides,
vectors
comprising these nucleic acids, and host cells containing these nucleic acids.
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
4.1. Klotho and Fibroblast growth factor polypeptides
The Klotho fusion polypeptides of the disclosure are expected to exhibit
biological
activities comparable to FGF in nature, such as binding to an FGF receptor and
inducing
the phosphorylation of an FGF receptor, FRS2 (FGF receptor substrate 2) and
ERKl/2
(extracellular signal-regulated protein kinase 1/2) and activating Egr-1
(early growth
response-1) gene. FGF is a secreted peptide growth factor that binds the FGF
receptor.
The amino acid and nucleic acid sequences of FGF are readily available to
those of skill
in the art. For example, example nucleotide sequences for FGF19, FGF21, and
FGF23
can be found in the GenBank database at Accession numbers: NM 005117,
NM_019113, and NM020638, respectively, and herein as SEQ ID NOs: 30, 32, and
34,
respectively. Example amino sequences for FGF 19, FGF2 1, and FGF23 can be
found in
the GenBank database at Accession numbers: NP 005108, NP 061986, and NP
065689,
respectively, and herein as SEQ ID NOs: 31, 35, and 35, respectively.
Additionally, FGF
may include one or more alterations which aid in the expression of the
protein, e.g., the
FGF23 (R179Q) variant (SEQ ID NO: 36).
The Klotho protein is a 130 kDa single pass type I transmembrane protein with
an
extracellular domain and a short cytoplasmic domain. The amino acid and
nucleic acid
sequences of Klotho are readily available to those of skill in the art. For
example,
example nucleotide sequences for alpha-Klotho and beta-Klotho can be found in
the
GenBank database at Accession numbers: NM004795 and NM_175737, respectively,
and herein as SEQ ID NOs: 7 and 8, respectively. Example amino acid sequences
for
alpha-Klotho and beta-Klotho can be found in the GenBank database at Accession
numbers: NP004786 and NP_783864, respectively, and herein as SEQ ID NOs: 2 and
4,
respectively.
The Klotho fusion polypeptide of the disclosure can bind to a fibroblast
growth
factor receptor and has an alpha-Klotho or beta-Klotho extracellular domain
operatively
linked to either fibroblast growth factor-19 (SEQ ID NO: 31), fibroblast
growth factor-21
(SEQ ID NO: 33), fibroblast growth factor-23 (SEQ ID NO: 35), or variants
thereof
(which include fibroblast growth factor-23 variant (R179Q) (SEQ ID NO: 36)).
Specifically, the Klotho fusion polypeptide of the disclosure may include an
alpha-Klotho (SEQ ID NO: 2) which is operatively coupled to fibroblast growth
factor-23
(SEQ ID NO: 35) or fibroblast growth factor-23 variant (R179Q) (SEQ ID NO:
36).
Additionally, the Klotho fusion polypeptide of the disclosure may have beta-
Klotho (SEQ
ID NO: 4), which is operatively coupled to fibroblast growth factor-19 (SEQ ID
NO: 31).
31
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
The Klotho fusion polypeptide of the disclosure may include a beta-Klotho (SEQ
ID NO:
4), which is operatively coupled to fibroblast growth factor-21 (SEQ ID NO:
33).
The disclosure includes homologs of the various Klotho and FGF genes and
proteins encoded by those genes. A "homolog," in reference to a gene refers to
a
nucleotide sequence that is substantially identical over at least part of the
gene or to its
complementary strand or a part thereof, provided that the nucleotide sequence
encodes a
protein that has substantially the same activity/function as the protein
encoded by the
gene which it is a homolog of. Homologs of the genes described herein can be
identified
by percent identity between amino acid or nucleotide sequences for putative
homologs
and the sequences for the genes or proteins encoded by them (e.g., nucleotide
sequences
for genes encoding Klotho and FGF or their complementary strands). Percent
identity
may be determined, for example, by visual inspection or by using various
computer
programs known in the art or as described herein. Sequence identity is
typically
measured using sequence analysis software (for example, Sequence Analysis
Software
Package of the Genetics Computer Group, University of Wisconsin Biotechnology
Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, BESTFIT, GAP, or
PILEUP/PRETTYBOX programs). Such software matches identical or similar
sequences
by assigning degrees of homology to various substitutions, deletions, and/or
other
modifications. Conservative amino acid substitutions typically include
substitutions
within the following groups:
glycine and alanine;
valine, isoleucine and leucine;
aspartic acid, glutamic acid, asparagine and glutamine;
serine and threonine;
lysine and arginine; and
phenylalanine and tyrosine.
Thus, mutating a glycine to alanine would be a conservative amino acid
substititon, as
would mutating an alanine to a glycine; mutating a valine to an isoleucine or
leucine
would be a conservative amino acid substation, as would replacing an
isoleucine with
valine or leucine, as would replacing leucine with valine or isoleucine, etc.
The
disclosure provides variants of all the amino acid sequences disclosed herein
with at least
one conservative amino acid substitution.
In an example approach to determining the degree of identity, a BLAST program
may be
used, with a probability score between e 3 and e10 indicating a closely
related sequence.
32
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
In one embodiment, the present disclosure provides a fusion polypeptide of SEQ
ID NO: 19.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 20.
In one embodiment, the present disclosure provides a fusion polypeptide of SEQ
ID NO: 40.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 41, or a variant thereof comprising at least one conservative amino
acid
substition.
In one embodiment, the present disclosure provides a fusion polypeptide of SEQ
ID NO: 46.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 47, or a variant thereof comprising at least one conservative amino
acid
substition.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 48.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 49, or a variant thereof comprising at least one conservative amino
acid
substition.
In one embodiment, the present disclosure provides a fusion polypeptide of SEQ
ID NO: 50.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 51, or a variant thereof comprising at least one conservative amino
acid
substition.
In one embodiment, the present disclosure provides a fusion polypeptide of SEQ
ID NO: 52.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 53, or a variant thereof comprising at least one conservative amino
acid
substition.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 54, or a variant thereof comprising at least one conservative amino
acid
substition.
33
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 55, or a variant thereof comprising at least one conservative amino
acid
substition.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 56, or a variant thereof comprising at least one conservative amino
acid
substition.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 57, or a variant thereof comprising at least one conservative amino
acid
substition.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 58, or a variant thereof comprising at least one conservative amino
acid
substition.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 59, or a variant thereof comprising at least one conservative amino
acid
substition.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 60, or a variant thereof comprising at least one conservative amino
acid
substition.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 61, or a variant thereof comprising at least one conservative amino
acid
substition.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 62, or a variant thereof comprising at least one conservative amino
acid
substition.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 63, or a variant thereof comprising at least one conservative amino
acid
substition.
34
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 64, or a variant thereof comprising at least one conservative amino
acid
substition.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 65, or a variant thereof comprising at least one conservative amino
acid
substition.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 66, or a variant thereof comprising at least one conservative amino
acid
substition.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 67, or a variant thereof comprising at least one conservative amino
acid
substition.
In another embodiment, the present disclosure provides a fusion polypeptide of
SEQ ID NO: 68, or a variant thereof comprising at least one conservative amino
acid
substition.
As used herein, the terms "homology" and "homologous" are not limited to
designate proteins having a theoretical common genetic ancestor, but includes
proteins
which may be genetically unrelated that have, nonetheless, evolved to perform
similar
functions and/or have similar structures. Functional homology to the various
proteins
described herein also encompasses proteins that have an activity of the
corresponding
protein of which it is a homolog. For proteins to have functional homology, it
is not
required that they have significant identity in their amino acid sequences,
but, rather,
proteins having functional homology are so defined by having similar or
identical
activities. For example, with respect to a Klotho molecule, the polypeptide
should have
the functional characteristics of binding to an FGF polypeptide and enable the
binding of
the FGF to an FGFR. With respect to an FGF molecule, the polypeptide should
have the
functional characteristics of binding to an FGFR and causing the activation of
FGFR
(e.g., phosphorylation). Assays for assessing FGF binding to the FGF receptor
and/or
activation of the FGF signaling pathway are known in the art and described
herein (See
Example 2). Assays for assessing Klotho activity are also known in the art and
described
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
herein (e.g., binding to a FGF polypeptide). Proteins with structural homology
are
defined as having analogous tertiary (or quaternary) structure and do not
necessarily
require amino acid identity or nucleic acid identity for the genes encoding
them. In
certain circumstances, structural homologs may include proteins which maintain
structural homology only at the active site or binding site of the protein.
In addition to structural and functional homology, the present disclosure
further
encompasses proteins having amino acid identity to the various Klotho and FGF
amino
acid sequences described herein. To determine the percent identity/homology of
two
amino acid sequences, the sequences are aligned for optimal comparison
purposes (e.g.,
gaps can be introduced in the amino acid sequence of one protein for optimal
alignment
with the amino acid sequence of another protein). The amino acid residues at
corresponding amino acid positions are then compared. When a position in one
sequence
is occupied by the same amino acid residue as the corresponding position in
the other,
then the molecules are identical at that position. The percent identity
between the two
sequences is a function of the number of identical positions shared by the
sequences (i.e.,
% identity= # of identical positions/total # of positions multiplied by 100).
The amino acid sequences of molecules of the disclosure described herein have
an
amino acid sequence which is at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%,
98%,
99% or more identical or homologous to an amino acid sequence described
herein.
The nucleic acid sequences of molecules of the disclosure described herein
have a
nucleotide sequence which hybridizes to or is at least about 60%, 70%, 80%,
90%, 95%,
96%, 97%, 98%, 99% or more identical or homologous to a nucleotide sequence
described herein.
Nucleic acid molecules appropriate for use in the fusion polypeptides of the
disclosure may have a Klotho or FGF nucleotide sequence which hybridizes under
stringent conditions to the complement of a nucleic acid molecule encoding
Klotho or
FGF, respectively. As used herein, the term "hybridizes under stringent
conditions" is
intended to describe conditions for hybridization and washing under which
nucleotide
sequences at least about 70%, 80%, 85%, 90% or more homologous to each other
typically remain hybridized to each other. Such stringent conditions are known
to those
skilled in the art and can be found in Ausubel et al. Current Protocols in
Molecular
Biology, Wiley Interscience, New York (2001), 6.3.1-6.3.6. A specific, non-
limiting
example of stringent hybridization conditions are hybridization in 6X sodium
36
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
chloride/sodium citrate (SSC) at about 45 C, followed by one or more washes in
0.2 X
SSC, 0.1% SDS at 50-65 C.
4.2. Klotho-FGF fusion polypeptides of the disclosure
In some embodiments of the disclosure, a Klotho fusion polypeptide has a
polypeptide chain having a first polypeptide sequence of a Klotho polypeptide
or an
active fragment thereof and a second polypeptide sequence encoding FGF or an
active
fragment thereof. In some embodiments, the fusion further comprises a modified
Fc
fragment having decreased affinity for Fc-gamma-receptor and/or increased
serum half-
life.
The disclosure includes fusion polypeptides which are at least about 95% or
more
homologous to an amino acid sequence presented in SEQ ID NO: 19-28. The amino
acid
sequence of SEQ ID NO: 19 encodes a Klotho fusion polypeptide having a Klotho
extracellular domain N-terminally linked to the FGF23 (R179Q) variant (SEQ ID
NO:
36). The amino acid sequence of SEQ ID NO: 20 encodes a Klotho fusion
polypeptide
having an IgG signal peptide N-terminally linked to a Klotho extracellular
domain
lacking a signal peptide N-terminally linked to the FGF23 (R179Q) variant. The
amino
acid sequence of SEQ ID NO: 21 encodes a Klotho fusion polypeptide having a KL-
D1
extracellular subdomain N-terminally linked to the FGF23 (R179Q) variant. The
amino
acid sequence of SEQ ID NO: 22 encodes a Klotho fusion polypeptide having a KL-
D2
extracellular subdomain N-terminally linked to the FGF23 (R179Q) variant. The
amino
acid sequence of SEQ ID NO: 23 encodes a Klotho fusion polypeptide having two
KL-D1
extracellular subdomains N-terminally linked to the FGF23 (R179Q) variant. The
amino
acid sequence of SEQ ID NO: 24 encodes a Klotho fusion polypeptide having two
KL-D2
extracellular subdomains N-terminally linked to the FGF23 (R179Q) variant. The
amino
acid sequence of SEQ ID NO: 25 encodes a Klotho fusion polypeptide having the
FGF23
(R179Q) variant N-terminally linked to a Klotho extracellular domain. The
amino acid
sequence of SEQ ID NO: 26 encodes a Klotho fusion polypeptide having the FGF23
(R179Q) variant N-terminally linked to a KL-D1 extracellular subdomain. The
amino
acid sequence of SEQ ID NO: 27 encodes a Klotho fusion polypeptide having the
FGF23
(R179Q) variant N-terminally linked to a KL-D2 extracellular subdomain. The
amino
acid sequence of SEQ ID NO: 28 encodes a Klotho fusion polypeptide having the
FGF23
(R179Q) variant N-terminally linked to two KL-D1 extracellular subdomains. The
amino
acid sequence of SEQ ID NO: 29 encodes a Klotho fusion polypeptide having the
FGF23
37
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
(R179Q) variant N-terminally linked to two KL-D2 extracellular subdomains. In
some
embodiments, the fusion further comprises a modified Fc fragment having
decreased
affinity for Fc-gamma-receptor and/or increased serum half-life.
The Klotho fusion polypeptide of the disclosure may include an amino acid
sequence which is at least about 95% identical to the amino acid sequence set
forth in
SEQ ID NO: 7. The amino acid sequence of SEQ ID NO: 7 encodes a Klotho
extracellular domain lacking a signal peptide. In some embodiments, the fusion
further
comprises a modified Fc fragment having decreased affinity for Fc-gamma-
receptor
and/or increased serum half-life.
The subject fusion proteins are described herein and can be made using methods
known in the art. For example, the fusion polypeptides of the disclosure may
be
constructed as described in U.S. No. Patent 6,194,177. The use of Klotho
polypeptides is
described in U.S. Patent No. 6,579,850. The use of FGF nucleic acid molecules
is
described in U.S. Patent No. 7,223,563.
In some embodiments, a nucleic acid molecule encoding the Klotho is cloned by
PCR and ligated, in frame, with a nucleic acid molecule encoding FGF. In some
embodiments, the fusion further comprises a modified Fc fragment having
decreased
affinity for Fc-gamma-receptor and/or increased serum half-life. The nucleic
acid
encoding the fusion polypeptide is operatively linked to a promoter to allow
for
expression. The nucleic acid molecule encoding the fusion polypeptide is
subsequently
transfected into a host cell for expression. The sequence of the final
construct can be
confirmed by sequencing.
When preparing the fusion proteins of the present disclosure, a nucleic acid
molecule encoding an extracellular subdomain of Klotho will be fused in frame
to the
nucleic acid molecule encoding FGF and the (optional) nucleic acid encoding
the
modified Fc fragment. Expression of the resulting nucleic acid molecule
results in the
extracellular subdomain of Klotho being fused N-terminal in relation to the
FGF
polypeptide. Fusions are also possible in which the extracellular subdomain of
Klotho is
fused C-terminal in relation to the FGF polypeptide. Methods for making fusion
proteins
are well known in the art.
The fusion polypeptides of the disclosure have at least two polypeptides that
are
covalently linked, in which one polypeptide comes from one protein sequence or
domain,
e.g., Klotho, and the other polypeptide comes from another protein sequence or
domain,
e.g., FGF. In some embodiments, the fusion further comprises a modified Fc
fragment
38
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
having decreased affinity for Fc-gamma-receptor and/or increased serum half-
life. In
another embodiment, the disclosure comprises a FGF fused to a modified Fc
fragment.
Klotho and/or FGF and/or the (optional) modified Fc fragment, of the fusion
polypeptides
of the disclosure, can be joined by methods well known to those of skill in
the art. These
methods include both chemical and recombinant means.
Nucleic acids encoding the domains to be incorporated into the fusion
polypeptides of the disclosure can be obtained using routine techniques in the
field of
recombinant genetics. Basic texts disclosing the general methods of use in
this disclosure
include Sambrook and Russell, Molecular Cloning, A Laboratory Manual (3rd ed.
2001);
Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and
Current
Protocols in Molecular Biology (Ausubel et al., eds., 1994-1999). In nucleic
acids
encoding a Klotho fusion polypeptide of the disclosure, the nucleic acid
sequence
encoding alpha-Klotho or beta-Klotho, represented by SEQ ID NO: 1 and SEQ ID
NO: 3,
respectively, may be used. In nucleic acids encoding a Klotho fusion
polypeptide, the
nucleic acid sequence encoding FGF19, FGF21, or FGF23, represented by SEQ ID
NO:
30, SEQ ID NO: 32 and SEQ ID NO: 34, respectively, may be used. Nucleic acid
sequences of molecules of the disclosure described herein comprise a
nucleotide sequence
which hybridizes to or is at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%,
98%,
99% or more identical or homologous to SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO:
30,
SEQ ID NO: 32, or SEQ ID NO: 34.
Nucleic acid sequences that encode the various components of the fusion
[Klotho,
and/or FGF peptide and/or the (optional) modified Fc fragment] can be obtained
using
any of a variety of methods. For example, the nucleic acid sequences encoding
the
polypeptides may be cloned from cDNA and genomic DNA libraries by
hybridization
with probes, or isolated using amplification techniques with oligonucleotide
primers.
More commonly, amplification techniques are used to amplify and isolate the
Klotho and
FGF sequences using a DNA or RNA template (see, e.g., Dieffenfach & Dveksler,
PCR
Primers: A Laboratory Manual (1995)). Alternatively, overlapping
oligonucleotides can
be produced synthetically and joined to produce one or more of the domains.
Nucleic
acids encoding Klotho or FGF can also be isolated from expression libraries
using
antibodies as probes.
According to the present disclosure, the various components of the fusion
[Klotho,
and/or, FGF and/or the (optional) modified Fc fragment] can be linked either
directly or
via a covalent linker, including amino acid linkers, such as a polyglycine
linker, or
39
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
another type of chemical linker, including, carbohydrate linkers, lipid
linkers, fatty acid
linkers, polyether linkers, such as PEG, etc. (See for example, Hermanson,
Bioconjugate
techniques (1996)). The polypeptides forming the fusion/fusion polypeptide are
typically
linked C-terminus to N-terminus, although they can also be linked C-terminus
to C-
terminus, N-terminus to N-terminus, or N-terminus to C-terminus. One or more
polypeptide domains may be inserted at an internal location within a fusion
polypeptide
of the disclosure. The polypeptides of the fusion protein can be in any order.
The fusion
polypeptides may be produced by covalently linking a chain of amino acids from
one
protein sequence, e.g., an extracellular subdomain of Klotho, to a chain of
amino acids
from another protein sequence, e.g., FGF, by preparing a recombinant
polynucleotide
contiguously encoding the fusion protein. The different chains of amino acids
in a fusion
protein may be directly spliced together or may be indirectly spliced together
via a
chemical linking group or an amino acid linking group. The amino acid linking
group
can be about 200 amino acids or more in length, or generally 1 to 100 amino
acids. In
some embodiments, proline residues are incorporated into the linker to prevent
the
formation of significant secondary structural elements by the linker. Linkers
can often be
flexible amino acid subsequences that are synthesized as part of a recombinant
fusion
protein. Such flexible linkers are known to persons of skill in the art.
According to the present disclosure, the amino acid sequences of the fusion
[an
extracellular subdomain of Klotho and/or the FGF and/or the (optional)
modified Fc
fragment] may be linked via a peptide linker. Example peptide linkers are well
known in
the art and described herein. For example, peptide linkers generally include
several Gly
and several Ser residues, such as: (G1y4 Ser)3 (SEQ ID NO: 11), G1y4 Ser
polypeptide
(SEQ ID NO: 12), Gly (SEQ ID NO: 13), Gly Gly (SEQ ID NO: 14), Gly Ser (SEQ ID
NO: 15), Gly2 Ser (SEQ ID NO: 16), Ala (SEQ ID NO: 17), and Ala Ala (SEQ ID
NO:
18). Specifically, a peptide linker for use in a fusion protein of the
disclosure may act as
a flexible hinge.
The signal sequence of Klotho or FGF may be excluded prior to incorporation of
Klotho into a fusion protein of the disclosure. The signal sequence for Klotho
or FGF of
the fusion protein may be included, e.g., the polypeptide represented by SEQ
ID NO: 19.
However, such sequences may also be omitted and replaced with the signal
sequence of a
different protein, e.g., the IgG signal sequence (SEQ ID NO: 9). Generally,
the
pharmaceutical compositions of the disclosure will contain the mature form of
Klotho and
FGF.
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
Generally, introns are excluded from either one or both the Klotho or the FGF
moieties prior to incorporation into a fusion polypeptide.
The fusion polypeptides of the disclosure may include one or more polymers
covalently attached to one or more reactive amino acid side chains. By way of
example,
not limitation, such polymers include polyethylene glycol (PEG), which can be
attached
to one or more free cysteine sulfhydryl residues, thereby blocking the
formation of
disulfide bonds and aggregation when the protein is exposed to oxidizing
conditions. In
addition, PEGylation of the fusion polypeptides of the disclosure is expected
to provide
such improved properties as increased half-life, solubility, and protease
resistance. The
fusion polypeptides of the disclosure may alternatively be modified by the
covalent
addition of polymers to free amino groups such as the lysine epsilon or the N-
terminal
amino group. Particular specific cysteines and lysines for covalent
modification will be
those not involved in receptor binding, heparin binding, or in proper protein
folding. It
will be apparent to one skilled in the art that the methods for assaying the
biochemical
and/or biological activity of the fusion polypeptides may be employed in order
to
determine if modification of a particular amino acid residue affects the
activity of the
protein as desired. Other similar suitable modifications are contemplated and
known in
the art.
The disclosure is also directed to the expression of a fusion polypeptide that
is at
least about 95% or more homologous to an amino acid sequence presented in SEQ
ID
NO: 19-28.
The present disclosure encompasses a fusion polypeptide comprising: (a) a
polypeptide comprising at least one extracellular subdomain of a Klotho
protein, or a
functionally active variant or derivative thereof, (b) a polypeptide
comprising a fibroblast
growth factor, or a functionally active variant or derivative thereof, and (c)
a modified Fc
fragment having decreased affinity for Fc-gamma-receptor and/or increased
serum half-
life. By "a functionally active variant or derivative thereof' is meant a
variant or
derivative comprising a longer, shorter or altered amino acid sequence than
the
corresponding wild-type polypeptide, while retaining the biological activity.
Thus "a
functionally active variant or derivative" of an extracellular subdomain of a
Klotho
protein or a fibroblast growth factor comprises fewer, more, or an altered
amino acid
sequence than a wild-type extracellular subdomain of a Klotho protein or a
fibroblast
growth factor, but still retains at least one biological activity of the wild-
type polypeptide
sequence. A functionally active variant or derivative of a polypeptide
disclosed herein
41
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
can also comprise the same amino acid sequence of a polypeptide disclosed
herein, but
vary in post-translational modification (e.g., pegylation, methylation and/or
glycosylation), or have additional moieties or elements added to it. In
various
embodiments, the variant or derivative of FGF23 comprises R179Q or does not.
In one embodiment, a functionally active variant or derivative polypeptide
includes an amino acid sequence at least about 60% identical to a sequence
disclosed
herein (e.g., at least one extracellular domain of a Klotho protein or a
fibroblast growth
factor). Preferably, the polypeptide is at least 55%, 60%, 65%, 70%, 75%, 80%,
85%,
90%, 95%, 98%, 99% or more identical to a sequence disclosed herein.
As used herein, percent identity of two amino acid sequences (or of two
nucleic
acid sequences) is determined using the algorithm of Karlin and Altschul (PNAS
USA
87:2264-2268, 1990), modified as in Karlin and Altschul, PNAS USA 90:5873-
5877,
1993). Such an algorithm is incorporated into the NBLAST and XBLAST programs
of
Altschul et al. (J. Mol. Biol. 215:403-410, 1990). BLAST nucleotide searches
are
performed with the NBLAST program, score=100, wordlength=12. BLAST protein
searches are performed with the XBLAST program, score=50, wordlength=3. To
obtain
gapped alignment for comparison purposes GappedBLAST is utilized as described
in
Altschul et al. (Nucleic Acids Res. 25:3389-3402, 1997). When utilizing BLAST
and
GappedBLAST programs the default parameters of the respective programs (e.g.,
XBLAST and NBLAST) are used to obtain nucleotide sequences homologous to a
nucleic acid molecule of the invention.
Identity or identical means amino acid sequence (or nucleic acid sequence)
similarity and has an art recognized meaning. Sequences with identity share
identical or
similar amino acids (or nucleic acids). Thus, a candidate sequence sharing 85%
amino
acid sequence identity with a reference sequence requires that, following
alignment of the
candidate sequence with the reference sequence, 85% of the amino acids in the
candidate
sequence are identical to the corresponding amino acids in the reference
sequence, and/or
constitute conservative amino acid changes.
Functionally active variants of a polypeptide disclosed herein retain
substantially
the same functional activity of the original polypeptide or fragment.
Naturally occurring
functionally active variants such as allelic variants and species variants and
non-naturally
42
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
occurring functionally active variants are included in the invention and can
be produced
by, for example, mutagenesis techniques or by direct synthesis.
A functionally active variant or derivative differs by about or at least, for
example,
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30,
35, 40, 45, 50, 55,
60 or more amino acid residues from a polypeptide disclosed herein. Where this
comparison requires alignment the sequences are aligned for maximum homology.
The
site of variation can occur anywhere in the polypeptide, as long as activity
substantially
similar to a polypeptide disclosed herein.
Guidance concerning how to make variants and derivatives with phenotypically
silent amino acid substitutions is provided in Bowie et al., Science, 247:1306-
1310
(1990), which teaches that there are two main strategies for studying the
tolerance of an
amino acid sequence to change.
The first strategy exploits the tolerance of amino acid substitutions by
natural
selection during the process of evolution. By comparing amino acid sequences
in different
species, the amino acid positions which have been conserved between species
can be
identified. See e.g., FIG. 5. These conserved amino acids are likely important
for protein
function. In contrast, the amino acid positions in which substitutions have
been tolerated
by natural selection indicate positions which are not critical for protein
function. Thus,
positions tolerating amino acid substitution can be modified while still
maintaining
specific binding activity of the polypeptide.
The second strategy uses genetic engineering to introduce amino acid changes
at
specific positions of a cloned gene to identify regions critical for protein
function. For
example, site-directed mutagenesis or alanine-scanning mutagenesis (the
introduction of
single alanine mutations at every residue in the molecule) can be used
(Cunningham et
al., Science, 244:1081-1085 (1989)).
Methods of introducing a mutation into amino acids of a protein is well known
to
those skilled in the art. See, e.g., Ausubel (ed.), Current Protocols in
Molecular Biology,
John Wiley and Sons, Inc. (1994); T. Maniatis, E. F. Fritsch and J. Sambrook,
Molecular
Cloning: A Laboratory Manual, Cold Spring Harbor laboratory, Cold Spring
Harbor,
N.Y. (1989)). Mutations can also be introduced using commercially available
kits such as
"QuikChange.TM. Site-Directed Mutagenesis Kit" (Stratagene). The generation of
a
43
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
polypeptide functionally active variant or derivative to a polypeptide by
replacing an
amino acid that does not influence the function of a polypeptide can be
accomplished by
one skilled in the art.
A variant or derivative can have, for example, one or more conservative
substitutions while still retaining at least one biological activity. A
conservative
substitution is one in which an amino acid is substituted for another amino
acid that has
similar properties, such that one skilled in the art of peptide chemistry
would expect the
secondary structure and hydropathic nature of the polypeptide to be
substantially
unchanged. In general, the following groups of amino acids represent
conservative
changes: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr,
thr; (3) val, ile, leu,
met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his.
Particular example variants and derivatives include, without limitation,
functionally active variants and derivatives of a polypeptide comprising at
least one
extracellular subdomain of a Klotho protein, e.g., a polypeptide comprising at
least about
100, 150, 200, 250, 300, 350, 375, 400, or 425 contiguous amino acids of an
extracellular
domain of Klotho (e.g., SEQ ID NO: 5 or 6), with no more than about 1, 2, 3,
4, 5, 6, 7, 8,
9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60
or more amino
acid residue differences from the wild-type sequence (as disclosed in SEQ ID
NO: 5 or
6), while retaining at least one biological activity of the wild-type
polypeptide. For
example, a functionally active variant or derivative of a polypeptide
comprising at least
one extracellular subdomain of a Klotho protein comprises a polypeptide
comprising at
least about 400 contiguous amino acids of SEQ ID NO: 5 or 6, with no more than
about
100 amino acid residue differences. For example, a functionally active variant
or
derivative of a polypeptide comprising at least one extracellular subdomain of
a Klotho
protein comprises a polypeptide comprising at least about 400 contiguous amino
acids of
SEQ ID NO: 5 or 6, with no more than about 50 amino acid residue differences.
For
example, a functionally active variant or derivative of a polypeptide
comprising at least
one extracellular subdomain of a Klotho protein comprises a polypeptide
comprising at
least about 425 contiguous amino acids of SEQ ID NO: 5 or 6, with no more than
about
25 amino acid residue differences. For example, a functionally active variant
or
derivative of a polypeptide comprising at least one extracellular subdomain of
a Klotho
protein comprises a polypeptide comprising at least about 425 contiguous amino
acids of
SEQ ID NO: 5 or 6, with no more than about 10 amino acid residue differences.
In
44
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
another example, a functionally active variant or derivative of a polypeptide
comprising at
least one extracellular subdomain of a Klotho protein comprises a polypeptide
comprising
at least about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650,
700, 750, 800,
850, 900, 925, 950 or 982 contiguous amino acids of SEQ ID NO: 7, with no more
than
about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,
25, 30, 35, 40, 45,
50, 55, 60, 70, 75, 80, 85, 90, 95, 100, 110, 120, 140, 150, 160, 170, 180,
190, or 200
amino acid residue differences from the wild-type sequence. For example, a
functionally
active variant or derivative of a polypeptide comprising at least one
extracellular
subdomain of a Klotho protein comprises a polypeptide comprising at least
about 500
contiguous amino acids of SEQ ID NO: 7, with no more than about 100 amino acid
residue differences. For example, a functionally active variant or derivative
of a
polypeptide comprising at least one extracellular subdomain of a Klotho
protein
comprises a polypeptide comprising at least about 600 contiguous amino acids
of SEQ ID
NO: 7, with no more than about 100 amino acid residue differences. For
example, a
functionally active variant or derivative of a polypeptide comprising at least
one
extracellular subdomain of a Klotho protein comprises a polypeptide comprising
at least
about 700 contiguous amino acids of SEQ ID NO: 7, with no more than about 100
amino
acid residue differences. For example, a functionally active variant or
derivative of a
polypeptide comprising at least one extracellular subdomain of a Klotho
protein
comprises a polypeptide comprising at least about 800 contiguous amino acids
of SEQ ID
NO: 7, with no more than about 100 amino acid residue differences. For
example, a
functionally active variant or derivative of a polypeptide comprising at least
one
extracellular subdomain of a Klotho protein comprises a polypeptide comprising
at least
about 900 contiguous amino acids of SEQ ID NO: 7, with no more than about 100
amino
acid residue differences. For example, a functionally active variant or
derivative of a
polypeptide comprising at least one extracellular subdomain of a Klotho
protein
comprises a polypeptide comprising at least about 900 contiguous amino acids
of SEQ ID
NO: 7, with no more than about 50 amino acid residue differences.
Particular example variants and derivatives include, without limitation,
functionally active variants and derivatives of a polypeptide comprising a
fibroblast
growth factor, e.g., a polypeptide comprising at least about 100, 125, 150,
150, 175, 200,
225, or 250 contiguous amino acids of a fibroblast growth factor, e.g., FGF19
(SEQ ID
NO: 31), FGF21 (SEQ ID NO: 33), or FGF23 (SEQ ID NO: 35), with no more than
about
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30,
35, 40, 45, 50, 55,
60 or more amino acid residue differences from the wild-type sequence (as
disclosed in
SEQ ID NOs: 31, 33 or 35), while retaining at least one biological activity of
the wild-
type polypeptide. In various embodiments, the variant or derivative can
comprise the
R179Q variation or not. For example, a functionally active variant or
derivative of a
polypeptide comprising a fibroblast growth factor comprises a polypeptide
comprising at
least about 150 contiguous amino acids of SEQ ID NOs: 31, 33 or 35, with no
more than
about 25 amino acid residue differences. For example, a functionally active
variant or
derivative of a polypeptide comprising a fibroblast growth factor comprises a
polypeptide
comprising at least about 175 contiguous amino acids of SEQ ID NOs: 31, 33 or
35, with
no more than about 25 amino acid residue differences. For example, a
functionally active
variant or derivative of a polypeptide comprising a fibroblast growth factor
comprises a
polypeptide comprising at least about 200 contiguous amino acids of SEQ ID
NOs: 31, 33
or 35, with no more than about 25 amino acid residue differences. For example,
a
functionally active variant or derivative of a polypeptide comprising a
fibroblast growth
factor comprises a polypeptide comprising at least about 225 contiguous amino
acids of
SEQ ID NO: 35, with no more than about 50 amino acid residue differences. For
example, a functionally active variant or derivative of a polypeptide
comprising a
fibroblast growth factor comprises a polypeptide comprising at least about 225
contiguous
amino acids of SEQ ID NO: 35, with no more than about 25 amino acid residue
differences.
4.3. Expression of fusion polypeptides of the disclosure
In order to express the fusion protein of the disclosure, DNA molecules
obtained
by any of the methods described herein or those that are known in the art, can
be inserted
into appropriate expression vectors by techniques well known in the art. For
example, a
double stranded cDNA can be cloned into a suitable vector by homopolymeric
tailing or
by restriction enzyme linking involving the use of synthetic DNA linkers or by
blunt-
ended ligation. DNA ligases are usually used to ligate the DNA molecules and
undesirable joining can be avoided by treatment with alkaline phosphatase.
Therefore, the disclosure includes vectors (e.g., recombinant plasmids and
bacteriophages) that include nucleic acid molecules (e.g., genes or
recombinant nucleic
acid molecules encoding genes) as described herein. The term "recombinant
vector"
46
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
includes a vector (e.g., plasmid, phage, phasmid, virus, cosmid, fosmid, or
other purified
nucleic acid vector) that has been altered, modified or engineered such that
it contains
greater, fewer or different nucleic acid sequences than those included in the
native or
natural nucleic acid molecule from which the recombinant vector was derived.
For
example, a recombinant vector may include a nucleotide sequence encoding a
Klotho-
FGF23 fusion operatively linked to regulatory sequences, e.g., promoter
sequences,
terminator sequences and/or artificial ribosome binding sites (RBSs), as
defined herein.
Recombinant vectors which allow for expression of the genes or nucleic acids
included in
them are referred to as "expression vectors."
For eukaryotic hosts, different transcriptional and translational regulatory
sequences may be employed, depending on the nature of the host. They may be
derived
from viral sources, such as adenovirus, bovine papilloma virus, Simian virus
or the like,
where the regulatory signals are associated with a particular gene which has a
high level
of expression. Examples include, but are not limited to, the TK promoter of
the Herpes
virus, the SV40 early promoter, the yeast gal4 gene promoter, etc.
Transcriptional
initiation regulatory signals may be selected which allow for repression or
activation, so
that expression of the genes can be modulated.
In some of the molecules of the disclosure described herein, one or more DNA
molecules having a nucleotide sequence encoding one or more polypeptide chains
of a
fusion polypeptide are operatively linked to one or more regulatory sequences,
which are
capable of integrating the desired DNA molecule into a host cell. Cells which
have been
stably transformed by the introduced DNA can be selected, for example, by
introducing
one or more markers which allow for selection of host cells which contain the
expression
vector. A selectable marker gene can either be linked directly to a nucleic
acid sequence
to be expressed, or be introduced into the same cell by co-transfection.
Additional
elements may also be needed for optimal synthesis of proteins described
herein. It would
be apparent to one of ordinary skill in the art which additional elements to
use.
Factors of importance in selecting a particular plasmid or viral vector
include, but
are not limited to, the ease with which recipient cells that contain the
vector are
recognized and selected from those recipient cells which do not contain the
vector; the
number of copies of the vector which are desired in a particular host; and
whether it is
desirable to be able to "shuttle" the vector between host cells of different
species.
Once the vector(s) is constructed to include a DNA sequence for expression, it
may be introduced into an appropriate host cell by one or more of a variety of
suitable
47
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
methods that are known in the art, including but not limited to, for example,
transformation, transfection, conjugation, protoplast fusion, electroporation,
calcium
phosphate-precipitation, direct micro injection, etc.
Host cells may either be prokaryotic or eukaryotic. Examples of eukaryotic
host
cells include, for example, mammalian cells, such as human, monkey, mouse, and
Chinese hamster ovary (CHO) cells. Such cells facilitate post-translational
modifications
of proteins, including, for example, correct folding or glycosylation.
Additionally, yeast
cells can also be used to express fusion polypeptides of the disclosure. Like
most
mammalian cells, yeast cells also enable post-translational modifications of
proteins,
including, for example, glycosylation. A number of recombinant DNA strategies
exist
which utilize strong promoter sequences and high copy number plasmids that can
be
utilized for production of proteins in yeast. Yeast transcription and
translation machinery
can recognize leader sequences on cloned mammalian gene products, thereby
enabling
the secretion of peptides bearing leader sequences (i.e., pre-peptides). A
particularmethod
of high-yield production of the fusion polypeptides of the disclosure is
through the use of
dihydrofolate reductase (DHFR) amplification in DHFR-deficient CHO cells, by
the use
of successively increasing levels of methotrexate as described in U.S. Patent
No.
4,889,803. The polypeptide obtained may be in a glycosylated form.
After the introduction of one or more vector(s), host cells are usually grown
in a
selective medium, which selects for the growth of vector-containing cells.
Purification of
the recombinant proteins can be carried out by any of the methods known in the
art or
described herein, for example, any conventional procedures involving
extraction,
precipitation, chromatography and electrophoresis. A further purification
procedure that
may be used for purifying proteins is affinity chromatography using monoclonal
antibodies which bind a target protein. Generally, crude preparations
containing a
recombinant protein are passed through a column on which a suitable monoclonal
antibody is immobilized. The protein usually binds to the column via the
specific
antibody while the impurities pass through. After washing the column, the
protein is
eluted from the gel by changing pH or ionic strength, for example.
4.4. Assays for assessing fusion polypeptide activity
Assays described herein (See Example 2) and those known in the art can be used
for detecting Klotho or FGF activity of the fusion polypeptides of the
disclosure. Suitable
activity assays include receptor binding assays, cellular proliferation assays
and cell
48
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
signaling assays. For example, a binding assay which may be used for
determining
whether a fusion polypeptide has Klotho or FGF activity includes, assaying the
binding of
a fusion polypeptide to an FGF receptor. FGF receptor binding assays include,
but are
not limited to, both competitive and non-competitive assay. For example, FGF
receptor
binding can be detected by contacting cells expressing an FGF receptor with a
labeled
FGF (for example, radio-active label) and increasing concentrations of an
unlabeled
Klotho-FGF fusion polypeptide. The two ligands that compete for binding to the
same
receptor are added to a reaction mixture containing the cell. The cells are
subsequently
washed and labeled FGF is measured. A decrease in the amount of the labeled
FGF to its
receptor in the presence of the unlabeled fusion polypeptide is indicative of
binding of the
Klotho-FGF fusion polypeptide to the receptor. Alternatively, the Klotho-FGF
fusion
polypeptide may be labeled and direct binding of the fusion polypeptide to the
cell is
detected.
Klotho or FGF activity can also be measured by determining whether the fusion
polypeptide induces a cellular response. For example, in some embodiments, an
assay for
detecting the biological activity of a Klotho-FGF fusion polypeptide involves
contacting
cells which express an FGF receptor with a fusion polypeptide, assaying a
cellular
response such as, for example, cell proliferation or Egr-1 activation, myotube
diameter in
C202 cells, and comparing the cellular response in the presence and absence of
the
fusion polypeptide. An increase in the cellular response in the presence of
the fusion
polypeptide complex relative to the absence indicates that the fusion
polypeptide has
biological activity. Also, an increase in a downstream signaling event from
the receptor
can also be measured as indicia of biological activity (e.g., phosphorylation
of FGFR,
FRS2, ERKl/2, p70S6K etc.).
4.5 Pharmaceutical compositions and methods of treatment
The disclosure also pertains to pharmaceutical compositions containing one or
more fusion polypeptides of the disclosure and a pharmaceutically acceptable
diluent or
carrier. The pharmaceutical compositions can further include a
pharmaceutically
effective dose of heparin. Such pharmaceutical compositions may be included in
a kit or
container. Such kit or container may be packaged with instructions pertaining
to the
extended in vivo half-life or the in vitro shelf life of the fusion
polypeptides. Optionally
associated with such kit or container(s) can be a notice in the form
prescribed by a
governmental agency regulating the manufacture, use or sale of pharmaceuticals
or
49
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
biological products, which notice reflects approval by the agency of
manufacture, use or
sale for human administration. Such compositions may be used in methods of
treating,
preventing, or ameliorating a disease or a disease symptom (e.g., age-related
condition or
metabolic disorder) in a patient, preferably a mammal and most preferably a
human, by
administering the pharmaceutical composition to the patient.
In general, a therapeutically effective amount of a pharmaceutical composition
of
the disclosure is from about 0.000 1 mg/kg to 0.00 1 mg/kg; 0.00 1 mg/kg to
about 10
mg/kg body weight or from about 0.02 mg/kg to about 5 mg/kg body weight.
Commonly,
a therapeutically effective amount of a fusion polypeptide is from about 0.001
mg to
about 0.01 mg, about 0.01 mg to about 100 mg, or from about 100 mg to about
1000 mg,
for example. Preferably, a therapeutically effective amount of a fusion
polypeptide is
from about 0.001 mg/kg to 2mg/kg.
The optimal pharmaceutical formulations for a fusion polypeptide can be
determined by one or ordinary skilled in the art depending upon the route of
administration and desired dosage. (See, for example, Remington's
Pharmaceutical
Sciences, 18th Ed. (1990), Mack Publishing Co., Easton, Pa., the entire
disclosure of
which is hereby incorporated by reference).
The fusion polypeptides of the disclosure may be administered as a
pharmaceutical composition that may be in the form of a solid, liquid or gas
(aerosol).
Typical routes of administration may include, without limitation, oral,
topical, parenteral,
sublingual, rectal, vaginal, intradermal and intranasal. Parenteral
administration includes
subcutaneous injections, intravenous, intramuscular, intraperitoneal,
intrapleural,
intrasternal injection or infusion techniques. Preferably, the compositions
are
administered parenterally. More preferably, the compositions are administered
intravenously. Pharmaceutical compositions of the disclosure can be formulated
so as to
allow a polypeptide of the disclosure to be bioavailable upon administration
of the
composition to a subject. Compositions can take the form of one or more dosage
units,
where, for example, a tablet can be a single dosage unit, and a container of a
polypeptide
of the disclosure in aerosol form can hold a plurality of dosage units.
Materials used in preparing the pharmaceutical compositions can be non-toxic
in
the amounts used. It will be evident to those of ordinary skill in the art
that the optimal
dosage of the active ingredient(s) in the pharmaceutical composition will
depend on a
variety of factors. Relevant factors include, without limitation, the type of
subject (e.g.,
human), the overall health of the subject, the type of age-related condition
or metabolic
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
disorder the subject in need of treatment of, the use of the composition as
part of a multi-
drug regimen, the particular form of the polypeptide of the disclosure, the
manner of
administration, and the composition employed.
The pharmaceutically acceptable carrier or vehicle may be particulate, so that
the
compositions are, for example, in tablet or powder form. The carrier(s) can be
liquid,
with the compositions being, for example, an oral syrup or injectable liquid.
In addition,
the carrier(s) can be gaseous, so as to provide an aerosol composition useful
in, e.g.,
inhalatory administration.
The term "carrier" refers to a diluent, adjuvant or excipient, with which a
polypeptide of the disclosure is administered. Such pharmaceutical carriers
can be
liquids, such as water and oils, including those of petroleum, animal,
vegetable or
synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and
the like. The
carriers can be saline, gum acacia, gelatin, starch paste, talc, keratin,
colloidal silica, urea,
and the like. In addition, auxiliary, stabilizing, thickening, lubricating and
coloring agents
can be used. In one embodiment, when administered to a subject, the
polypeptides of the
disclosure and pharmaceutically acceptable carriers are sterile. Water is a
particular
carrier when the polypeptide of the disclosure is administered intravenously.
Saline
solutions and aqueous dextrose and glycerol solutions can also be employed as
liquid
carriers, particularly for injectable solutions. Suitable pharmaceutical
carriers also
include excipients such as starch, glucose, lactose, sucrose, gelatin, malt,
rice, flour,
chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium
chloride, dried skim
milk, glycerol, propylene, glycol, water, ethanol and the like. The present
compositions,
if desired, can also contain minor amounts of wetting or emulsifying agents,
or pH
buffering agents.
The composition may be intended for oral administration, and if so, the
composition is preferably in solid or liquid form, where semi-solid, semi-
liquid,
suspension and gel forms are included within the forms considered herein as
either solid
or liquid.
As a solid composition for oral administration, the composition can be
formulated
into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer
or the like
form. Such a solid composition typically contains one or more inert diluents.
In addition,
one or more of the following can be present: binders such as ethyl cellulose,
carboxymethylcellulose, microcrystalline cellulose, or gelatin; excipients
such as starch,
lactose or dextrins, disintegrating agents such as alginic acid, sodium
alginate, Primogel,
51
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
corn starch and the like; lubricants such as magnesium stearate or Sterotex;
glidants such
as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin,
a flavoring
agent such as peppermint, methyl salicylate or orange flavoring, and a
coloring agent.
When the pharmaceutical composition is in the form of a capsule, e.g., a
gelatin
capsule, it can contain, in addition to materials of the above type, a liquid
carrier such as
polyethylene glycol, cyclodextrin or a fatty oil.
The pharmaceutical composition can be in the form of a liquid, e.g., an
elixir,
syrup, solution, emulsion or suspension. The liquid can be useful for oral
administration
or for delivery by injection. When intended for oral administration, a
composition can
contain one or more of a sweetening agent, preservatives, dye/colorant and
flavour
enhancer. In a composition for administration by injection, one or more of a
surfactant,
preservative, wetting agent, dispersing agent, suspending agent, buffer,
stabilizer and
isotonic agent can also be included.
The liquid compositions of the disclosure, whether they are solutions,
suspensions
or other like form, can also include one or more of the following: sterile
diluents such as
water for injection, saline solution, preferably physiological saline,
Ringer's solution,
isotonic sodium chloride, fixed oils such as synthetic mono or digylcerides
which can
serve as the solvent or suspending medium, polyethylene glycols, glycerin,
cyclodextrin,
propylene glycol or other solvents; antibacterial agents such as benzyl
alcohol or methyl
paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating
agents such as
ethylenediaminetetraacetic acid; buffers such as acetates, citrates or
phosphates and
agents for the adjustment of tonicity such as sodium chloride or dextrose. A
parenteral
composition can be enclosed in an ampoule, a disposable syringe or a multiple-
dose vial
made of glass, plastic or other material. Physiological saline is a particular
specific
adjuvant. An injectable composition is preferably sterile.
The pharmaceutical compositions contain an effective amount of a compound of
the disclosure (e.g., fusion polypeptide) such that a suitable dosage will be
obtained. The
pharmaceutical compositions may contain the known effective amount of the
compounds
as currently prescribed for their respective disorders.
The route of administration of the polypeptide of the disclosure used in the
prophylactic and/or therapeutic regimens which will be effective in the
prevention,
treatment, and/or management of a age-related condition or metabolic disorder
can be
based on the currently prescribed routes of administration for other
therapeutics known in
the art. The polypeptides of the disclosure can be administered by any
convenient route,
52
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
for example, by infusion or bolus injection, by absorption through epithelial
or
mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.).
Administration can be systemic or local. Various delivery systems are known,
e.g.,
microparticles, microcapsules, capsules, etc., and may be useful for
administering a
polypeptide of the disclosure. More than one polypeptides of the disclosure
may be
administered to a subject. Methods of administration may include, but are not
limited to,
oral administration and parenteral administration; parenteral administration
including, but
not limited to, intradermal, intramuscular, intraperitoneal, intravenous,
subcutaneous,
intranasal, epidural, sublingual, intranasal, intracerebral, intraventricular,
intrathecal,
intravaginal, transdermal, rectally, by inhalation, or topically to the ears,
nose, eyes, or
skin.
The polypeptides of the disclosure may be administered parenterally.
Specifically, the polypeptides of the disclosure may be administered
intravenously.
Pulmonary administration can also be employed, e.g., by use of an inhaler or
nebulizer, and formulation with an aerosolizing agent, or via perfusion in a
fluorocarbon
or synthetic pulmonary surfactant. The polypeptides of the disclosure can also
be
formulated as a suppository, with traditional binders and carriers such as
triglycerides.
The polypeptides of the disclosure can be delivered in a controlled release
system.
For example, a pump can be used (see Sefton, CRC Crit. Ref. Biomed. Eng. 1987,
14,
201; Buchwald et al., Surgery 1980, 88: 507; Saudek et al., N. Engl. J. Med.
1989, 321:
574). Polymeric materials can also be used for controlled release of the
polypeptides of
the disclosure (see Medical Applications of Controlled Release, Langer and
Wise (eds.),
CRC Pres., Boca Raton, FL, 1974; Controlled Drug Bioavailability, Drug Product
Design and Performance, Smolen and Ball (eds.), Wiley, New York, 1984; Ranger
and
Peppas, J. Macromol. Sci. Rev. Macromol. Chem. 1983, 23, 61; see also Levy et
al.,
Science 1985, 228, 190; During et al., Ann. Neurol., 1989, 25, 351; Howard et
al., J.
Neurosurg., 1989, 71, 105). Specifically, a controlled-release system can be
placed in
proximity of the target of the polypeptides of the disclosure, e.g., the
brain, thus requiring
only a fraction of the systemic dose (see, e.g., Goodson, in Medical
Applications of
Controlled Release, supra, vol. 2, 1984, pp. 115-138). Other controlled-
release systems
discussed in the review by Langer (Science 1990, 249, 1527-1533) can be used.
Polymeric materials used to achieve controlled or sustained release of the
polypeptides of the disclosure are disclosed, e.g., in U.S. Patent No.
5,679,377; U.S.
Patent No. 5,916,597; U.S. Patent No. 5,912,015; U.S. Patent No. 5,989,463;
U.S. Patent
53
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
No. 5,128,326; PCT Publication No. WO 99/15154; and PCT Publication No. WO
99/20253. Examples of polymers used in sustained release formulations include,
but are
not limited to, poly(2-hydroxy ethyl methacrylate), poly(methyl methacrylate),
poly(acrylic acid), poly(ethylene-co-vinyl acetate), poly(methacrylic acid),
polyglycolides
(PLG), polyanhydrides, poly(N-vinyl pyrrolidone), poly(vinyl alcohol),
polyacrylamide,
poly(ethylene glycol), polylactides (PLA), poly(lactide-co-glycolides) (PLGA),
and
polyorthoesters. Preferably, the polymer used in a sustained release
formulation is inert,
free of leachable impurities, stable on storage, sterile, and biodegradable.
In general, a therapeutically effective amount of a pharmaceutical composition
of
the disclosure is from about 0.000 1 mg/kg to 0.00 1 mg/kg; 0.00 1 mg/kg to
about 10
mg/kg body weight or from about 0.02 mg/kg to about 5 mg/kg body weight.
In other embodiments, the prophylactic and/or therapeutic regimen involves
administering to a patient one or more doses of an effective amount of a
polypeptide of
the disclosure, wherein the dose of an effective amount achieves a plasma
level of at least
0.01 ug/mL to at least 400,ug/mL of the polypeptide of the disclosure.
A prophylactic and/or therapeutic regimen may involve administering to a
patient
a plurality of doses of an effective amount of a polypeptide of the
disclosure, wherein the
plurality of doses maintains a plasma level of at least 0.01 ,ug/mL, to
400,ug/mL of the
polypeptide of the disclosure. The prophylactic and/or therapeutic regimen may
be
administered for at least 1 day, 1 month, 2 months, 3 months, 4 months, 5
months, 6
months, 7 months, 8 months or 9 months.
The prophylactic and/or therapeutic regimen may involve administration of a
polypeptide of the disclosure in combination with one or more additional
therapeutics.
The recommended dosages of the one or more therapeutics currently used for the
prevention, treatment, and/or management of an age-related condition or
metabolic
disorder can be obtained from any reference in the art including, but not
limited to,
Hardman et at., eds., Goodman & Gilman's The Pharmacological Basis Of Basis Of
Therapeutics, 10th ed., McGraw-Hill, New York, 2001; Physician's Desk
Reference (60th
ed., 2006), which is incorporated herein by reference in its entirety.
The disclosure includes methods of treating disorders wherein agonistic
activity of Klotho
protein and FGF are desirable. The disclosure furthermore includes the use of
the
disclosed proteins, fusion proteins, nucleic acid molecules or pharmaceutical
composition
in therapy or as medicament for the treatment of a pathological disorder
wherein agonistic
54
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
activity of Klotho protein and FGF are desirable. Examples of such methods or
uses of
the disclosure include, but are not limited to age-related condition or
metabolic disorders.
The disclosure includes methods for treating or preventing an age-related
condition in an individual; and the use of the disclosed proteins, fusion
proteins, nucleic
acid molecules or pharmaceutical composition in therapy or as medicament for
treating or
preventing an age-related condition in an individual. An individual in need of
treatment
is administered a pharmacologically effective dose of a pharmaceutical
composition
containing a Klotho fusion polypeptide, having at least one extracellular
subdomain of a
Klotho protein and a fibroblast growth factor and an (optional) modified Fc
fragment, so
as to treat or prevent the age-related condition. In some embodiments, the
Klotho fusion
polypeptide is co-administered with a pharmacologically effective dose of
heparin. Age-
related conditions include sarcopenia, skin atrophy, muscle wasting, brain
atrophy,
atherosclerosis, arteriosclerosis, pulmonary emphysema, osteoporosis,
osteoarthritis,
immunologic incompetence, high blood pressure, dementia, Huntington's disease,
Alzheimer's disease, cataracts, age-related macular degeneration, prostate
cancer, stroke,
diminished life expectancy, memory loss, wrinkles, impaired kidney function,
and age-
related hearing loss. In some embodiments, the Klotho fusion polypeptide
contains at
least one extracellular domain of an alpha Klotho protein. In a particular
embodiment, a
Klotho fusion protein containing at least one extracellular domain of alpha
Klotho protein
and fibroblast growth factor 23 is administered to an individual in need of
treatment for
muscle wasting.
The disclosure is also directed to a method for treating or preventing a
metabolic
disorder in an individual; and to the use of the disclosed proteins, fusion
proteins, nucleic
acid molecules or pharmaceutical composition in therapy or as medicament for
treating or
preventing metabolic disorder in an individual. An individual in need of
treatment is
administered a pharmacologically effective dose of a pharmaceutical
composition
containing a Klotho fusion polypeptide, having at least one extracellular
subdomain of a
Klotho protein and a fibroblast growth factor so as to treat the metabolic
disorder, and an
(optional) modified Fc fragment having decreased binding to FcRn and/or
increased
serum half-life and/or stability. In some embodiments, the Klotho fusion
polypeptide is
co-administered with a pharmacologically effective dose of heparin. The method
may be
used in the treatment or prevention of Type II Diabetes, Metabolic Syndrome,
hyperglycemia, and obesity. In a particular embodiment, a Klotho fusion
protein
containing at least one extracellular domain of a beta-Klotho protein and
fibroblast
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
growth factor 21 is administered to an individual in need of treatment for a
metabolic
disorder.
The disclosure also provides methods for treating or preventing
hyperphosphatemia or calcinosis in an individual; and the use of the disclosed
proteins,
fusion proteins, nucleic acid molecules or pharmaceutical composition in
therapy or as
medicament for treating or preventing hyperphosphatemia or calcinosis in an
individual.
An individual in need of treatment is administered a pharmacologically
effective dose of a
pharmaceutical composition containing a Klotho fusion polypeptide, having at
least one
extracellular subdomain of a Klotho protein, a fibroblast growth factor and an
(optional)
modified Fc fragment so as to treat hyperphosphatemia or calcinosis. In some
embodiments, the Klotho fusion polypeptide is co-administered with a
pharmacologically
effective dose of heparin. In a particular embodiment, a Klotho fusion protein
containing
at least one extracellular domain of an alpha Klotho protein and fibroblast
growth factor
23 and an (optional) modified Fc fragment is administered to an individual in
need of
treatment for a hyperphosphatemia or calcinosis.
The disclosure is also directed to a method for treating or preventing chronic
renal
disease or chronic renal failure in an individual; and to the use of the
disclosed proteins,
fusion proteins, nucleic acid molecules or pharmaceutical composition in
therapy or as
medicament for treating or preventing chronic renal disease or chronic renal
failure in an
individual. An individual in need of treatment is administered a
pharmacologically
effective dose of a pharmaceutical composition containing a Klotho fusion
polypeptide,
having at least one extracellular subdomain of a Klotho protein, a fibroblast
growth factor
and an (optional) modified Fc fragment so as to treat chronic renal disease or
chronic
renal failure. In some embodiments, the Klotho fusion polypeptide is co-
administered
with a pharmacologically effective dose of heparin. In some embodiments, a
Klotho
fusion protein containing at least one extracellular domain of an alpha Klotho
protein is
administered to an individual in need of treatment for chronic renal disease
or chronic
renal failure.
The disclosure also includes methods for treating or preventing cancer in an
individual; and the use of the disclosed proteins, fusion proteins, nucleic
acid molecules
or pharmaceutical composition in therapy or as medicament for treating or
preventing
cancer in an individual. An individual in need of treatment is administered a
pharmacologically effective dose of a pharmaceutical composition containing a
Klotho
fusion polypeptide, having at least one extracellular subdomain of a Klotho
protein, a
56
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
fibroblast growth factor and an (optional) modified Fc fragment so as to treat
cancer. The
method may be used in the treatment or prevention of breast cancer. In some
embodiments, the Klotho fusion polypeptide is co-administered with a
pharmacologically
effective dose of heparin. In some embodiments, a Klotho fusion protein
containing at
least one extracellular domain of an alpha Klotho protein is administered to
an individual
in need of treatment for cancer.
In methods of treating disorders by administering a pharmaceutical composition
containing a Klotho fusion polypeptide; or when using pharmaceutical
composition
containing a Klotho fusion polypeptide in therapy, the Klotho fusion
polypeptide and an
(optional) modified Fc fragment has at least one extracellular subdomain of a
Klotho
protein and a fibroblast growth factor. In a particular embodiment, the Klotho
fusion
protein contains at least one extracellular domain of a beta Klotho protein
and fibroblast
growth factor 21.
In another embodiment, the fusion comprises a FGF (e.g., FGF19, FGF21, FGF23
or FGF23 variant) and a modified Fc fragment with decreased binding to FcRn
and/or
increased serum stability. This type of fusion can be used in various
diseases, as
described above, or used to treat or prevent any FGF-related disease known in
the art.
The fusion can be administered to an individual in need thereof.
The fusion polypeptide compositions can be administered according to any
method of administration known to those of skill in the art and described
herein.
Particular specific methods of administration include subcutaneous or
intravenous. Other
effective modes of administration are described herein.
4.6. Methods of Treatment and Assays for Assessing Efficacy
Methods or uses of the disclosure which provide administering the fusion
polypeptides described herein to an individual can be used to treat a variety
of disorders
including an age-related disorder or a metabolic disorder. Without being
limited by any
particular theory, fusion polypeptides may be used to treat disorders in which
there is
dysregulation of Klotho or FGF. Example disorders include metabolic disorders
and age-
related disorders. For example, both FGF23 or Klotho knock-out mice display a
variety
of similar phenotypes including, low physical activity, growth retardation,
muscle
wasting, skin atrophy, atherosclerosis, short life spans, etc. (See Razzaque
and Lanske, J.
of Endrocrinology, 194:1-10 (2007), which is herein incorporated by
reference).
57
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
In particular, fusion polypeptides of the disclosure are particularly useful
in the
treatment of aging-related disorders, including muscle wasting. Without being
bound to
theory, the ability of Klotho and FGF23 to control mineral (e.g., phosphate
and calcium)
and vitamin D homeostasis may be the means by which these proteins modulate
aging
and muscle atrophy.
On the other hand, fusion polypeptides of the disclosure may be used for
treating a
metabolic disorder. For example, beta-Klotho and FGF19 have been shown to
control
bile acid homeostasis by regulating cholesterol 7-a-hydroxylase (CYP7A1). A
non-
limiting example of bile homeostasis disorder is cholestasis. The beta-Klotho
and FGF21
have been shown to induce lipolysis in adipocytes and, therefore, reduced fat
storage and
increased glucose uptake. Non-limiting examples of lipolysis/fat storage
disorders are
obesity and associated metabolic and cardiovascular diseases.
Based at least in part on the finding that FGF23 is able to stimulate
excretion of
phosphate in the urine and thereby reduce phosphate levels in the serum,
Klotho-FGF23
fusion polypeptides of the disclosure can be used for treating or preventing
hyperphosphatemia or calcinosis in an individual. For example, it has been
shown that a
homozygous missense mutation in Klotho resulting in a deficiency in Klotho in
a patient
can cause severe tumoral calcinosis and artery calcification (Ichikawa et al.,
J. Clin.
Invest. 117:2684-2691 (2007), which is herein incorporated by reference). An
individual
is administered a pharmacologically effective dose of a pharmaceutical
composition
containing the Klotho fusion polypeptide, having at least one extracellular
subdomain of a
Klotho protein, a fibroblast growth factor and an (optional) modified Fc
fragment so as to
treat or prevent hyperphosphatemia or calcinosis. In particular, a Klotho
fusion
polypeptide containing at least one extracellular domain of an alpha Klotho
protein, a
fibroblast growth factor and an (optional) modified Fc fragment is useful for
treating
hyperphosphatemia or calcinosis.
Klotho fusion polypeptides of the disclosure can also be used for treating or
preventing chronic renal disease or chronic renal failure in an individual.
For example, it
has been shown that Klotho expression is reduced in kidney of patients with
chronic renal
failure, compared to that in unaffected kidneys (Koh et al., Biochem. Biophys.
Res.
Comm. 280:1015-1020 (2001), which is herein incorporated by reference). An
individual
is administered a pharmacologically effective dose of a pharmaceutical
composition
containing the Klotho fusion polypeptide, having at least one extracellular
subdomain of a
Klotho protein, a fibroblast growth factor and an (optional) modified Fc
fragment so as to
58
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
treat or prevent chronic renal disease or chronic renal failure. In
particular, a Klotho
fusion polypeptide containing at least one extracellular domain of an alpha
Klotho protein
is useful for treating chronic renal disease or chronic renal failure.
Klotho fusion polypeptides of the disclosure can also be used for treating or
preventing cancer in an individual. For example, it has been shown that Klotho
expression is reduced in breast cancer tissue, compared to normal breast
cancer tissue
(Wolf et al., Oncogene (2008) advance online publication, which is herein
incorporated
by reference). An individual is administered a pharmacologically effective
dose of a
pharmaceutical composition containing the Klotho fusion polypeptide, having at
least one
extracellular subdomain of a Klotho protein, a fibroblast growth factor and an
(optional)
modified Fc fragment so as to treat or prevent cancer or breast cancer. In
particular, a
Klotho fusion protein containing at least one extracellular domain of an alpha
Klotho
protein is useful for treating cancer or breast cancer.
Methods for evaluating the efficacy and/or determining the effective dose of a
Klotho fusion polypeptide of the disclosure on an age-related disorder or
metabolic
disorder include organismal based assays, e.g., using a mammal (e.g., a mouse,
rat,
primate, or some other non-human), or other animal (e.g., Xenopus, zebrafish,
or an
invertebrate such as a fly or nematode). The Klotho fusion polypeptide can be
administered to the organism once or as a regimen (regular or irregular). A
parameter of
the organism is then evaluated, e.g., an age-associated parameter. Klotho
fusion
polypeptides that are of interest result in a change in the parameter relative
to a reference,
e.g., a parameter of a control organism. Other parameters (e.g., related to
toxicity,
clearance, and pharmacokinetics) can also be evaluated.
The Klotho fusion polypeptide of the disclosure may be evaluated using an
animal
that has a particular disorder, e.g., a disorder described herein, e.g., an
age-related
disorder, a metabolic disorder. These disorders can also provide a sensitized
system in
which the test polypeptide's effects on physiology can be observed. Example
disorders
include: denervation, disuse atrophy; metabolic disorders (e.g., disorder of
obese and/or
diabetic animals such as db/db mouse and ob/ob mouse); cerebral, liver
ischemia;
cisplatin/taxol/vincristine models; various tissue (xenograph) transplants;
transgenic bone
models; pain syndromes (include inflammatory and neuropathic disorders);
Paraquat,
genotoxic, and oxidative stress models; and tumor I models.
For measuring an age-related disorder, the animal model can be an animal that
has
an altered phenotype when calorically restricted. For example, F344 rats
provide a useful
59
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
assay system for evaluating a Klotho fusion polypeptide. When calorically
restricted,
F344 rats have a 0 to 10% incidence of nephropathy. However, when fed ad
libitum, they
have a 60 to 100% incidence of nephropathy.
To evaluate a Klotho fusion polypeptide of the disclosure, it is administered
to the
animal (e.g., an F344 rat or other suitable animal) and a parameter of the
animal is
evaluated, e.g., after a period of time. The animal can be fed ad libitum or
normally (e.g.,
not under caloric restriction, although some parameters can be evaluated under
such
conditions). Typically, a cohort of such animals is used for the assay.
Generally, a test
polypeptide can be indicated as favorably altering lifespan regulation in the
animal if the
test polypeptide affects the parameter in the direction of the phenotype of a
similar animal
subject to caloric restriction. Such test polypeptides may cause at least some
of the
lifespan regulatory effects of caloric restriction, e.g., a subset of such
effects, without
having to deprive the organism of caloric intake.
The parameter to be tested may be an age-associated or disease associated
parameter, e.g., a symptom of the disorder associated with the animal model.
For
example, the test polypeptide can be administered to a SH Rat, and blood
pressure is
monitored. A test polypeptide that is favorably indicated can cause an
amelioration of the
symptom relative to a similar reference animal not treated with the
polypeptide. Other
parameters relevant to a disorder or to aging can include: antioxidant levels
(e.g..
antioxidant enzyme levels or activity), stress resistance (e.g., paraquat
resistance), core
body temperature, glucose levels, insulin levels, thyroid-stimulating hormone
levels,
prolactin levels, and leutinizing hormone levels.
To measure the effectiveness of the polypeptides of the disclosure for
treating an
age-related disorder, an animal having decreased Klotho expression may be
used, e.g.,
mouse with a mutant Klotho; See Kuroo, et al. Nature, 390; 45 (1997) and U.S.
Pub. No.
2003/0119910, both of which are herein incorporated by reference in their
entirety. For
example, the test polypeptide is administered to the mutant mouse and age-
related
parameters are monitored. A test polypeptide that is favorably indicated can
cause an
amelioration of the symptom relative to a similar reference animal not treated
with the
polypeptide. A parameter relevant to a metabolic disorder or to aging can be
assessed by
measurement of body weight, examination on the acquisition of reproductive
ability,
measurement of blood sugar level, observation of life span, observation of
skin,
observation of motor functions such as walking, and the like. The assessment
can also be
made by measurement of thymus weight, observation of the size of calcified
nodules
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
formed on the inner surface of thoracic cavity, and the like. Further,
quantitative
determination of mRNA for the Klotho gene or Klotho protein is also useful for
the
assessment.
Still other in vivo models and organismal assays include evaluating an animal
for
a metabolic parameter, e.g., a parameter relevant to an insulin disorder, type
II diabetes.
Example metabolic parameters include: glucose concentration, insulin
concentration, and
insulin sensitivity.
Another example system features tumors, e.g., in an animal model. The tumors
can be spontaneous or induced. For example, the tumors can be developed from
cells that
have a variety of genetic constitutions, e.g., they can be p53+ or p53-. It is
also possible to
use organisms that an autoimmune disorder, e.g., an NZB mouse, which is
predisposed to
SLE. To evaluate features of bone disease, it is possible, for example, to use
an animal
that has an ovariectomy as a model,. e.g., for osteoporosis. Similarly, for
joint disease, the
model can be based on adjuvant arthritis (e.g., mice can be immunized with
cartilage
proteoglycans, high mobility group proteins, streptococcal cell wall material,
or
collagens); for kidney disease, kd/kd mice can be used. Animal models of
cognition,
particularly learning and memory are also available. Animal models of diabetes
and its
complications are also available, e.g., the streptozotocin model. Canine
models can be
used, for example, for evaluating stroke and ischemia.
In assessing whether a test polypeptide is capable of altering life span
regulation, a
number of age-associated parameters or biomarkers can be monitored or
evaluated.
Example age associated parameters include: (i) lifespan of the cell or the
organism; (ii)
presence or abundance of a gene transcript or gene product in the cell or
organism that
has a biological age dependent expression pattern; (iii) resistance of the
cell or organism
to stress; (iv) one so or more metabolic parameters of the cell or organism
(example
parameters include circulating insulin levels, blood glucose levels; fat
content; core body
temperature and so forth); (v) proliferative capacity of the cell or a set of
cells present in
the organism; and (vi) physical appearance or behavior of the cell or
organism.
The term "average lifespan" refers to the average of the age of death of a
cohort of
organisms. In some cases, the "average lifespan" is assessed using a cohort of
genetically
identical organisms under controlled environmental conditions. Deaths due to
mishap are
discarded. Where average lifespan cannot be determined (e.g., for humans)
under
controlled environmental conditions, reliable statistical information (e.g.,
from actuarial
tables) for a sufficiently large population can be used as the average
lifespan.
61
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
Characterization of molecular differences between two such organisms, e.g.,
one
reference organism and one organism treated with a Klotho fusion polypeptide
can reveal
a difference in the physiological state of the organisms. The reference
organism and the
treated organism are typically the same chronological age. The term
"chronological age"
as used herein refers to time elapsed since a preselected event, such as
conception, a
defined embryological or fetal stage, or, more preferably, birth. A variety of
criteria can
be used to determine whether organisms are of the "same" chronological age for
the
comparative analysis. Typically, the degree of accuracy required is a function
of the
average lifespan of a wildtype organism. For example, for the nematode C.
elegans, for
which the laboratory wildtype strain N2 lives an to average of about 16 days
under some
controlled conditions, organisms of the same age may have lived for the same
number of
days. For mice, organism of the same age may have lived for the same number of
weeks
or months; for primates or humans, the same number of years (or within 2, 3,
or 5 years);
and so forth. Generally, organisms of the same chronological age may have
lived for an
amount of time within 15, 10, 5, 3, 2 or I% of the average lifespan of a
wildtype
organism of that species. Preferably, the organisms are adult organisms, e.g.,
the
organisms have lived for at least an amount of time in which the average
wildtype
organism has matured to an age at which it is competent to reproduce.
The organismal screening assay can be performed before the organisms exhibit
overt physical features of aging. For example, the organisms may be adults
that have
lived only 10, 30, 40, 50, 60, or 70% of the average lifespan of a wildtype
organism of the
same species. Age-associated changes in metabolism, immune competence, and
chromosomal structure have been reported. Any of these changes can be
evaluated, either
in a test subject (e.g., for an organism based assay), or for a patient (e.g.,
prior, during or
after treatment with a therapeutic described herein.
A marker associated with caloric restriction can also be evaluated in a
subject
organism of a screening assay (or a treated subject). Although these markers
may not be
age-associated, they may be indicative of a physiological state that is
altered when the
Klotho pathway is modulated. The marker can be an mRNA or protein whose
abundance
changes in calorically restricted animals. WOO 1/12851 and U.S. Patent No.
6,406, 853
describe example markers. Cellular models derived from cells of an animal
described
herein or analogous to an animal model described herein can be used for a cell-
based
assay.
62
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
Models for evaluating the effect of a test polypeptide on muscle atrophy
include:
1) rat medial gastrocnemius muscle mass loss resulting from denervation, e.g.,
by
severing the right sciatic nerve at mid-thigh; 2) rat medial gastrocnemius
muscle mass
loss resulting from immobilization, e.g., by fixed the right ankle joint at 90
degrees of
flexion; 3) rat medial gastrocnemius muscle mass loss resulting from hind limb
suspension; (see, e.g., U.S. 2003-0129686); 4) skeletal muscle atrophy
resulting from
treatment with the cachectic cytokine, interleukin-1 (IL-1) (R. N. Cooney, S.
R. Kimball,
T. C. Vary, Shock 7, 1-16 (1997)); and 5) skeletal muscle atrophy resulting
from
treatment with the glucocorticoid, dexamethasone (A. L. Goldberg, J. Biol.
Chem. 244,
3223-9 (1969).)
Example animal models for AMD include: laser-induced mouse model simulating
exudative (wet) macular degeneration Bora et at., Proc. Natl. Acad. Sci. U S
A.,
100:2679-84 (2003); a transgenic mouse expressing a mutated form of cathepsin
D
resulting in features associated with the "geographic atrophy" form of AMD
(Rakoczy et
at., Am. J. Pathol., 161:1515-24 (2002)); and a transgenic mouse over
expressing VEGF
in the retinal pigment epithelium resulting in CNV. Schwesinger et at., Am. J.
Pathol.
158:1161-72 (2001).
Example animal models of Parkinson's disease include primates rendered
Parkinsonian by treatment with the dopaminergic neurotoxin 1-methyl-4 phenyl
1,2,3,6-
tetrahydropyridine (MPTP) (see, e.g., U.S. Patent Publication No. 20030055231
and
Wichmann et at., Ann. N. Y. Acad. Sci., 991:199-213 (2003); 6-hydroxydopamine-
lesioned
rats (e.g., Lab. Anim. Sci.,49:363-71 (1999)) ; and transgenic invertebrate
models (e.g.,
Lakso et at., J. Neurochem. 86:165-72 (2003) and Link, Mech. Ageing Dev.,
122:1639-49
(2001)).
Example molecular models of Type II diabetes include: a transgenic mouse
having
defective Nkx-2.2 or Nkx-6.1; (U.S. Patent No. 6,127,598); Zucker Diabetic
Fatty fa/fa
(ZDF) rat. (U.S. Patent No. 6,569,832); and Rhesus monkeys, which
spontaneously
develop obesity and subsequently frequently progress to overt type 2 diabetes
(Hotta et
at., Diabetes, 50:1126-33 (2001); and a transgenic mouse with a dominant-
negative IGF-I
receptor (KR-IGF-IR) having Type 2 diabetes-like insulin resistance.
Example animal and cellular models for neuropathy include: vincristine induced
sensory-motor neuropathy in mice (U.S. Patent No. 5,420,112) or rabbits (Ogawa
et at.,
Neurotoxicology, 21:501-11 (2000)); a streptozotocin (STZ)-diabetic rat for
study of
63
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
autonomic neuropathy (Schmidt et at., Am. J. Pathol., 163:21-8 (2003)); and a
progressive motor neuropathy (pmn) mouse (Martin et at., Genomics, 75:9-16
(2001)).
Example animal models of hyperphosphatemia or tumoral calcinosis include
Klotho knockout mice and FGF23 knockout mice (Yoshida et al., Endocrinology
143:683-689 (2002)).
Example animal models of chronic renal disease or chronic renal failure
include
COL4A3+/-mice (Beirowski et al., J. Am. Soc. Nephrol. 17:1986-1994 (2006)).
Example animal models of cancer include the transplantation or implantation of
cancer cells or tissue into nude mice, as is known in the art (Giovanella et
al., Adv.
Cancer Res. 44:69-120 (1985)). For example, animal models of breast cancer
include
nude mice transplanted or implanted with breast cancer cells or tissue (e.g.,
Yue et al.,
Cancer Res. 54:5092-5095 (1994); Glinsky et al., Cancer Res. 56:5319-5324
(1996);
Visonneau Am. J. Path. 152:1299-1311 (1998)).
The compositions can be administered to a subject, e.g., an adult subject,
particularly a healthy adult subject or a subject having an age-related
disease. In the latter
case, the method can include evaluating a subject, e.g., to characterize a
symptom of an
age-related disease or other disease marker, and thereby identifying a subject
as having a
neurodegenerative disease, e.g., Alzheimer's or an age-related disease or
being pre-
disposed to such a disease.
Skeletal Muscle Atrophy
Methods or uses of the disclosure which provide administering the Klotho
fusion
polypeptide to an individual can be used to treat skeletal muscle atrophy.
Muscle atrophy
includes numerous neuromuscular, metabolic, immunological and neurological
disorders
and diseases as well as starvation, nutritional deficiency, metabolic stress,
diabetes, aging,
muscular dystrophy, or myopathy. Muscle atrophy occurs during the aging
process.
Muscle atrophy also results from reduced use or disuse of the muscle. Symptoms
include
a decline in skeletal muscle tissue mass. In human males, muscle mass declines
by one-
third between the ages of 50 and 80. Some molecular features of muscle atrophy
include
the upregulation of ubiquitin ligases, and the loss of myofibrillar proteins
(Furuno et al.,
J. Biol. Chem., 265:8550-8557, 1990). The breakdown of these proteins can be
followed,
e.g., by measuring 3-methyl-histidine production, which is a specific
constituent of actin,
and in certain muscles of myosin (Goodman, Biochem. J. 241:121-12, 1987 and
Lowell,
et al., Metabolism, 35:1121-112, 1986; Stein and Schluter, Am. J. Physiol.
Endocrinol.
64
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
Metab. 272: E688-E696, 1997). Release of creatine kinase (a cell damage
marker)
(Jackson, et al., Neurology, 41: 101 104, 1991) can also be indicative.
Non-insulin-dependent Diabetes
Methods or uses of the disclosure which provide administering the Klotho
fusion
polypeptide to an individual can be used to treat Non-insulin-dependent
Diabetes. Non-
insulin-dependent Diabetes is also called "adult onset" diabetes and Type 2
diabetes. Type
2 diabetes also includes "non-obese type 2" and "obese type 2." Type II
diabetes can be
characterized by (1) reduced pancreatic-beta-islet-cell secretion of insulin
such that less
than necessary amounts of insulin are produced to keep blood glucose levels in
balance
and/or (2) "insulin resistance," wherein the body fails to respond normally to
insulin.
(U.S. Patent No. 5,266,561 and U.S. Patent No. 6,518,069). For example,
glucose-
stimulated insulin levels typically fail to rise above 4.0 nmoIlL. (U.S.
Patent No.
5,266,561). Example symptoms of Type II diabetes include: hyperglycemia while
fasting (U.S. Patent No. 5,266,561); fatigue; excessive thirst; frequent
urination; blurred
vision; and an increased rate of infections. Molecular indications of Type II
diabetes
include islet amyloid deposition in the pancreases.
Neuropathy
Neuropathy can include a central and/or peripheral nerve dysfunction caused by
systemic disease, hereditary condition or toxic agent affecting motor,
sensory,
sensorimotor or autonomic nerves. (see, e.g., US Patent Application No.
20030013771).
Symptoms can vary depending upon the cause of the nerve damage and the
particular
types of nerves affected. For example, symptoms of motor neuropathy include
clumsiness
in performing physical tasks or as muscular weakness, exhaustion after minor
exertion,
difficulty in standing or walking and attenuation or absence of a
neuromuscular reflex.
(U.S. Patent Application No. 20030013771) symptoms of autonomic neuropathy
include
constipation, cardiac irregularities and attenuation of the postural
hypotensive reflex.
(U.S. Patent Application No. 20030013771), symptoms of sensory neuropathy
include
pain and numbness; tingling in the hands, legs or feet; and extreme
sensitivity to touch,
and symptoms of retinopathy include blurred vision, sudden loss of vision,
black spots,
and flashing lights.
Alzheimer's Disease
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
Methods or uses of the disclosure which provide administering the Klotho
fusion
polypeptide to an individual can be used to treat Alzheimer's Disease (AD).
Alzheimer's
Disease is a complex neurodegenerative disease that results in the
irreversible loss of
neurons. It provides merely one example of a neurodegenerative disease that is
also an
age-related condition. Clinical hallmarks of Alzheimer's Disease include
progressive
impairment in memory, judgment, orientation to physical surroundings, and
language.
Neuropathological hallmarks of AD include region-specific neuronal loss,
amyloid
plaques, and neurofibrillary tangles. Amyloid plaques are extracellular
plaques containing
the amyloid peptide (also known as Ap, or Ap42), which is a cleavage product
of the, 8-
amyloid precursor protein (also known as APP). Neurofibrillary tangles are
insoluble
intracellular aggregates composed of filaments of the abnormally
hyperphosphorylated
microtubule-associated protein, taut Amyloid plaques and neurofibrillary
tangles may
contribute to secondary events that lead to neuronal loss by apoptosis (Clark
and
Karlawish, Ann. Intern. Med. 138(5):400-410 (2003). For example, p-amyloid
induces
caspase-2-dependent apoptosis in cultured neurons (Troy et at. JNeurosci.
20(4):1386-
1392). The deposition of plaques in viva may trigger apoptosis of proximal
neurons in a
similar manner.
A variety of criteria, including genetic, biochemical, physiological, and
cognitive
criteria, can be used to evaluate AD in a subject. Symptoms and diagnosis of
AD are
known to medical practitioners. Some example symptoms and markers of AD are
presented below. Information about these indications and other indications
known to be
associated with AD can be used as an "AD-related parameter." An AD related
parameter
can include qualitative or quantitative information. An example of
quantitative
information is a numerical value of one or more dimensions, e.g., a
concentration of a
protein or a tomographic map. Qualitative information can include an
assessment, e.g., a
physician's comments or a binary ("yes"/"no") and so forth. An AD-related
parameter
includes information that indicates that the subject is not diagnosed with AD
or does not
have a particular indication of AD, e.g., a cognitive test result that is not
typical of AD or
a genetic APOE polymorphism not associated with AD.
Progressive cognitive impairment is a hallmark of AD. This impairment can
present as decline in memory, judgment, decision making, orientation to
physical
surroundings, and language (Nussbaum and Ellis, New Eng J. Med. 348(14):1356
35
1364 (2003)). Exclusion of other forms of dementia can assist in making a
diagnosis of
AD. Neuronal death leads to progressive cerebral atrophy in AD patients.
Imaging
66
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
techniques (e.g., magnetic resonance imaging, or computer assisted tomography)
can be
used to detect AD-associated lesions in the brain and/or brain atrophy.
AD patients may exhibit biochemical abnormalities that result from the
pathology
of the disease. For example, levels of tan protein in the cerebrospinal fluid
is elevated in
AD patients (Andreasen, N. et at. Arch Neurol. 58:349-350 (2001)).
Levels of amyloid beta 42 (A,B42) peptide can be reduced in CSF of AD
patients.
Levels of Ap42 can be increased in the plasma of AD patients (Ertekein-Taner,
N., et at.
Science 290:2303 2304 (2000)). Techniques to detect biochemical abnormalities
in a
sample from a subject include cellular, immunological, and other biological
methods
known in the art. For general guidance, see, e.g., techniques described in
Sambrook &
Russell, Molecular Cloning: A Laboratory Manual, 3r Edition, Cold Spring
Harbor
Laboratory, N.Y. (2001), Ausubel et al., Current Protocols in Molecular
Biology (Greene
Publishing Associates and Wiley Interscience, N.Y. (1989), (Harrow, E. and
Lane, D.
(1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press,
Cold
Spring Harbor, NY), and updated editions thereof.
For example, antibodies, other immunoglobulins, and other specific binding
ligands can be used to detect a biomolecule, e.g., a protein or other antigen
associated
with AD. For example, one or more specific antibodies can be used to probe a
sample.
Various formats are possible, e.g., ELISAs, fluorescence-based assays, Western
blots, and
protein arrays. Methods of producing polypeptide arrays are described in the
art, e.g., in
De Wildt et al. (2000). Nature Biotech. 18, 989-994; Lucking et al. (1999).
Anal.
Biochem. 270, 103-111; Ge, H. (2000). Nucleic Acids Res. 28, e3, I-VII;
MacBeath, G.,
and Schreiber, S.L. (2000). Science 289, 1760 to 1 763; and WO 99/5 1 773A1.
In one assay, a non-human animal model of AD (e.g., a mouse model) is used,
e.g., to evaluate a polypeptide or a therapeutic regimen. For example, U.S.
Patent No.
6,509,515 describes one such model animal which is naturally able to be used
with
learning and memory tests. The animal expresses an amyloid precursor protein
(APP)
sequence at a level in brain tissues such that the animal develops a
progressive necrologic
disorder within a short period of time from birth, generally within a year
from birth,
preferably within 2 to 6 months, from birth. The APP protein sequence is
introduced into
the animal, or an ancestor of the animal, at an embryonic stage, preferably
the one cell, or
fertilized oocyte, stage, and generally not later than about the 8-cell stage.
The zygote or
embryo is then developed to term in a pseudo-pregnant as foster female. The
amyloid
precursor protein genes are introduced into an animal embryo so as to be
chromosomally
67
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
incorporated in a state which results in super endogenous expression of the
amyloid
precursor protein and the development of a progressive necrologic disease in
the cortico-
limbic areas of the brain, areas of the brain which are prominently affected
in progressive
necrologic disease states such as AD. The gliosis and clinical manifestations
in affected
transgenic animals model necrologic disease. The progressive aspects of the
neurologic
disease are characterized by diminished exploratory and/or locomotor behavior
and
diminished deoxyglucose uptake/utilization and hypertrophic gliosis in the
cortico-limbic
regions of the brain. Further, the changes that are seen are similar to those
that are seen in
some aging animals. Other animal models are also described in US 5,387,742;
5,877,399;
6,358,752; and 6, 187,992.
Parkinson's Disease
Methods or uses of the disclosure which provide administering the Klotho
fusion
polypeptide to an individual can be used to treat Parkinson's Disease.
Parkinson's disease
includes neurodegeneration of dopaminergic neurons in the substantia nigra
resulting in
the degeneration of the nigrostriatal dopamine system that regulates motor
function. This
pathology, in turn, leads to motor dysfunctions.(see, e.g., and Lotharius et
at., Nat. Rev.
Neurosci., 3:932-42 (2002)). Example motor symptoms include: akinesia, stooped
posture, gait difficulty, postural instability, catalepsy, muscle rigidity,
and tremor.
Example non-motor symptoms include: depression, lack of motivation, passivity,
dementia and gastrointestinal dysfunction (see, e. g., Fahn, Ann. N.Y Acad.
Sci., 991:1-14
(2003) and Pfeiffer, Lancet Neurol., 2:107-16 (2003)) Parkinson's has been
observed in
0.5 to 1 percent of persons 65 to 69 years of age and 1 to 3 percent among
persons 80
years of age and older. (see, e.g., Nussbaum et at., N. Engl. J. Med.,
348:1356-64 (2003)).
Molecular markers of Parkinson's disease include reduction in aromatic L amino
acid
decarboxylase (AADC) (see, e.g., US App.. No. 20020172664); and loss of
dopamine
content in the nigrostriatal neurons (see, e.g., Fahn, Ann. N.Y Acad. Sci.,
991:1-14 (2003)
and Lotharius et al., Nat. Rev. Neurosci., 3:932-42 (2002)). In some familial
cases, PD is
linked to mutations in single genes encoding alpha-synuclein and parkin (an E3
ubiquitin
ligase) proteins. (e.g., Riess et al., J. Neurol. 250 Suppl 1:13 10 (2003) and
Nussbaum et
al., N. Engl. J. Med., 348:1356-64 (2003)). A missense mutation in a neuron-
specific C-
terminal ubiquitin hydrolase gene is also associated with Parkinson's. (e.g.,
Nussbaum et
al., N. Engl. J. Med., 348:1356-64 (2003))
68
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
Huntington's Disease
Methods or uses of the disclosure which provide administering the Klotho
fusion
polypeptide to an individual can be used to treat Huntington's Disease.
Methods for
evaluating the efficacy and/or determining the effective dose of a Klotho
fusion
polypeptide on Huntington's Disease include organismal based assays, e.g.,
using a
mammal (e.g., a mouse, rat, primate, or some other non-human), or other animal
(e.g.,
Xenopus, zebrafish, or an invertebrate such as a fly or nematode). A number of
animal
model system for Huntington's disease are available. See, e.g., Brouillet,
Functional
Neurology 15(4): 239-251 (2000); Ona et at. Nature 399: 263-267 (1999), Bates
et at.
Hum Mol Genet. 6(10):1633-7 (1997); Hansson et at. J. of Neurochemistry 78:
694-703;
and Rubinsztein, D. C., Trends in Genetics, Vol. IS, No. 4, pp. 202-209 (a
review on
various animal and non-human models of HD).
An example of such an animal model is the transgenic mouse strain is the R6/2
line (Mangiarini et al. Cell 87: 493-506 (1996)). The R6/2 mice are transgenic
Huntington's disease mice, which over-express exon 1 of the human HD gene
(under the
control of the endogenous promoter). The exon 1 of the R6/2 human HD gene has
an
expanded CAG/polyglutamine repeat lengths (150 CAG repeats on average). These
mice
develop a progressive, ultimately fatal neurological disease with many
features of human
Huntington's disease. Abnormal aggregates, constituted in part by the N
terminal part of
Huntingtin (encoded by HD exon 1), are observed in R6/2 mice, both 45 in the
cytoplasm
and nuclei of cells (Davies et at. Cell 90: 537-548 (1997)). For example, the
human
Huntingtin protein in the transgenic animal is encoded by a gene that includes
at least 55
CAG repeats and more preferably about 150 CAG repeats. These transgenic
animals can
develop a Huntington's disease-like phenotype.
These transgenic mice are characterized by reduced weight gain, reduced
lifespan
and motor impairment characterized by abnormal gait, resting tremor, hindlimb
clasping
and hyperactivity from 8 to 10 weeks after birth (for example the R6/2 strain;
see
Mangiarini et al. Cell 87: 493-506 (1996)). The phenotype worsens
progressively toward
hypokinesia. The brains of these transgenic mice also demonstrate
neurochemical and
histological abnormalities, such as changes in neurotransmitter receptors
(glutamate,
dopaminergic), decreased concentration of N-acetylaspartate (a marker of
neuronal
integrity) and reduced striatum and brain size. Accordingly, evaluating can
include
assessing parameters related to neurotransmitter levels, neurotransmitter
receptor levels,
brain size and striatum size. In addition, abnormal aggregates containing the
transgenic
69
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
part of or full-length human Huntingtin protein are present in the brain
tissue of these
animals (e.g., the R6/2 transgenic mouse strain). See, e.g., Mangiarini et at.
Cell 87: 493-
506 (1996), Davies et at. Cell 90: 537-548 (1997), Brouillet, Functional
Neurology 15(4):
239-251 (2000) and Cha et at. Proc. Natl. Acad. Sci. USA 95: 6480-6485 (1998).
To test the effect of the test polypeptide or known polypeptide described in
the
application in an animal model, different concentrations of test polypeptide
are
administered to the transgenic animal, for example by injecting the test
polypeptide into
circulation of the animal. A Huntington's disease-like symptom may be
evaluated in the
animal. The progression of the Huntington's disease-like symptoms, e.g., as
described
above for the mouse model, is then monitored to determine whether treatment
with the
test polypeptide results in reduction or delay of symptoms. In another assay,
disaggregation of the Huntingtin protein aggregates in these animals is
monitored. The
animal can then be sacrificed and brain slices are obtained. The brain slices
are then
analyzed for the presence of aggregates containing the transgenic human
Huntingtin
protein, a portion thereof, or a fusion protein comprising human Huntingtin
protein, or a
portion thereof. This analysis can includes, for example, staining the slices
of brain tissue
with anti-Huntingtin antibody and adding a secondary antibody conjugated with
FITC
which recognizes the anti-Huntington's antibody (e.g., the anti-Huntingtin
antibody is
mouse anti-human antibody and the secondary antibody is specific for human
antibody)
and visualizing the protein aggregates by fluorescent microscopy.
A variety of methods are available to evaluate and/or monitor Huntington's
disease. A variety of clinical symptoms and indicia for the disease are known.
Huntington's disease causes a movement disorder, psychiatric difficulties and
cognitive
changes. The degree, age of onset, and manifestation of these symptoms can
vary. The
movement disorder can include quick, random, dance-like movements called
chorea.
Example motor evaluations include: ocular pursuit, saccade initiation, saccade
velocity, dysarthria, tongue protrusion, finger tap ability, pronate/supinate,
a lo fist-hand-
palm sequence, rigidity of arms, bradykinesia, maximal dystonia (trunk, upper
and lower
extremities), maximal chorea (e.g., trunk, face, upper and lower extremities),
gait, tandem
walking, and retropulsion. An example treatment can cause a change in the
Total Motor
Score 4 (TMS-4), a subscale of the UHDRS, e.g., over a one-year period.
Cancer
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
Methods or uses of the disclosure which provide administering the Klotho
fusion
polypeptide to an individual can be used to treat cacner. Cancer includes any
disease that
is caused by or results in inappropriately high levels of cell division,
inappropriately low
levels of apoptosis, or both. Examples of cancers include, without limitation,
leukemias
(e.g., acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia,
acute
myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic
leukemia,
acute monocytic leukemia, acute erythro leukemia, chronic leukemia, chronic
myelocytic
leukemia, chronic lymphocytic leukemia), polycythemia vera, lymphoma
(Hodgkin's
disease, non-Hodgkin's disease), Waldenstrom's macroglobulinemia, heavy chain
disease,
and solid tumors such as sarcomas and carcinomas (e.g., fibrosarcoma,
myxosarcoma,
liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma,
endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma,
mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon
carcinoma,
pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous
cell
carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma,
sebaceous
gland carcinoma, papillary carcinoma, papillary adenocarcinomas,
cystadenocarcinoma,
medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma,
nile duct
carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor,
cervical
cancer, uterine cancer, testicular cancer, lung carcinoma, small cell lung
carcinoma,
bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma,
craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma,
oligodenroglioma, schwannoma, meningioma, melanoma, neuroblastoma, and
retinoblastoma). Lymphoproliferative disorders are also considered to be
proliferative
diseases.
All patents, patent applications, and published references cited herein are
hereby
incorporated by reference in their entirety. While this disclosure has been
particularly
shown and described with references to embodiments thereof, it will be
understood by
those skilled in the art that various changes in form and details may be made
therein
without departing from the scope of the disclosure encompassed by the appended
claims.
5. EXAMPLES
Example 1. Expression and purification of Klotho fusion polypeptides
Expression of the Klotho fusion polypeptide
71
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
The polypeptides of the disclosure were made by transiently transfecting
HEK293T cells with an expression vector encoding a Klotho fusion polypeptide
having
the extracellular domain of alpha Klotho and the FGF23 (R179Q) variant.
Conditioned
media containing expressed polypeptides were generated by transient
transfection of the
respective expression plasmids for Klotho, FGF23, and the Klotho-FGF23(R179Q)
fusion
protein. The transfections were performed in 6-well plates using Lipofectamine
2000
(Invitrogen, Cat # 11668-019). Five hours after transfection, the transfection
mix was
replaced with 3 ml DMEM plus 1% FBS. Conditioned media were collected 72 hours
after the addition of 3 ml DMEM plus 1% FBS. Samples of conditioned medium
from
various transiently transfected HEK293T cells were separated by SDS-
polyacrylamide gel
electrophoresis (SDS-PAGE) and analyzed by Western blot (Figure 3A) or stained
with
Coomassie blue (Figure 3B).
SDS-polyacrylamide gel electrophoresis was performed on various samples (lane
1, Control; lane 2, FGF23; lane 3, sKlotho; lanes 4-6, sKlotho-FGF23).
Coomassie blue
staining revealed the expression of a high, >180 kDa band (Figure 3B,
indicated by arrow
on the right) that was not present in lanes 1-3, which contained samples that
had not been
transfected with the vector encoding the Klotho fusion polypeptide. The
quality of the
Klotho fusion polypeptide secreted into the media was evaluated by Western
blot (Figure
3A). An anti-FGF23 rat monoclonal IgG2A (R&D Systems, Cat# MAB26291) was used
as the primary antibody to detect the Klotho fusion polypeptides by Western
blot. The
Western blot confirmed that the additional bands observed in the Coomassie
stained gels
were Klotho fusion polypeptides. The Western blot confirmed that the Klotho
fusion
polypeptides had the expected molecular weight for the Klotho fusion
polypeptide. This
analysis shows the expression of the Klotho-FGF23(R179Q) fusion protein.
Purification of the Klotho fusion polypeptide
The polypeptides of the disclosure were purified from conditioned media from a
culture of HEK293T cells transiently transfected with an expression vector
encoding a
Klotho fusion polypeptide having the extracellular domain of alpha Klotho and
the
FGF23 R179Q variant. To generate conditioned medium, an expression vector
encoding
sKlotho-FGF23-6xHis was transfected (500 gg DNA in 18 ml of OptiMEM 1 (GIBCO,
Cat #11058) mixed with 18 ml of 2 gg/ml polyethlinimine (PEI) into HEK293
cells
grown in suspension in expression medium (464 ml of HEK293T cells at 106
cells/ml in
Freestype 293 expression medium (GIBCO, Cat #12338)). After transfection, the
culture
was allowed to grow (120 hours; 37 C in a 5% CO2 incubator; shaking at 125
rpm). At
72
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
the end of incubation, conditioned medium was harvested by centrifugation
(1000 rpm for
five minutes). The conditioned medium was then applied to a nickel-agarose
column.
The sKlotho-FGF23-6xHis bound tightly to the column and was eluted with 50 mM
imidazole. The resulting purified material was then dialyzed in PBS to remove
imidazole.
A sample of the purified sKlotho-FGF23-6xHis was separated by SDS-PAGE (lane
1,
purified sKlotho-FGF23-6xHis; lane 2, molecular weight marker) and analyzed by
staining with Coomassie blue (Figure 3C). The stained SDS-PAGE gel confirmed
that
the purified sKlotho-FGF23-6xHis had the expected molecular weight. The
inability to
detect bands corresponding to proteins other than full-length sKlotho-FGF23-
6xHis in the
lane loaded with the purified material also showed that the sKlotho-FGF23-
6xHis was
purified.
Example 2. In vitro assay assessing the activity of the Klotho fusion
polypeptide.
Egr-l -luciferase
The biological activity of the expressed alpha Klotho fusion polypeptide was
tested in Egr-l-luciferase reporter assays. Binding of the Klotho fusion
polypeptide to the
FGF23 receptor resulted in the downstream activation of Egr-1 and the
expression of a
luciferase reporter regulated by the Egr-1 promoter. The Egr-l-luciferase
reporter gene
was constructed based on that reported by Urakawa et al. (Nature, 2006, Vol
444, 770-
774). HEK293T cells seeded in 48-well poly-D-lysine plate were transfected
with the
Egr-l-luciferase reporter gene together with a transfection normalization
reporter gene
(Renilla luciferase). Five hours after transfection of the Egr-1 luciferase
reporter gene,
the transfection mix was replaced with 3 ml DMEM plus 1% FBS. Conditioned
media
were collected 72 hours after the addition of 3 ml DMEM plus 1% FBS. Five
hours later,
the transfection mix was replaced with a sample to be tested for activity. In
initial
experiments, 50% conditioned medium (alone or containing Klotho, FGF23, Klotho
and
FGF23, and the Klotho-FGF23(R179Q) fusion protein) and 50% DMEM with 1% FBS in
the presence or absence of 20 gg/ml heparin (Sigma, Cat#H8537; dissolved in
DMEM as
2 mg/ml stock) were tested in the Egr-l-luciferase reporter assays (Figure 4).
Further
experiments used defined quantities of the purified polypeptides (Figures 5A
and 5B).
Cells were lysed 20 hours later in passive lysis buffer (Promega, Cat #E I
94A) and
luciferase activities were determined using Dual-Glo Luciferase Assay System
(Promega,
Cat #E2940).
73
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
In initial experiments, Klotho fusion polypeptide activity was demonstrated in
unfractionated conditioned medium. Using the Egr-l-luciferase reporter gene
(Figure 4)
these experiments quantified the fold changes in the expression of the
luciferase reporter.
Conditioned medium containing a combination of FGF23 and the extracellular
domain of
Klotho protein activated Egr-l-luciferase, but conditioned medium containing
only
FGF23 or conditioned medium containing only the extracellular domain of
Klotho, did
not activate Egr-l-luciferase. Conditioned medium containing the fusion
protein sKlotho-
FGF23(R179Q) activated the Egr-l-luciferase reporter gene in contrast to
conditioned
media containing either FGF23 or Klotho alone. In these experiments,
conditioned
medium containing the fusion protein sKlotho-FGF23(R179Q) activated the Egr-l-
luciferase reporter gene significantly better than conditioned medium
containing a
combination of FGF23 and Klotho. In the presence of heparin, the inductions by
conditioned medium containing the fusion protein sKlotho-FGF23(R179Q) and the
conditioned medium containing a combination of FGF23 and Klotho were
significantly
enhanced. Table 1 lists the relative expression of various FGF-Klotho fusion
polypeptides in conditioned medium and the relative activity of the
unfractionated
conditioned medium corresponding to the various FGF-Klotho fusion polypeptides
in
Egr-l-luciferase reporter assays.
Table 1. Expression and Activities of sKlotho-FGF23 fusion variants
Activity in Egr-l-luc
sKlotho-FGF23 fusion constructs Expression reporter gene
1 sKlotho-FGF23 good yes
2 IgG sp-sKlotho-FGF23 good yes
3 sKL-D1-FGF23 good no
4 sKL-D2-FGF23 no n.a.
5 s(KL-D1)2-FGF23 good no
6 sKL-DI/D2-FGF23 no n.a.
7 ssKlotho(AN-26)-FGF23 poor no*
8 sKLD I -D2(A692-965)-FGF23 poor no*
9 sKL-Dl-D2(A507-798)-FGF23 poor no*
10 FGF23-sKlotho poor no*
74
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
* lack of activity may be the result of low expression
Egr-l-luciferase reporter assays were also performed using defined quantities
of
proteins purified from the conditioned medium, using the purification
procedure as
described in Example 1. Consistent with previous results using unfractionated
conditioned medium containing the expressed polypeptides, treatment with a
combination
of purified FGF23 and sKlotho resulted in luciferase reporter activity, but
treatment with
purified FGF23 alone did not (Figure 5A). The luciferase reporter activity
from the
combination of purified FGF23 and sKlotho was further dependent on the dose of
purified
sKlotho, and the effect could be enhanced by the presence of heparin (20
gg/ml). An
effect of the sKlotho-FGF23-6xHis fusion polypeptide on luciferase activity
could be
detected at concentrations as low as about 1.21 nM (1.2 fold change) and at
least up to
about 19.3 nM (2.4 fold change) in Egr-l-luciferase reporter assays (Figure
5B). The
activity of the sKlotho-FGF23-6xHis fusion polypeptide on luciferase activity
was
significantly enhanced in the presence of heparin (20 gg/ml). In the presence
of heparin,
the effect of the sKlotho-FGF23-6xHis fusion polypeptide on luciferase
activity could be
detected at a concentration as low as about 0.6 nM (2.0 fold change). The
result showed
that purified sKlotho-FGF23-6xHis dose-dependently induced the EGR-1-luc
reporter
gene, and that treatment with sKlotho-FGF23-6xHis.
Example 3. In vitro assay assessing the effect of the Klotho fusion
polypeptide on
muscle cells.
The biological effect of the expressed Klotho fusion polypeptide was tested on
C2C12 myoblasts. Treatment of C2C12 myoblasts with IGF-1, FGF2, or sKlotho-
FGF23
resulted in myotube growth and phosphorylation of signaling proteins. C2C12
myoblasts
were seeded at a density of 40,000 cells/well in 6-well poly-D-lysine and
fibronectin
coated plates in growth medium (3 parts DMEM and 1 part F 12), 10% FBS, 1%
Glut; 1%
P/S; 1% Linolic acid; 0.1% ITS: [insulin (10 mg/ml), transferrin (5.5 mg/ml),
and
selenium (5 ng/ml)]. After myoblasts reached confluence (3 days), medium was
changed
into differentiation medium (DMED with 2% horse serum; I% Glut; I% P/S).
For the myotube diameter experiments, three days after confluent media was
changed into differentiation medium, cells were treated with IGF-1 (10 nM),
FGF2 (20
ng/ml) or sKlotho-FGF23 (20 nM) in the absence or presence of dexamethasone
(100
M) for 24 hours in differentiation medium. At the end of treatment, cells were
fixed
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
with glutaraldehyde (5% in PBS) and multiple fluorescent images were
collected.
Myotube diameter was measured using the Pipeline Pilot program to determine
hypertrophy or atrophy.
For the signaling protein phosphorylation,experiments, three days after
confluent
media was changed into differentiation medium, cells were starved for four
hours with
DMEM without FBS and then treated with IGF-1 (10 nM), FGF2 (20 ng/ml) or
sKlotho-
FGF23 (20 nM) in the absence or presence of Rapamycin (40 nM) for 30 min.
Cells were
lysed in RIPA buffer in the presence of protease and phosphatase inhibitors.
Western blot
analysis was carried out and membranes were probed with different antibodies
as
indicated in the figure and developed on X-ray films, which were scanned.
The results of this study showed that sKlotho-FGF23 resulted in an increase in
myotube diameter compared to the control and induced C2C12 myotube hypertrophy
similar to results for IGF-1 and FGF2 (Figure 5A). In addition, treatment with
sKlotho-
FGF23, IGF-1, and FGF2 could partially reverse myotube atrophy induced by
dexamethasone, based on measurements of myotube diameter. No difference was
observed between sKlotho-FGF23 and FGF2 on myotube morphology (measured by
thickness of the myotubes) in the absence or presence of dexamethasone. The
trophic
effects of sKlotho-FGF23, IGF-1, and FGF2 were statistically significant.
Consistent with the effects on C2C12 myotubes, sKlotho-FGF23 fusion protein
signaling led to the phosphorylation of p70S6K and ERK, but not AKT or FoxO,
in
C2C12 myotubes (Figure 5B). The effect of sKlotho-FGF23 on signaling was
similar to
that of FGF2, but was distinct from that of IGF- 1. The extent of ERK
phosphorylation by
sKlotho-FGF23 was observed to be less than that of IGF-1 or FGF2. The
phosphorylation of p70S6K by sKlotho-FGF23 was rapamycin sensitive. In the
experiments involving C2C12 cells, heparin was not required to activate
signaling. These
results show that a sKlotho-FGF23 fusion polypeptide activated signaling in
C2C12
myotubes.
Example 4. Fusion polypeptides comprising sKlotho, FGF23 and FcLALA
Various fusion polypeptides are constructed using sKlotho, FGF23, and a
modified Fc fragment of an antibody. These modified Fc molecules have altered
(decreased) binding to FcRn and thus increased serum half-life. They also have
modified
bioavailability and alterered transport to mucosal surfaces and other targets
in the body.
In this example, the FGF23 and sKlotho are fused to FcLALA, which is described
in U.S.
Patent No. 7,217,798 and Hessell et al. 2007 Nature 449:101-104, Intervening
between
the various components of these fusion polypeptides are linkers, as described
in Lode et
76
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
al. 1998 Proc. Natl. Acad. Sci. USA 95: 2475-2480. These fusions are inserted
into
constructs, e.g., pcDNA3.1
(Invitrogen, Carlsbad, CA), and expressed in HEK293 cells.
A. sKlotho-FGF23-FcLALA vl
A fusion is constructed which comprises: sKlotho, a linker, FGF23, another
linker, and
FcLALA. This embodiment, designated sKlotho-FGF23-FcLALA vl, is presented in
SEQ ID NOs: 46 and 47, below.
The nucleotide sequence of sKlotho-FGF23-FcLALA vl (wherein initiation ATG as
1) is
presented as SEQ ID NO: 46.
The amino acid sequence of sKlotho-FGF23-FcLALA vl is presented below as SEQ
ID
NO: 47.
In this sequence, the various components of the fusion are as follows:
sKlotho: 1-982; Linkerl: 983-1001; FGF23: 1002-1228; Linker 2; 1229-1233;
FcLALA:
1234-1459.
B. sKlotho-FGF23-FcLALA v2
A fusion is constructed which comprises: sKlotho, a linker, FGF23, another
linker, and
FcLALA. This embodiment is designated sKlotho-FGF23-FcLALA v2 and presented as
SEQ ID NOs: 48 and 49, below.
The nucleotide sequence of sKlotho-FGF23-FcLALA v2 (wherein initiation ATG as
1) is
presented as SEQ ID NO: 48.
The amino acid sequence of sKlotho-FGF23-FcLALA v2 is presented below as SEQ
ID
NO: 49.
In this sequence, the various components of the fusion are as follows:
sKlotho: (aa or amino acids) 1-982; Linker 1: 983-1001; FGF23: 1002-1228;
Linker 2;
1229-1233; FcLALA: 1234-1450.
Other fusion polypeptides can be constructed by combining in various
combinations the
FGF, Klotho, modified Fc fragments, and (optionally) linker sequences, and
variants and
derivatives thereof, as described herein or known in the art.
Example 5. Fusion polypeptides comprising FGF23 and FcLALA.
Various fusion polypeptides are constructed using FGF23, and a modified Fc
fragment of an antibody, as described in U.S. Patent No. 7,217,798. These
modified Fc
molecules have altered (decreased) binding to FcRn and thus increased serum
half-life.
They also have modified bioavailability and alterered transport to mucosal
surfaces and
77
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
other targets in the body. In this example, FGF23 is fused to FcLALA,
Intervening
between the various components of these fusion polypeptides are linkers, as
described in
Lode et al. 1998 Proc. Natl. Acad. Sci. USA 95: 2475-2480. These fusions are
inserted
constructs, e.g., pcDNA3.1 (Invitrogen, Carlsbad, CA), and expressed in HEK293
cells.
C. FGF23-FcLALA vl
A fusion is constructed which comprises: FGF23, a linker, and FcLALA. This
construct
is designated FGF23-FcLALA vl and presented below as SEQ ID NOs: 50 and 51.
The nucleotide sequence of FGF23-FcLALA vl (wherein initiation ATG as 1) is
presented below as SEQ ID NO: 50.
The amino acid sequence of FGF23(R179Q)-FcLALAvl is presented below as SEQ ID
NO: 51.
In this sequence, the various components of the fusion are as follows:
FGF23: (aa) 1-251; Linker: 252-256; FcLALA: 257-482.
D. FGF23-FcLALA v2
A fusion is constructed which comprises: FGF23-FcLALA v2, which comprises
FGF23
and FcLALA.
The nucleotide sequence of FGF23-FcLALA v2 (wherein initiation ATG as 1) is
presented below as SEQ ID NO: 52.
The amino acid sequence of FGF23(R179Q)-FcLALAv2 is presented below as SEQ ID
NO: 53.
In this sequence, the various components of the fusion are as follows:
FGF23: 1-251; Linker: 252-256; FcLALA: 257-473.
Other fusion polypeptides can be constructed by combining in various
combinations the
FGF sequences, modified Fc fragments, and (optionally) linkers, and variants
and
derivatives thereof, as described herein or known in the art.
E. Activation of Egr-l-luc reporter gene by sKlotho-FGF23(R179Q)-FcLALA fusion
proteins; activation of Egr-l-luc reporter gene by FGF23(R179Q)-FcLALA
proteins; and
pharmacokinetic profile of FGF23(R179Q) vs FGF23(R179Q)-FcLaLav2 are
determined.
Figure 7 shows the activation of Egr-l-luc reporter gene by sKlotho-
FGF23(R179Q)-
FcLALA fusion proteins. HEK293T cells are transiently transfected with the Egr-
l-luc
reporter gene and incubated with the indicated conditioned media in the
absence or
78
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
presence of 20 gg/ml heparin. Luciferase activities are then determined 18
hours later.
The result shows that sklotho-FGF23-FcLALA fusion proteins induces the
reporter gene
activity. These inductions are significantly enhanced in the presence of
heparin. sKF-
Fcvl: sKlotho-FGF23-FcLALAv1; sKF-Fcv2: sKlotho-FGF23-FcLALAv2
Figure 8 shows the activation of Egr-l-luc reporter gene by FGF23(R179Q)-
FcLALA
proteins. HEK293T cells are transiently transfected with the Egr-l-luc
reporter gene
together with the full-length transmembrane form of Klotho and incubated with
the
indicated 30% conditioned media. Luciferase activities are then determined 18
hours
later. The results show that FGF23-FcLALA fusion proteins induce the reporter
gene
activity in a similar manner as the FGF23.
Figure 9 shows the pharmacokinetic profile of FGF23(R179Q) vs FGF23(R179Q)-
FcLALAv2. Four mice per group are injected subcutaneously with FGF23(R179Q)-
6xHis
or FGF23(R179Q)-FcLALAv2 at 2 mg/kg. At the indicated times, serum samples are
collected and analyzed for FGF23 by ELISA. FGF23(R179Q)-FcLALA concentration
in
serum remains elevated at the 24 hr time point, while FGF23(R179Q)-6xHis is
back to
basal level. This results indicate that with the addition of FcLALA, the in
vivo half-life of
FGF23(R179Q) is significantly improved.
Example 6. In vivo efficacy of sKlotho-FGF23 fusion in enhancing muscle growth
after dexamethasone-induced muscle atrophy
Experimental data shows that intramuscular injection of sKlotho-FGF23
significantly
enhanced growth of muscle mass after dexamethasone-induced muscle atrophy. In
this
experiment, the peptide corresponding to that of SEQ ID NO: 41 is used.
Figure 10 shows absolute weights (A) and percent weight change (B) of the
gastrocnemius-soleus-plantaris (GSP) muscles showing that intramuscular
injection of
sKlotho-FGF23 (KLOFGF) significantly enhanced regrowth of muscle mass after
dexamethasone (DEX)-induced muscle atrophy compared with intramuscular
injection
of sKlotho (sKLO) or phosphate buffered saline (PBS).
Eighty male C57BL/6 mice, aged 15 weeks, are randomized by body weight into 8
groups each of 10 mice. Four groups receive water without DEX (W21d) while the
other
79
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
four receive DEX in drinking water at 2.4 mg/kg/day for three weeks (D21d).
After the
three weeks, DEX treatment is stopped and one W21d and one D21d group is
immediately sacrificed to establish the degree of muscle atrophy induced by
the DEX
treatment. The remaining three groups of W21d or D21d mice are allowed to
recover for
another 14 days (R14d) during which period they receive an intramuscular
injection of
2x50 l of PBS, sKlotho-FGF23 (KLOFGF;1.6 mg/ml), or sKlotho (sKLO;1.6 mg/ml),
respectively, every other day into the right gastrocnemius-soleus-plantaris
muscle
complex. The mice are sacrificed 24h after the last intramuscular injection
and the
muscle weights determined and expressed as absolute weight (A) or percent
change
compared to the W21d+PBS group.
These data show the in vivo efficacy of sKlotho-FGF23 fusion in enhancing
muscle
growth after dexamethasone-induced muscle atrophy.
Example 7. Additional mutations in the FGF23 portion of fusion proteins which
reduce aggregation, reduce undesired protease-induced cleavage, and increase
production
Several mutations are investigated within the FGF23 portion of sKlotho-FGF23
and
FGF23-FcLaLa fusion polypeptides. These include Q156, C206 and C244 (wherein
the
number is based on the FGF23 amino acid sequence). Example individual
mutations
include Q156A, C206S and C244S, and mutations at any of these sites can be
combined
with a mutation at R179 (e.g., R179Q). Example sequences are provided in SEQ
ID NO:
54 to 68 of Figure 2.
C206 and C244 are suspected to be involved in dimerization; and Q156 is a site
identified
by the inventors as a protease sensitive site. Mutating these amino acids to
any other
amino acid enhances the qualities of the proteins, by reducing aggregation,
reducing
undesired protease-induced cleavage, and increasing protein production from
cells,
without interfering with FGF23 activity. This is an unexpected result, as
these three
positions are conserved in the FGF23 proteins found in human, rhesus, bovine,
mouse and
rat. This conservation is shown below in the comparison between SEQ ID NOs:
69, 70,
71, 72 and 73, with the Q156, C206 and C244 in bold, underlined font.
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
hFGF23 MLGARLRLWVCALCSVCSMSVLRAYPNASPLLGSSWGGLIHLYTATARNSYHLQIHKNGH
rhesus MLGARLRLWVCALCSVCSMSVIRAYPNASPLLGSSWGGLIHLYTATARNSYHLQIHKNGH
bovine MLGARLGLWVCTLSCV VQAYPNSSPLLGSSWGGLTHLYTATARNSYHLQIHGDGH
mouse MLGTCLRLLVGVLCTVCSLGTARAYPDTSPLLGSNWGSLTHLYTATARTSYHLQIHRDGH
rat MLGACLRLLVGALCTVCSLGTARAYSDTSPLLGSNWGSLTHLYTATARNSYHLQIHRDGH
hFGF23 VDGAPHQTIYSALMIRSEDAGFVVITGVMSRRYLCMDFRGNIFGSHYFDPENCRFQHQTL
rhesus VDGAPHQTIYSALMIRSEDAGFVVITGVMSRRYLCMDFRGNIFGSITYFNPENCRFRHWTL
bovine VDGSPQQTVYSALMIRSEDAGFVVITGVMSRRYLCMDFTGNIFGSHHFSPESCRFRQRTL
mouse VDGTPHQTIYSALMITSEDAGSVVITGAMTRRFLCMDLHGNIFGSLHFSPENCKFRQWTL
rat VDGTPHQTIYSALMITSEDAGSVVIIGAMTRRFLCMDLRGNIFGSYHFSPENCRFRQWTL
hFGF23 ENGYDVYHSPQYHFLVSLGRAKRAFLPGMNPPPYSQFLSRRNEIPLIHFNTPI-PRRHTR
rhesus ENGYDVYHSPQHHFLVSLGRAKRAFLPGMNPPPYSQFLSRRNEIPLIHFNTPR-PRRHTR
bovine ENGYDVYHSPQHRFLVSLGRAKRAFLPGTNPPPYAQFLSRRNEIPLPHFAATARPRRHTR
mouse ENGYDVYLSQKHHYLVSLGRAKRIFQPGTNPPPFSQFLARRNEVPLLHFYTVR-PRRHTR
rat ENGYDVYLSPKHHYLVSLGRSKRIFQPGTNPPPFSQFLARRNEVPLLHFYTAR-PRRHTR
hFGF23 SAEDDSERDPLNVLKPRARMTPAPASCSQELPSAEDNSPMASDPLGVVRGGRVNTHAGGT
rhesus SAEDDSERDPLNVLKPRARMTPAPASCSQELPSAEDNSPVASDPLGVVRGGRVNTHAGGT
bovine SAHDSG-- DPLSVLKPRARATPVPAACSQELPSAEDSGPAASDPLGVLRGHRLDVRAGSA
mouse SAEDPPERDPLNVLKPRPRATPVPVSCSRELPSAEEGGPAASDPLGVLRRGRGDARGGAG
rat SAEDPPERDPLNVLKPRPRATPIPVSCSRELPSAEEGGPAASDPLGVLRRGRGDARRGAG
hFGF23 GPEGCRPFAKFI (SEQ ID NO: 69)
rhesus GPEACRPFPKFI (SEQ ID NO: 70)
bovine GAERCRPFPGFA (SEQ ID NO: 71)
mouse GADRCRPFPRFV (SEQ ID NO: 72)
rat GTDRCRPFPRFV (SEQ ID NO: 73)
The fact that these three mutations do not prevent FGF23 activity is shown in
Figure 11.
This figure shows activation of Egr-l-luc reporter gene by FGF23(R179Q)-FcLALA
and
Q156A, C206S, C244S and C206S/C244S mutants.
HEK293T cells are transiently transfected with the EGR-1-luc reporter gene
together with
the full-length transmembrane form of Klotho and indicated FGF23-FcLaLa
mutants.
Luciferase activities are then determined 18 hours later. The results show
that C206S,
C244S, C206S/C244S (three independent clones) and Q156A (three independent
clones)
mutants are equally effective as FGF23-FcLALA fusion proteins in activating
EGR-1-
Luc reporter gene activity.
Data showing that mutating C244 and C206 alter dimerization and aggregation of
FGF23
is shown in Figure 12. This figure shows protein qualities of WT, Q156A,
C206S, C244S
and C206S/C244S mutants of FGF23(R179Q)-FcLaLa. Conditioned medium from
HEK293T cells transient transfected with the indicated FGF23-FcLaLa expression
vectors are analyzed by Western blot using an FGF23 antibody. The result shows
that
C206S/C244S mutation prevents protein dimerization and Q156A mutation has
reduced
proteolytic fragments.
81
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
Thus, surprisingly, even though these Q156, C206 and C244 residues are
conserved
across species, they can mutated without reducing FGF23 activity and can
enhance the
qualities of the protein by reducing aggregation and cleavage and by improving
production.
Unless defined otherwise, the technical and scientific terms used herein have
the same
meaning as that usually understood by a specialist familiar with the field to
which the
disclosure belongs.
Unless indicated otherwise, all methods, steps, techniques and manipulations
that are not
specifically described in detail can be performed and have been performed in a
manner
known per se, as will be clear to the skilled person. Reference is for example
again made
to the standard handbooks and the general background art mentioned herein and
to the
further references cited therein.
Claims to the invention are non-limiting and are provided below.
Although particular embodiments and claims have been disclosed herein in
detail, this has
been done by way of example for purposes of illustration only, and is not
intended to be
limiting with respect to the scope of the appended claims, or the scope of
subject matter
of claims of any corresponding future application. In particular, it is
contemplated by the
inventors that various substitutions, alterations, and modifications may be
made to the
disclosure without departing from the spirit and scope of the disclosure as
defined by the
claims. The choice of nucleic acid starting material or clone of interest is
believed to be a
matter of routine for a person of ordinary skill in the art with knowledge of
the
embodiments described herein. Other aspects, advantages, and modifications
considered
to be within the scope of the following claims. Redrafting of claim scope in
later filed
corresponding applications may be due to limitations by the patent laws of
various
countries and should not be interpreted as giving up subject matter of the
claims.
82
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
SEQUENCE LISTING (Figure 2)
Human Klotho nucleic acid sequence (NM_004795) (SEQ ID NO: 1)
Protein coding region: 9-3047
1 cgcgcagcat gcccgccagc gccccgccgc gccgcccgcg gccgccgccg
ccgtcgctgt
61 cgctgctgct ggtgctgctg ggcctgggcg gccgccgcct gcgtgcggag
ccgggcgacg
121 gcgcgcagac ctgggcccgt ttctcgcggc ctcctgcccc cgaggccgcg
ggcctcttcc
181 agggcacctt ccccgacggc ttcctctggg ccgtgggcag cgccgcctac
cagaccgagg
241 gcggctggca gcagcacggc aagggtgcgt ccatctggga tacgttcacc
caccaccccc
301 tggcaccccc gggagactcc cggaacgcca gtctgccgtt gggcgccccg
tcgccgctgc
361 agcccgccac cggggacgta gccagcgaca gctacaacaa cgtcttccgc
gacacggagg
421 cgctgcgcga gctcggggtc actcactacc gcttctccat ctcgtgggcg
cgagtgctcc
481 ccaatggcag cgcgggcgtc cccaaccgcg aggggctgcg ctactaccgg
cgcctgctgg
541 agcggctgcg ggagctgggc gtgcagcccg tggtcaccct gtaccactgg
gacctgcccc
601 agcgcctgca ggacgcctac ggcggctggg ccaaccgcgc cctggccgac
cacttcaggg
661 attacgcgga gctctgcttc cgccacttcg gcggtcaggt caagtactgg
atcaccatcg
721 acaaccccta cgtggtggcc tggcacggct acgccaccgg gcgcctggcc
cccggcatcc
781 ggggcagccc gcggctcggg tacctggtgg cgcacaacct cctcctggct
catgccaaag
841 tctggcatct ctacaatact tctttccgtc ccactcaggg aggtcaggtg
tccattgccc
901 taagctctca ctggatcaat cctcgaagaa tgaccgacca cagcatcaaa
gaatgtcaaa
961 aatctctgga ctttgtacta ggttggtttg ccaaacccgt atttattgat
ggtgactatc
1021 ccgagagcat gaagaataac ctttcatcta ttctgcctga ttttactgaa
tctgagaaaa
1081 agttcatcaa aggaactgct gacttttttg ctctttgctt tggacccacc
ttgagttttc
1141 aacttttgga ccctcacatg aagttccgcc aattggaatc tcccaacctg
aggcaactgc
1201 tttcctggat tgaccttgaa tttaaccatc ctcaaatatt tattgtggaa
aatggctggt
1261 ttgtctcagg gaccaccaag agagatgatg ccaaatatat gtattacctc
aaaaagttca
1321 tcatggaaac cttaaaagcc atcaagctgg atggggtgga tgtcatcggg
tataccgcat
1381 ggtccctcat ggatggtttc gagtggcaca gaggttacag catcaggcgt
ggactcttct
1441 atgttgactt tctaagccag gacaagatgt tgttgccaaa gtcttcagcc
ttgttctacc
1501 aaaagctgat agagaaaaat ggcttccctc ctttacctga aaatcagccc
ctagaaggga
1561 catttccctg tgactttgct tggggagttg ttgacaacta cattcaagta
gataccactc
83
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
1621 tgtctcagtt taccgacctg aatgtttacc tgtgggatgt ccaccacagt
aaaaggctta
1681 ttaaagtgga tggggttgtg accaagaaga ggaaatccta ctgtgttgac
tttgctgcca
1741 tccagcccca gatcgcttta ctccaggaaa tgcacgttac acattttcgc
ttctccctgg
1801 actgggccct gattctccct ctgggtaacc agtcccaggt gaaccacacc
atcctgcagt
1861 actatcgctg catggccagc gagcttgtcc gtgtcaacat caccccagtg
gtggccctgt
1921 ggcagcctat ggccccgaac caaggactgc cgcgcctcct ggccaggcag
ggcgcctggg
1981 agaaccccta cactgccctg gcctttgcag agtatgcccg actgtgcttt
caagagctcg
2041 gccatcacgt caagctttgg ataacgatga atgagccgta tacaaggaat
atgacataca
2101 gtgctggcca caaccttctg aaggcccatg ccctggcttg gcatgtgtac
aatgaaaagt
2161 ttaggcatgc tcagaatggg aaaatatcca tagccttgca ggctgattgg
atagaacctg
2221 cctgcccttt ctcccaaaag gacaaagagg tggccgagag agttttggaa
tttgacattg
2281 gctggctggc tgagcccatt ttcggctctg gagattatcc atgggtgatg
agggactggc
2341 tgaaccaaag aaacaatttt cttcttcctt atttcactga agatgaaaaa
aagctaatcc
2401 agggtacctt tgactttttg gctttaagcc attataccac catccttgta
gactcagaaa
2461 aagaagatcc aataaaatac aatgattacc tagaagtgca agaaatgacc
gacatcacgt
2521 ggctcaactc ccccagtcag gtggcggtag tgccctgggg gttgcgcaaa
gtgctgaact
2581 ggctgaagtt caagtacgga gacctcccca tgtacataat atccaacgga
atcgatgacg
2641 ggctgcatgc tgaggacgac cagctgaggg tgtattatat gcagaattac
ataaacgaag
2701 ctctcaaagc ccacatactg gatggtatca atctttgcgg atactttgct
tattcgttta
2761 acgaccgcac agctccgagg tttggcctct atcgttatgc tgcagatcag
tttgagccca
2821 aggcatccat gaaacattac aggaaaatta ttgacagcaa tggtttcccg
ggcccagaaa
2881 ctctggaaag attttgtcca gaagaattca ccgtgtgtac tgagtgcagt
ttttttcaca
2941 cccgaaagtc tttactggct ttcatagctt ttctattttt tgcttctatt
atttctctct
3001 cccttatatt ttactactcg aagaaaggca gaagaagtta caaatagttc
tgaacatttt
3061 tctattcatt cattttgaaa taattatgca gacacatcag ctgttaacca
tttgcacctc
3121 taagtgttgt gaaactgtaa atttcataca tttgacttct agaaaacatt
tttgtggctt
3181 atgacagagg ttttgaaatg ggcataggtg atcgtaaaat attgaataat
gcgaatagtg
3241 cctgaatttg ttctcttttt gggtgattaa aaaactgaca ggcactataa
tttctgtaac
3301 acactaacaa aagcatgaaa aataggaacc acaccaatgc aacatttgtg
cagaaatttg
3361 aatgacaaga ttaggaatat tttcttctgc acccacttct aaatttaatg
tttttctgga
3421 agtagtaatt gcaagagttc gaatagaaag ttatgtacca agtaaccatt
tctcagctgc
84
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
3481 cataataatg cctagtggct tcccctctgt caaatctagt ttcctatgga
aaagaagatg
3541 gcagatacag gagagacgac agagggtcct aggctggaat gttcctttcg
aaagcaatgc
3601 ttctatcaaa tactagtatt aatttatgta tctggttaat gacatacttg
gagagcaaat
3661 tatggaaatg tgtattttat atgatttttg aggtcctgtc taaaccctgt
gtccctgagg
3721 gatctgtctc actggcatct tgttgagggc cttgcacata ggaaactttt
gataagtatc
3781 tgcggaaaaa caaacatgaa tcctgtgata ttgggctctt caggaagcat
aaagcaattg
3841 tgaaatacag tataccgcag tggctctagg tggaggaaag gaggaaaaag
tgcttattat
3901 gtgcaacatt atgattaatc tgattataca ccatttttga gcagatcttg
gaatgaatga
3961 catgaccttt ccctagagaa taaggatgaa ataatcactc attctatgaa
cagtgacact
4021 actttctatt ctttagctgt actgtaattt ctttgagttg atagttttac
aaattcttaa
4081 taggttcaaa agcaatctgg tctgaataac actggatttg tttctgtgat
ctctgaggtc
4141 tattttatgt ttttgctgct acttctgtgg aagtagcttt gaactagttt
tactttgaac
4201 tttcacgctg aaacatgcta gtgatatcta gaaagggcta attaggtctc
atcctttaat
4261 gccccttaaa taagtcttgc tgattttcag acagggaagt ctctctatta
cactggagct
4321 gttttataga taagtcaata ttgtatcagg caagataaac caatgtcata
acaggcattg
4381 ccaacctcac tgacacaggg tcatagtgta taataatata ctgtactata
taatatatca
4441 tctttagagg tatgattttt tcatgaaaga taagcttttg gtaatattca
ttttaaagtg
4501 gacttattaa aattggatgc tagagaatca agtttatttt atgtatatat
ttttctgatt
4561 ataagagtaa tatatgttca ttgtaaaaat ttttaaaaca cagaaactat
atgcaaagaa
4621 aaaataaaaa ttatctataa tctcagaacc cagaaatagc cactattaac
atttcctacg
4681 tattttattt tacatagatc atattgtata tagttagtat ctttattaat
ttttattatg
4741 aaactttcct ttgtcattat tagtcttcaa aagcatgatt tttaatagtt
gttgagtatt
4801 ccaccacagg aatgtatcac aacttaaccg ttcccgtttg ttagactagt
ttcttattaa
4861 tgttgatgaa tgttgtttaa aaataatttt gttgctacat ttactttaat
ttccttgact
4921 gtaaagagaa gtaattttgc tccttgataa agtattatat taataataaa
tctgcctgca
4981 actttttgcc ttctttcata atc
Klotho amino acid sequence (NP_004786) (SEQ ID NO: 2)
1 MPASAPPRRP RPPPPSLSLL LVLLGLGGRR LRAEPGDGAQ TWARFSRPPA PEAAGLFQGT
61 FPDGFLWAVG SAAYQTEGGW QQHGKGASIW DTFTHHPLAP PGDSRNASLP LGAPSPLQPA
121 TGDVASDSYN NVFRDTEALR ELGVTHYRFS ISWARVLPNG SAGVPNREGL RYYRRLLERL
181 RELGVQPVVT LYHWDLPQRL QDAYGGWANR ALADHFRDYA ELCFRHFGGQ VKYWITIDNP
241 YVVAWHGYAT GRLAPGIRGS PRLGYLVAHN LLLAHAKVWH LYNTSFRPTQ GGQVSIALSS
301 HWINPRRMTD HSIKECQKSL DFVLGWFAKP VFIDGDYPES MKNNLSSILP DFTESEKKFI
361 KGTADFFALC FGPTLSFQLL DPHMKFRQLE SPNLRQLLSW IDLEFNHPQI FIVENGWFVS
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
421 GTTKRDDAKY MYYLKKFIME TLKAIKLDGV DVIGYTAWSL MDGFEWHRGY SIRRGLFYVD
481 FLSQDKMLLP KSSALFYQKL IEKNGFPPLP ENQPLEGTFP CDFAWGVVDN YIQVDTTLSQ
541 FTDLNVYLWD VHHSKRLIKV DGVVTKKRKS YCVDFAAIQP QIALLQEMHV THFRFSLDWA
601 LILPLGNQSQ VNHTILQYYR CMASELVRVN ITPVVALWQP MAPNQGLPRL LARQGAWENP
661 YTALAFAEYA RLCFQELGHH VKLWITMNEP YTRNMTYSAG HNLLKAHALA WHVYNEKFRH
721 AQNGKISIAL QADWIEPACP FSQKDKEVAE RVLEFDIGWL AEPIFGSGDY PWVMRDWLNQ
781 RNNFLLPYFT EDEKKLIQGT FDFLALSHYT TILVDSEKED PIKYNDYLEV QEMTDITWLN
841 SPSQVAVVPW GLRKVLNWLK FKYGDLPMYI ISNGIDDGLH AEDDQLRVYY MQNYINEALK
901 AHILDGINLC GYFAYSFNDR TAPRFGLYRY AADQFEPKAS MKHYRKIIDS NGFPGPETLE
961 RFCPEEFTVC TECSFFHTRK SLLAFIAFLF FASIISLSLI FYYSKKGRRS YK
beta-Klotho nucleic acid sequence (NM_175737) (SEQ ID NO: 3)
Protein coding region: 98-3232
1 atcctcagtc tcccagttca agctaatcat tgacagagct ttacaatcac aagcttttac
61 tgaagctttg ataagacagt ccagcagttg gtggcaaatg aagccaggct gtgcggcagg
121 atctccaggg aatgaatgga ttttcttcag cactgatgaa ataaccacac gctataggaa
181 tacaatgtcc aacgggggat tgcaaagatc tgtcatcctg tcagcactta ttctgctacg
241 agctgttact ggattctctg gagatggaag agctatatgg tctaaaaatc ctaattttac
301 tccggtaaat gaaagtcagc tgtttctcta tgacactttc cctaaaaact ttttctgggg
361 tattgggact ggagcattgc aagtggaagg gagttggaag aaggatggaa aaggaccttc
421 tatatgggat catttcatcc acacacacct taaaaatgtc agcagcacga atggttccag
481 tgacagttat atttttctgg aaaaagactt atcagccctg gattttatag gagtttcttt
541 ttatcaattt tcaatttcct ggccaaggct tttccccgat ggaatagtaa cagttgccaa
601 cgcaaaaggt ctgcagtact acagtactct tctggacgct ctagtgctta gaaacattga
661 acctatagtt actttatacc actgggattt gcctttggca ctacaagaaa aatatggggg
721 gtggaaaaat gataccataa tagatatctt caatgactat gccacatact gtttccagat
781 gtttggggac cgtgtcaaat attggattac aattcacaac ccatatctag tggcttggca
841 tgggtatggg acaggtatgc atgcccctgg agagaaggga aatttagcag ctgtctacac
901 tgtgggacac aacttgatca aggctcactc gaaagtttgg cataactaca acacacattt
961 ccgcccacat cagaagggtt ggttatcgat cacgttggga tctcattgga tcgagccaaa
1021 ccggtcggaa aacacgatgg atatattcaa atgtcaacaa tccatggttt ctgtgcttgg
1081 atggtttgcc aaccctatcc atggggatgg cgactatcca gaggggatga gaaagaagtt
1141 gttctccgtt ctacccattt tctctgaagc agagaagcat gagatgagag gcacagctga
1201 tttctttgcc ttttcttttg gacccaacaa cttcaagccc ctaaacacca tggctaaaat
1261 gggacaaaat gtttcactta atttaagaga agcgctgaac tggattaaac tggaatacaa
1321 caaccctcga atcttgattg ctgagaatgg ctggttcaca gacagtcgtg tgaaaacaga
1381 agacaccacg gccatctaca tgatgaagaa tttcctcagc caggtgcttc aagcaataag
1441 gttagatgaa atacgagtgt ttggttatac tgcctggtct ctcctggatg gctttgaatg
1501 gcaggatgct tacaccatcc gccgaggatt attttatgtg gattttaaca gtaaacagaa
1561 agagcggaaa cctaagtctt cagcacacta ctacaaacag atcatacgag aaaatggttt
1621 ttctttaaaa gagtccacgc cagatgtgca gggccagttt ccctgtgact tctcctgggg
1681 tgtcactgaa tctgttctta agcccgagtc tgtggcttcg tccccacagt tcagcgatcc
1741 tcatctgtac gtgtggaacg ccactggcaa cagactgttg caccgagtgg aaggggtgag
1801 gctgaaaaca cgacccgctc aatgcacaga ttttgtaaac atcaaaaaac aacttgagat
1861 gttggcaaga atgaaagtca cccactaccg gtttgctctg gattgggcct cggtccttcc
1921 cactggcaac ctgtccgcgg tgaaccgaca ggccctgagg tactacaggt gcgtggtcag
1981 tgaggggctg aagcttggca tctccgcgat ggtcaccctg tattatccga cccacgccca
2041 cctaggcctc cccgagcctc tgttgcatgc cgacgggtgg ctgaacccat cgacggccga
2101 ggccttccag gcctacgctg ggctgtgctt ccaggagctg ggggacctgg tgaagctctg
2161 gatcaccatc aacgagccta accggctaag tgacatctac aaccgctctg gcaacgacac
2221 ctacggggcg gcgcacaacc tgctggtggc ccacgccctg gcctggcgcc tctacgaccg
2281 gcagttcagg ccctcacagc gcggggccgt gtcgctgtcg ctgcacgcgg actgggcgga
2341 acccgccaac ccctatgctg actcgcactg gagggcggcc gagcgcttcc tgcagttcga
2401 gatcgcctgg ttcgccgagc cgctcttcaa gaccggggac taccccgcgg ccatgaggga
2461 atacattgcc tccaagcacc gacgggggct ttccagctcg gccctgccgc gcctcaccga
2521 ggccgaaagg aggctgctca agggcacggt cgacttctgc gcgctcaacc acttcaccac
2581 taggttcgtg atgcacgagc agctggccgg cagccgctac gactcggaca gggacatcca
2641 gtttctgcag gacatcaccc gcctgagctc ccccacgcgc ctggctgtga ttccctgggg
2701 ggtgcgcaag ctgctgcggt gggtccggag gaactacggc gacatggaca tttacatcac
2761 cgccagtggc atcgacgacc aggctctgga ggatgaccgg ctccggaagt actacctagg
86
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
2821 gaagtacctt caggaggtgc tgaaagcata cctgattgat aaagtcagaa tcaaaggcta
2881 ttatgcattc aaactggctg aagagaaatc taaacccaga tttggattct tcacatctga
2941 ttttaaagct aaatcctcaa tacaatttta caacaaagtg atcagcagca ggggcttccc
3001 ttttgagaac agtagttcta gatgcagtca gacccaagaa aatacagagt gcactgtctg
3061 cttattcctt gtgcagaaga aaccactgat attcctgggt tgttgcttct tctccaccct
3121 ggttctactc ttatcaattg ccatttttca aaggcagaag agaagaaagt tttggaaagc
3181 aaaaaactta caacacatac cattaaagaa aggcaagaga gttgttagct aaactgatct
3241 gtctgcatga tagacagttt aaaaattcat cccagttcc
beta-Klotho amino acid sequence (NP_783864) (SEQ ID NO: 4)
1 mkpgcaagsp gnewiffstd eittryrntm sngglqrsvi lsalillrav tgfsgdgrai
61 wsknpnftpv nesqlflydt fpknffwgig tgalqvegsw kkdgkgpsiw dhfihthlkn
121 vsstngssds yiflekdlsa ldfigvsfyq fsiswprlfp dgivtvanak glqyystlld
181 alvlrniepi vtlyhwdlpl alqekyggwk ndtiidifnd yatycfqmfg drvkywitih
241 npylvawhgy gtgmhapgek gnlaavytvg hnlikahskv whnynthfrp hqkgwlsitl
301 gshwiepnrs entmdifkcq qsmvsvlgwf anpihgdgdy pegmrkklfs vlpifseaek
361 hemrgtadff afsfgpnnfk plntmakmgq nvslnlreal nwikleynnp riliaengwf
421 tdsrvktedt taiymmknfl sqvlqairld eirvfgytaw slldgfewqd aytirrglfy
481 vdfnskqker kpkssahyyk qiirengfsl kestpdvqgq fpcdfswgvt esvlkpesva
541 sspqfsdphl yvwnatgnrl lhrvegvrlk trpaqctdfv nikkqlemla rmkvthyrfa
601 ldwasvlptg nlsavnrqal ryyrcvvseg lklgisamvt lyypthahlg lpepllhadg
661 wlnpstaeaf qayaglcfqe lgdlvklwit inepnrlsdi ynrsgndtyg aahnllvaha
721 lawrlydrqf rpsqrgavsl slhadwaepa npyadshwra aerflqfeia wfaeplfktg
781 dypaamreyi askhrrglss salprlteae rrllkgtvdf calnhfttrf vmheqlagsr
841 ydsdrdigfl qditrlsspt rlavipwgvr kllrwvrrny gdmdiyitas giddqaledd
901 rlrkyylgky lqevlkayli dkvrikgyya fklaeekskp rfgfftsdfk akssiqfynk
961 vissrgfpfe nsssrcsqtq entectvclf lvqkkplifl gccffstlvl llsiaifgrq
1021 krrkfwkakn lqhiplkkgk rvvs
Human Klotho domain 1 (KL-D1) amino acid sequence (SEQ ID NO: 5)
58 qgt
61 fpdgflwavg saayqteggw qqhgkgasiw dtfthhplap pgdsrnaslp lgapsplqpa
121 tgdvasdsyn nvfrdtealr elgvthyrfs iswarvlpng sagvpnregl ryyrrllerl
181 relgvqpvvt lyhwdlpqrl qdayggwanr aladhfrdya elcfrhfggq vkywitidnp
241 yvvawhgyat grlapgirgs prlgylvahn lllahakvwh lyntsfrptq ggqvsialss
301 hwinprrmtd hsikecqksl dfvlgwfakp vfidgdypes mknnlssilp dftesekkfi
361 kgtadffalc fgptlsfqll dphmkfrqle spnlrqllsw idlefnhpqi fivengwfvs
421 gttkrddaky myylkkfime tlkaikldgv dvigytawsl mdgfewhrgy sirrglfyvd
481 flsqdkmllp kssalfyqkl iekngf
Human Klotho domain 2 (KL-D2) amino acid sequence (SEQ ID NO: 6)
517 gtfp cdfawgvvdn yiqvdttlsq
541 ftdlnvylwd vhhskrlikv dgvvtkkrks ycvdfaaiqp qiallqemhv thfrfsldwa
601 lilplgnqsq vnhtilqyyr cmaselvrvn itpvvalwqp mapnqglprl larqgawenp
661 ytalafaeya rlcfqelghh vklwitmnep ytrnmtysag hnllkahala whvynekfrh
721 aqngkisial qadwiepacp fsqkdkevae rvlefdigwl aepifgsgdy pwvmrdwlnq
781 rnnfllpyft edekkliqgt fdflalshyt tilvdseked pikyndylev qemtditwln
841 spsqvavvpw glrkvlnwlk fkygdlpmyi isngiddglh aeddqlrvyy mqnyinealk
901 ahildginlc gyfaysfndr taprfglyry aadqfepkas mkhyrkiids ngf
Klotho extracellular domain (without signal peptide) amino acid sequence (SEQ
ID
NO: 7)
28 epgdgaq twarfsrppa peaaglfqgt
61 fpdgflwavg saayqteggw qqhgkgasiw dtfthhplap pgdsrnaslp lgapsplqpa
121 tgdvasdsyn nvfrdtealr elgvthyrfs iswarvlpng sagvpnregl ryyrrllerl
87
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
181 relgvqpvvt lyhwdlpqrl qdayggwanr aladhfrdya elcfrhfggq vkywitidnp
241 yvvawhgyat grlapgirgs prlgylvahn lllahakvwh lyntsfrptq ggqvsialss
301 hwinprrmtd hsikecgksl dfvlgwfakp vfidgdypes mknnlssilp dftesekkfi
361 kgtadffalc fgptlsfgll dphmkfrgle spnlrgllsw idlefnhpgi fivengwfvs
421 gttkrddaky myylkkfime tlkaikldgv dvigytawsl mdgfewhrgy sirrglfyvd
481 flsgdkmllp kssalfygkl iekngfpplp engplegtfp cdfawgvvdn yigvdttlsq
541 ftdlnvylwd vhhskrlikv dgvvtkkrks ycvdfaaiqp giallgemhv thfrfsldwa
601 lilplgngsq vnhtilgyyr cmaselvrvn itpvvalwgp mapngglprl larggawenp
661 ytalafaeya rlcfqelghh vklwitmnep ytrnmtysag hnllkahala whvynekfrh
721 aqngkisial qadwiepacp fsqkdkevae rvlefdigwl aepifgsgdy pwvmrdwlnq
781 rnnfllpyft edekkliqgt fdflalshyt tilvdseked pikyndylev qemtditwln
841 spsqvavvpw glrkvlnwlk fkygdlpmyi isngiddglh aeddqlrvyy mqnyinealk
901 ahildginlc gyfaysfndr taprfglyry aadqfepkas mkhyrkiids ngfpgpetle
961 rfcpeeftvc tecsffhtrk sl
Klotho signal peptide amino acid sequence (SEQ ID NO: 8)
1 mpasapprrp rppppslsll lvllglggrr lra
IgG signal peptide amino acid sequence (SEQ ID NO: 9)
1 msvltgvlal lllwltgtrc rrlra
(Gly4 Ser)3 polypeptide linker nucleic acid sequence (SEQ ID NO: 10)
1 ggaggtggag gttcaggagg tggaggttca ggaggtggag gttca
(Gly4 Ser)3 polypeptide linker amino acid sequence (SEQ ID NO: 11)
1 GGGGSGGGGS GGGGS
(Gly4 Ser) polypeptide linker amino acid sequence (SEQ ID NO: 12)
1 GGGGS
(Gly) polypeptide linker amino acid sequence (SEQ ID NO: 13)
1 G
(Gly Gly) polypeptide linker amino acid sequence (SEQ ID NO: 14)
1 GG
(Gly Ser) polypeptide linker amino acid sequence (SEQ ID NO: 15)
1 GS
(Gly2 Ser) polypeptide linker amino acid sequence (SEQ ID NO: 16)
1 GGS
(Ala) polypeptide linker amino acid sequence (SEQ ID NO: 17)
88
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
1 A
(Ala Ala) polypeptide linker amino acid sequence (SEQ ID NO: 18)
1 AA
Klotho signal peptide-Klotho extracellular domain-FGF23 (R179Q)
amino acid sequence (SEQ ID NO: 19)
1 MPASAPPRRP RPPPPSLSLL LVLLGLGGRR LRAEPGDGAQ TWARFSRPPA
51 PEAAGLFQGT FPDGFLWAVG SAAYQTEGGW QQHGKGASIW DTFTHHPLAP
101 PGDSRNASLP LGAPSPLQPA TGDVASDSYN NVFRDTEALR ELGVTHYRFS
151 ISWARVLPNG SAGVPNREGL RYYRRLLERL RELGVQPVVT LYHWDLPQRL
201 QDAYGGWANR ALADHFRDYA ELCFRHFGGQ VKYWITIDNP YVVAWHGYAT
251 GRLAPGIRGS PRLGYLVAHN LLLAHAKVWH LYNTSFRPTQ GGQVSIALSS
301 HWINPRRMTD HSIKECQKSL DFVLGWFAKP VFIDGDYPES MKNNLSSILP
351 DFTESEKKFI KGTADFFALC FGPTLSFQLL DPHMKFRQLE SPNLRQLLSW
401 IDLEFNHPQI FIVENGWFVS GTTKRDDAKY MYYLKKFIME TLKAIKLDGV
451 DVIGYTAWSL MDGFEWHRGY SIRRGLFYVD FLSQDKMLLP KSSALFYQKL
501 IEKNGFPPLP ENQPLEGTFP CDFAWGVVDN YIQVDTTLSQ FTDLNVYLWD
551 VHHSKRLIKV DGVVTKKRKS YCVDFAAIQP QIALLQEMHV THFRFSLDWA
601 LILPLGNQSQ VNHTILQYYR CMASELVRVN ITPVVALWQP MAPNQGLPRL
651 LARQGAWENP YTALAFAEYA RLCFQELGHH VKLWITMNEP YTRNMTYSAG
701 HNLLKAHALA WHVYNEKFRH AQNGKISIAL QADWIEPACP FSQKDKEVAE
751 RVLEFDIGWL AEPIFGSGDY PWVMRDWLNQ RNNFLLPYFT EDEKKLIQGT
801 FDFLALSHYT TILVDSEKED PIKYNDYLEV QEMTDITWLN SPSQVAVVPW
851 GLRKVLNWLK FKYGDLPMYI ISNGIDDGLH AEDDQLRVYY MQNYINEALK
901 AHILDGINLC GYFAYSFNDR TAPRFGLYRY AADQFEPKAS MKHYRKIIDS
951 NGFPGPETLE RFCPEEFTVC TECSFFHTRK SLGSGGGGSG GGGSGGGGSL
1001 KYPNASPLLG SSWGGLIHLY TATARNSYHL QIHKNGHVDG APHQTIYSAL
1051 MIRSEDAGFV VITGVMSRRY LCMDFRGNIF GSHYFDPENC RFQHQTLENG
1101 YDVYHSPQYH FLVSLGRAKR AFLPGMNPPP YSQFLSRRNE IPLIHFNTPI
1151 PRRHTQSAED DSERDPLNVL KPRARMTPAP ASCSQELPSA EDNSPMASDP
1201 LGVVRGGRVN THAGGTGPEG CRPFAKFI*
IgG signal peptide-Klotho extracellular domain-FGF23 (R179Q)
amino acid sequence (SEQ ID NO: 20)
1 MSVLTQVLAL LLLWLTGLGG RRLRAEPGDG AQTWARFSRP PAPEAAGLFQ
51 GTFPDGFLWA VGSAAYQTEG GWQQHGKGAS IWDTFTHHPL APPGDSRNAS
101 LPLGAPSPLQ PATGDVASDS YNNVFRDTEA LRELGVTHYR FSISWARVLP
151 NGSAGVPNRE GLRYYRRLLE RLRELGVQPV VTLYHWDLPQ RLQDAYGGWA
201 NRALADHFRD YAELCFRHFG GQVKYWITID NPYVVAWHGY ATGRLAPGIR
251 GSPRLGYLVA HNLLLAHAKV WHLYNTSFRP TQGGQVSIAL SSHWINPRRM
301 TDHSIKECQK SLDFVLGWFA KPVFIDGDYP ESMKNNLSSI LPDFTESEKK
351 FIKGTADFFA LCFGPTLSFQ LLDPHMKFRQ LESPNLRQLL SWIDLEFNHP
401 QIFIVENGWF VSGTTKRDDA KYMYYLKKFI METLKAIKLD GVDVIGYTAW
451 SLMDGFEWHR GYSIRRGLFY VDFLSQDKML LPKSSALFYQ KLIEKNGFPP
501 LPENQPLEGT FPCDFAWGVV DNYIQVDTTL SQFTDLNVYL WDVHHSKRLI
551 KVDGVVTKKR KSYCVDFAAI QPQIALLQEM HVTHFRFSLD WALILPLGNQ
601 SQVNHTILQY YRCMASELVR VNITPVVALW QPMAPNQGLP RLLARQGAWE
651 NPYTALAFAE YARLCFQELG HHVKLWITMN EPYTRNMTYS AGHNLLKAHA
701 LAWHVYNEKF RHAQNGKISI ALQADWIEPA CPFSQKDKEV AERVLEFDIG
751 WLAEPIFGSG DYPWVMRDWL NQRNNFLLPY FTEDEKKLIQ GTFDFLALSH
801 YTTILVDSEK EDPIKYNDYL EVQEMTDITW LNSPSQVAVV PWGLRKVLNW
851 LKFKYGDLPM YIISNGIDDG LHAEDDQLRV YYMQNYINEA LKAHILDGIN
901 LCGYFAYSFN DRTAPRFGLY RYAADQFEPK ASMKHYRKII DSNGFPGPET
951 LERFCPEEFT VCTECSFFHT RKSLGSGGGG SGGGGSGGGG SLKYPNASPL
89
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
1001 LGSSWGGLIH LYTATARNSY HLQIHKNGHV DGAPHQTIYS ALMIRSEDAG
1051 FVVITGVMSR RYLCMDFRGN IFGSHYFDPE NCRFQHQTLE NGYDVYHSPQ
1101 YHFLVSLGRA KRAFLPGMNP PPYSQFLSRR NEIPLIHFNT PIPRRHTQSA
1151 EDDSERDPLN VLKPRARMTP APASCSQELP SAEDNSPMAS DPLGVVRGGR
1201 VNTHAGGTGP EGCRPFAKFI *
KL-DI-FGF23 (R179Q) amino acid sequence (SEQ ID NO: 21)
1 MPASAPPRRP RPPPPSLSLL LVLLGLGGRR LRAEPGDGAQ TWARFSRPPA
51 PEAAGLFQGT FPDGFLWAVG SAAYQTEGGW QQHGKGASIW DTFTHHPLAP
101 PGDSRNASLP LGAPSPLQPA TGDVASDSYN NVFRDTEALR ELGVTHYRFS
151 ISWARVLPNG SAGVPNREGL RYYRRLLERL RELGVQPVVT LYHWDLPQRL
201 QDAYGGWANR ALADHFRDYA ELCFRHFGGQ VKYWITIDNP YVVAWHGYAT
251 GRLAPGIRGS PRLGYLVAHN LLLAHAKVWH LYNTSFRPTQ GGQVSIALSS
301 HWINPRRMTD HSIKECQKSL DFVLGWFAKP VFIDGDYPES MKNNLSSILP
351 DFTESEKKFI KGTADFFALC FGPTLSFQLL DPHMKFRQLE SPNLRQLLSW
401 IDLEFNHPQI FIVENGWFVS GTTKRDDAKY MYYLKKFIME TLKAIKLDGV
451 DVIGYTAWSL MDGFEWHRGY SIRRGLFYVD FLSQDKMLLP KSSALFYQKL
501 IEKNGFPPLP ENQPLEGSGG GGSGGGGSGG GGSLKYPNAS PLLGSSWGGL
551 IHLYTATARN SYHLQIHKNG HVDGAPHQTI YSALMIRSED AGFVVITGVM
601 SRRYLCMDFR GNIFGSHYFD PENCRFQHQT LENGYDVYHS PQYHFLVSLG
651 RAKRAFLPGM NPPPYSQFLS RRNEIPLIHF NTPIPRRHTQ SAEDDSERDP
701 LNVLKPRARM TPAPASCSQE LPSAEDNSPM ASDPLGVVRG GRVNTHAGGT
751 GPEGCRPFAK FI*
KL-D2-FGF23 (R179Q) amino acid sequence (SEQ ID NO: 22)
1 MPASAPPRRP RPPPPSLSLL LVLLGLGGRR LPLPENQPLE GTFPCDFAWG
51 VVDNYIQVDT TLSQFTDLNV YLWDVHHSKR LIKVDGVVTK KRKSYCVDFA
101 AIQPQIALLQ EMHVTHFRFS LDWALILPLG NQSQVNHTIL QYYRCMASEL
151 VRVNITPVVA LWQPMAPNQG LPRLLARQGA WENPYTALAF AEYARLCFQE
201 LGHHVKLWIT MNEPYTRNMT YSAGHNLLKA HALAWHVYNE KFRHAQNGKI
251 SIALQADWIE PACPFSQKDK EVAERVLEFD IGWLAEPIFG SGDYPWVMRD
301 WLNQRNNFLL PYFTEDEKKL IQGTFDFLAL SHYTTILVDS EKEDPIKYND
351 YLEVQEMTDI TWLNSPSQVA VVPWGLRKVL NWLKFKYGDL PMYIISNGID
401 DGLHAEDDQL RVYYMQNYIN EALKAHILDG INLCGYFAYS FNDRTAPRFG
451 LYRYAADQFE PKASMKHYRK IIDSNGFPGP ETLERFCPEE FTVCTECSFF
501 HTRKSLGSGG GGSGGGGSGG GGSLKYPNAS PLLGSSWGGL IHLYTATARN
551 SYHLQIHKNG HVDGAPHQTI YSALMIRSED AGFVVITGVM SRRYLCMDFR
601 GNIFGSHYFD PENCRFQHQT LENGYDVYHS PQYHFLVSLG RAKRAFLPGM
651 NPPPYSQFLS RRNEIPLIHF NTPIPRRHTQ SAEDDSERDP LNVLKPRARM
701 TPAPASCSQE LPSAEDNSPM ASDPLGVVRG GRVNTHAGGT GPEGCRPFAK
751 FI*
(KL-D1)2-FGF23 (R179Q) amino acid sequence (SEQ ID NO: 23)
1 MPASAPPRRP RPPPPSLSLL LVLLGLGGRR LRAEPGDGAQ TWARFSRPPA
51 PEAAGLFQGT FPDGFLWAVG SAAYQTEGGW QQHGKGASIW DTFTHHPLAP
101 PGDSRNASLP LGAPSPLQPA TGDVASDSYN NVFRDTEALR ELGVTHYRFS
151 ISWARVLPNG SAGVPNREGL RYYRRLLERL RELGVQPVVT LYHWDLPQRL
201 QDAYGGWANR ALADHFRDYA ELCFRHFGGQ VKYWITIDNP YVVAWHGYAT
251 GRLAPGIRGS PRLGYLVAHN LLLAHAKVWH LYNTSFRPTQ GGQVSIALSS
301 HWINPRRMTD HSIKECQKSL DFVLGWFAKP VFIDGDYPES MKNNLSSILP
351 DFTESEKKFI KGTADFFALC FGPTLSFQLL DPHMKFRQLE SPNLRQLLSW
401 IDLEFNHPQI FIVENGWFVS GTTKRDDAKY MYYLKKFIME TLKAIKLDGV
451 DVIGYTAWSL MDGFEWHRGY SIRRGLFYVD FLSQDKMLLP KSSALFYQKL
501 IEKNGFPPLP ENQPLEGSGT FPDGFLWAVG SAAYQTEGGW QQHGKGASIW
551 DTFTHHPLAP PGDSRNASLP LGAPSPLQPA TGDVASDSYN NVFRDTEALR
601 ELGVTHYRFS ISWARVLPNG SAGVPNREGL RYYRRLLERL RELGVQPVVT
651 LYHWDLPQRL QDAYGGWANR ALADHFRDYA ELCFRHFGGQ VKYWITIDNP
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
701 YVVAWHGYAT GRLAPGIRGS PRLGYLVAHN LLLAHAKVWH LYNTSFRPTQ
751 GGQVSIALSS HWINPRRMTD HSIKECQKSL DFVLGWFAKP VFIDGDYPES
801 MKNNLSSILP DFTESEKKFI KGTADFFALC FGPTLSFQLL DPHMKFRQLE
851 SPNLRQLLSW IDLEFNHPQI FIVENGWFVS GTTKRDDAKY MYYLKKFIME
901 TLKAIKLDGV DVIGYTAWSL MDGFEWHRGY SIRRGLFYVD FLSQDKMLLP
951 KSSALFYQKL IEKNGFPEFG SGGGGSGGGG SGGGGSLKYP NASPLLGSSW
1001 GGLIHLYTAT ARNSYHLQIH KNGHVDGAPH QTIYSALMIR SEDAGFVVIT
1051 GVMSRRYLCM DFRGNIFGSH YFDPENCRFQ HQTLENGYDV YHSPQYHFLV
1101 SLGRAKRAFL PGMNPPPYSQ FLSRRNEIPL IHFNTPIPRR HTQSAEDDSE
1151 RDPLNVLKPR ARMTPAPASC SQELPSAEDN SPMASDPLGV VRGGRVNTHA
1201 GGTGPEGCRP FAKFI*
(KL-D2)2-FGF23 (R179Q) amino acid sequence (SEQ ID NO: 24)
1 MPASAPPRRP RPPPPSLSLL LVLLGLGGRR LPLPENQPLE GTFPCDFAWG
51 VVDNYIQVDT TLSQFTDLNV YLWDVHHSKR LIKVDGVVTK KRKSYCVDFA
101 AIQPQIALLQ EMHVTHFRFS LDWALILPLG NQSQVNHTIL QYYRCMASEL
151 VRVNITPVVA LWQPMAPNQG LPRLLARQGA WENPYTALAF AEYARLCFQE
201 LGHHVKLWIT MNEPYTRNMT YSAGHNLLKA HALAWHVYNE KFRHAQNGKI
251 SIALQADWIE PACPFSQKDK EVAERVLEFD IGWLAEPIFG SGDYPWVMRD
301 WLNQRNNFLL PYFTEDEKKL IQGTFDFLAL SHYTTILVDS EKEDPIKYND
351 YLEVQEMTDI TWLNSPSQVA VVPWGLRKVL NWLKFKYGDL PMYIISNGID
401 DGLHAEDDQL RVYYMQNYIN EALKAHILDG INLCGYFAYS FNDRTAPRFG
451 LYRYAADQFE PKASMKHYRK IIDSNGFPGP ETLERFCPEE FTVCTECSFF
501 HTRKSLGTFP CDFAWGVVDN YIQVDTTLSQ FTDLNVYLWD VHHSKRLIKV
551 DGVVTKKRKS YCVDFAAIQP QIALLQEMHV THFRFSLDWA LILPLGNQSQ
601 VNHTILQYYR CMASELVRVN ITPVVALWQP MAPNQGLPRL LARQGAWENP
651 YTALAFAEYA RLCFQELGHH VKLWITMNEP YTRNMTYSAG HNLLKAHALA
701 WHVYNEKFRH AQNGKISIAL QADWIEPACP FSQKDKEVAE RVLEFDIGWL
751 AEPIFGSGDY PWVMRDWLNQ RNNFLLPYFT EDEKKLIQGT FDFLALSHYT
801 TILVDSEKED PIKYNDYLEV QEMTDITWLN SPSQVAVVPW GLRKVLNWLK
851 FKYGDLPMYI ISNGIDDGLH AEDDQLRVYY MQNYINEALK AHILDGINLC
901 GYFAYSFNDR TAPRFGLYRY AADQFEPKAS MKHYRKIIDS NGFGSGGGGS
951 GGGGSGGGGS LKYPNASPLL GSSWGGLIHL YTATARNSYH LQIHKNGHVD
1001 GAPHQTIYSA LMIRSEDAGF VVITGVMSRR YLCMDFRGNI FGSHYFDPEN
1051 CRFQHQTLEN GYDVYHSPQY HFLVSLGRAK RAFLPGMNPP PYSQFLSRRN
1101 EIPLIHFNTP IPRRHTQSAE DDSERDPLNV LKPRARMTPA PASCSQELPS
1151 AEDNSPMASD PLGVVRGGRV NTHAGGTGPE GCRPFAKFI*
FGF23 (R179Q) -Klotho extracellular domain amino acid sequence (SEQ ID NO:
25)
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS
51 YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG
101 NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN
151 PPPYSQFLSR RNEIPLIHFN TPIPRRHTQS AEDDSERDPL NVLKPRARMT
201 PAPASCSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGCRPFAKF
251 IGSGGGGSGG GGSGGGGSLK EPGDGAQTWA RFSRPPAPEA AGLFQGTFPD
301 GFLWAVGSAA YQTEGGWQQH GKGASIWDTF THHPLAPPGD SRNASLPLGA
351 PSPLQPATGD VASDSYNNVF RDTEALRELG VTHYRFSISW ARVLPNGSAG
401 VPNREGLRYY RRLLERLREL GVQPVVTLYH WDLPQRLQDA YGGWANRALA
451 DHFRDYAELC FRHFGGQVKY WITIDNPYVV AWHGYATGRL APGIRGSPRL
501 GYLVAHNLLL AHAKVWHLYN TSFRPTQGGQ VSIALSSHWI NPRRMTDHSI
551 KECQKSLDFV LGWFAKPVFI DGDYPESMKN NLSSILPDFT ESEKKFIKGT
601 ADFFALCFGP TLSFQLLDPH MKFRQLESPN LRQLLSWIDL EFNHPQIFIV
651 ENGWFVSGTT KRDDAKYMYY LKKFIMETLK AIKLDGVDVI GYTAWSLMDG
701 FEWHRGYSIR RGLFYVDFLS QDKMLLPKSS ALFYQKLIEK NGFPPLPENQ
751 PLEGTFPCDF AWGVVDNYIQ VDTTLSQFTD LNVYLWDVHH SKRLIKVDGV
801 VTKKRKSYCV DFAAIQPQIA LLQEMHVTHF RFSLDWALIL PLGNQSQVNH
851 TILQYYRCMA SELVRVNITP VVALWQPMAP NQGLPRLLAR QGAWENPYTA
91
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
901 LAFAEYARLC FQELGHHVKL WITMNEPYTR NMTYSAGHNL LKAHALAWHV
951 YNEKFRHAQN GKISIALQAD WIEPACPFSQ KDKEVAERVL EFDIGWLAEP
1001 IFGSGDYPWV MRDWLNQRNN FLLPYFTEDE KKLIQGTFDF LALSHYTTIL
1051 VDSEKEDPIK YNDYLEVQEM TDITWLNSPS QVAVVPWGLR KVLNWLKFKY
1101 GDLPMYIISN GIDDGLHAED DQLRVYYMQN YINEALKAHI LDGINLCGYF
1151 AYSFNDRTAP RFGLYRYAAD QFEPKASMKH YRKIIDSNGF PGPETLERFC
1201 PEEFTVCTEC SFFHTRKSL*
FGF23 (R179Q) -KL-D1 amino acid sequence (SEQ ID NO: 26)
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS
51 YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG
101 NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN
151 PPPYSQFLSR RNEIPLIHFN TPIPRRHTQS AEDDSERDPL NVLKPRARMT
201 PAPASCSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGCRPFAKF
251 IQGTFPDGFL WAVGSAAYQT EGGWQQHGKG ASIWDTFTHH PLAPPGDSRN
301 ASLPLGAPSP LQPATGDVAS DSYNNVFRDT EALRELGVTH YRFSISWARV
351 LPNGSAGVPN REGLRYYRRL LERLRELGVQ PVVTLYHWDL PQRLQDAYGG
401 WANRALADHF RDYAELCFRH FGGQVKYWIT IDNPYVVAWH GYATGRLAPG
451 IRGSPRLGYL VAHNLLLAHA KVWHLYNTSF RPTQGGQVSI ALSSHWINPR
501 RMTDHSIKEC QKSLDFVLGW FAKPVFIDGD YPESMKNNLS SILPDFTESE
551 KKFIKGTADF FALCFGPTLS FQLLDPHMKF RQLESPNLRQ LLSWIDLEFN
601 HPQIFIVENG WFVSGTTKRD DAKYMYYLKK FIMETLKAIK LDGVDVIGYT
651 AWSLMDGFEW HRGYSIRRGL FYVDFLSQDK MLLPKSSALF YQKLIEKNGF
652 *
FGF23 (R179Q) -KL-D2 amino acid sequence (SEQ ID NO: 27)
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS
51 YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG
101 NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN
151 PPPYSQFLSR RNEIPLIHFN TPIPRRHTQS AEDDSERDPL NVLKPRARMT
201 PAPASCSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGCRPFAKF
251 IGTFPCDFAW GVVDNYIQVD TTLSQFTDLN VYLWDVHHSK RLIKVDGVVT
301 KKRKSYCVDF AAIQPQIALL QEMHVTHFRF SLDWALILPL GNQSQVNHTI
351 LQYYRCMASE LVRVNITPVV ALWQPMAPNQ GLPRLLARQG AWENPYTALA
401 FAEYARLCFQ ELGHHVKLWI TMNEPYTRNM TYSAGHNLLK AHALAWHVYN
451 EKFRHAQNGK ISIALQADWI EPACPFSQKD KEVAERVLEF DIGWLAEPIF
501 GSGDYPWVMR DWLNQRNNFL LPYFTEDEKK LIQGTFDFLA LSHYTTILVD
551 SEKEDPIKYN DYLEVQEMTD ITWLNSPSQV AVVPWGLRKV LNWLKFKYGD
601 LPMYIISNGI DDGLHAEDDQ LRVYYMQNYI NEALKAHILD GINLCGYFAY
651 SFNDRTAPRF GLYRYAADQF EPKASMKHYR KIIDSNGF*
FGF23 (R179Q) -(KL-D1)2 amino acid sequence (SEQ ID NO: 28)
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS
51 YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG
101 NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN
151 PPPYSQFLSR RNEIPLIHFN TPIPRRHTQS AEDDSERDPL NVLKPRARMT
201 PAPASCSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGCRPFAKF
251 IQGTFPDGFL WAVGSAAYQT EGGWQQHGKG ASIWDTFTHH PLAPPGDSRN
301 ASLPLGAPSP LQPATGDVAS DSYNNVFRDT EALRELGVTH YRFSISWARV
351 LPNGSAGVPN REGLRYYRRL LERLRELGVQ PVVTLYHWDL PQRLQDAYGG
401 WANRALADHF RDYAELCFRH FGGQVKYWIT IDNPYVVAWH GYATGRLAPG
451 IRGSPRLGYL VAHNLLLAHA KVWHLYNTSF RPTQGGQVSI ALSSHWINPR
501 RMTDHSIKEC QKSLDFVLGW FAKPVFIDGD YPESMKNNLS SILPDFTESE
551 KKFIKGTADF FALCFGPTLS FQLLDPHMKF RQLESPNLRQ LLSWIDLEFN
601 HPQIFIVENG WFVSGTTKRD DAKYMYYLKK FIMETLKAIK LDGVDVIGYT
651 AWSLMDGFEW HRGYSIRRGL FYVDFLSQDK MLLPKSSALF YQKLIEKNGF
701 QGTFPDGFLW AVGSAAYQTE GGWQQHGKGA SIWDTFTHHP LAPPGDSRNA
92
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
751 SLPLGAPSPL QPATGDVASD SYNNVFRDTE ALRELGVTHY RFSISWARVL
801 PNGSAGVPNR EGLRYYRRLL ERLRELGVQP VVTLYHWDLP QRLQDAYGGW
851 ANRALADHFR DYAELCFRHF GGQVKYWITI DNPYVVAWHG YATGRLAPGI
901 RGSPRLGYLV AHNLLLAHAK VWHLYNTSFR PTQGGQVSIA LSSHWINPRR
951 MTDHSIKECQ KSLDFVLGWF AKPVFIDGDY PESMKNNLSS ILPDFTESEK
1001 KFIKGTADFF ALCFGPTLSF QLLDPHMKFR QLESPNLRQL LSWIDLEFNH
1051 PQIFIVENGW FVSGTTKRDD AKYMYYLKKF IMETLKAIKL DGVDVIGYTA
1101 WSLMDGFEWH RGYSIRRGLF YVDFLSQDKM LLPKSSALFY QKLIEKNGF*
FGF23 (R179Q) -(KL-D2)2 amino acid sequence (SEQ ID NO: 29)
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS
51 YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG
101 NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN
151 PPPYSQFLSR RNEIPLIHFN TPIPRRHTQS AEDDSERDPL NVLKPRARMT
201 PAPASCSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGCRPFAKF
251 IGTFPCDFAW GVVDNYIQVD TTLSQFTDLN VYLWDVHHSK RLIKVDGVVT
301 KKRKSYCVDF AAIQPQIALL QEMHVTHFRF SLDWALILPL GNQSQVNHTI
351 LQYYRCMASE LVRVNITPVV ALWQPMAPNQ GLPRLLARQG AWENPYTALA
401 FAEYARLCFQ ELGHHVKLWI TMNEPYTRNM TYSAGHNLLK AHALAWHVYN
451 EKFRHAQNGK ISIALQADWI EPACPFSQKD KEVAERVLEF DIGWLAEPIF
501 GSGDYPWVMR DWLNQRNNFL LPYFTEDEKK LIQGTFDFLA LSHYTTILVD
551 SEKEDPIKYN DYLEVQEMTD ITWLNSPSQV AVVPWGLRKV LNWLKFKYGD
601 LPMYIISNGI DDGLHAEDDQ LRVYYMQNYI NEALKAHILD GINLCGYFAY
651 SFNDRTAPRF GLYRYAADQF EPKASMKHYR KIIDSNGFGT FPCDFAWGVV
701 DNYIQVDTTL SQFTDLNVYL WDVHHSKRLI KVDGVVTKKR KSYCVDFAAI
751 QPQIALLQEM HVTHFRFSLD WALILPLGNQ SQVNHTILQY YRCMASELVR
801 VNITPVVALW QPMAPNQGLP RLLARQGAWE NPYTALAFAE YARLCFQELG
851 HHVKLWITMN EPYTRNMTYS AGHNLLKAHA LAWHVYNEKF RHAQNGKISI
901 ALQADWIEPA CPFSQKDKEV AERVLEFDIG WLAEPIFGSG DYPWVMRDWL
951 NQRNNFLLPY FTEDEKKLIQ GTFDFLALSH YTTILVDSEK EDPIKYNDYL
1001 EVQEMTDITW LNSPSQVAVV PWGLRKVLNW LKFKYGDLPM YIISNGIDDG
1051 LHAEDDQLRV YYMQNYINEA LKAHILDGIN LCGYFAYSFN DRTAPRFGLY
1101 RYAADQFEPK ASMKHYRKII DSNGF*
FGF19 nucleic acid sequence (NM_005117) (SEQ ID NO: 30)
Protein coding region (464-1114)
1 gctcccagcc aagaacctcg gggccgctgc gcggtgggga ggagttcccc gaaacccggc
61 cgctaagcga ggcctcctcc tcccgcagat ccgaacggcc tgggcggggt caccccggct
121 gggacaagaa gccgccgcct gcctgcccgg gcccggggag ggggctgggg ctggggccgg
181 aggcggggtg tgagtgggtg tgtgcggggg gcggaggctt gatgcaatcc cgataagaaa
241 tgctcgggtg tcttgggcac ctacccgtgg ggcccgtaag gcgctactat ataaggctgc
301 cggcccggag ccgccgcgcc gtcagagcag gagcgctgcg tccaggatct agggccacga
361 ccatcccaac ccggcactca cagccccgca gcgcatcccg gtcgccgccc agcctcccgc
421 acccccatcg ccggagctgc gccgagagcc ccagggaggt gccatgcgga gcgggtgtgt
481 ggtggtccac gtatggatcc tggccggcct ctggctggcc gtggccgggc gccccctcgc
541 cttctcggac gcggggcccc acgtgcacta cggctggggc gaccccatcc gcctgcggca
601 cctgtacacc tccggccccc acgggctctc cagctgcttc ctgcgcatcc gtgccgacgg
661 cgtcgtggac tgcgcgcggg gccagagcgc gcacagtttg ctggagatca aggcagtcgc
721 tctgcggacc gtggccatca agggcgtgca cagcgtgcgg tacctctgca tgggcgccga
781 cggcaagatg caggggctgc ttcagtactc ggaggaagac tgtgctttcg aggaggagat
841 ccgcccagat ggctacaatg tgtaccgatc cgagaagcac cgcctcccgg tctccctgag
901 cagtgccaaa cagcggcagc tgtacaagaa cagaggcttt cttccactct ctcatttcct
961 gcccatgctg cccatggtcc cagaggagcc tgaggacctc aggggccact tggaatctga
1021 catgttctct tcgcccctgg agaccgacag catggaccca tttgggcttg tcaccggact
1081 ggaggccgtg aggagtccca gctttgagaa gtaactgaga ccatgcccgg gcctcttcac
1141 tgctgccagg ggctgtggta cctgcagcgt gggggacgtg cttctacaag aacagtcctg
1201 agtccacgtt ctgtttagct ttaggaagaa acatctagaa gttgtacata ttcagagttt
1261 tccattggca gtgccagttt ctagccaata gacttgtctg atcataacat tgtaagcctg
93
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
1321 tagcttgccc agctgctgcc tgggccccca ttctgctccc tcgaggttgc tggacaagct
1381 gctgcactgt ctcagttctg cttgaatacc tccatcgatg gggaactcac ttcctttgga
1441 aaaattctta tgtcaagctg aaattctcta attttttctc atcacttccc caggagcagc
1501 cagaagacag gcagtagttt taatttcagg aacaggtgat ccactctgta aaacagcagg
1561 taaatttcac tcaaccccat gtgggaattg atctatatct ctacttccag ggaccatttg
1621 cccttcccaa atccctccag gccagaactg actggagcag gcatggccca ccaggcttca
1681 ggagtagggg aagcctggag ccccactcca gccctgggac aacttgagaa ttccccctga
1741 ggccagttct gtcatggatg ctgtcctgag aataacttgc tgtcccggtg tcacctgctt
1801 ccatctccca gcccaccagc cctctgccca cctcacatgc ctccccatgg attggggcct
1861 cccaggcccc ccaccttatg tcaacctgca cttcttgttc aaaaatcagg aaaagaaaag
1921 atttgaagac cccaagtctt gtcaataact tgctgtgtgg aagcagcggg ggaagaccta
1981 gaaccctttc cccagcactt ggttttccaa catgatattt atgagtaatt tattttgata
2041 tgtacatctc ttattttctt acattattta tgcccccaaa ttatatttat gtatgtaagt
2101 gaggtttgtt ttgtatatta aaatggagtt tgtttgtaaa aaaaaaaaaa aaaaaaa
FGF19 amino acid sequence (NP_005108) (SEQ ID NO: 31)
1 MRSGCVVVHV WILAGLWLAV AGRPLAFSDA GPHVHYGWGD PIRLRHLYTS GPHGLSSCFL
61 RIRADGVVDC ARGQSAHSLL EIKAVALRTV AIKGVHSVRY LCMGADGKMQ GLLQYSEEDC
121 AFEEEIRPDG YNVYRSEKHR LPVSLSSAKQ RQLYKNRGFL PLSHFLPMLP MVPEEPEDLR
181 GHLESDMFSS PLETDSMDPF GLVTGLEAVR SPSFEK
FGF21 nucleic acid sequence (NM_019113 ) (SEQ ID NO: 32)
Protein coding region 151-780
1 CTGTCAGCTG AGGATCCAGC CGAAAGAGGA GCCAGGCACT CAGGCCACCT GAGTCTACTC
61 ACCTGGACAA CTGGAATCTG GCACCAATTC TAAACCACTC AGCTTCTCCG AGCTCACACC
121 CCGGAGATCA CCTGAGGACC CGAGCCATTG ATGGACTCGG ACGAGACCGG GTTCGAGCAC
181 TCAGGACTGT GGGTTTCTGT GCTGGCTGGT CTTCTGCTGG GAGCCTGCCA GGCACACCCC
241 ATCCCTGACT CCAGTCCTCT CCTGCAATTC GGGGGCCAAG TCCGGCAGCG GTACCTCTAC
301 ACAGATGATG CCCAGCAGAC AGAAGCCCAC CTGGAGATCA GGGAGGATGG GACGGTGGGG
361 GGCGCTGCTG ACCAGAGCCC CGAAAGTCTC CTGCAGCTGA AAGCCTTGAA GCCGGGAGTT
421 ATTCAAATCT TGGGAGTCAA GACATCCAGG TTCCTGTGCC AGCGGCCAGA TGGGGCCCTG
481 TATGGATCGC TCCACTTTGA CCCTGAGGCC TGCAGCTTCC GGGAGCTGCT TCTTGAGGAC
541 GGATACAATG TTTACCAGTC CGAAGCCCAC GGCCTCCCGC TGCACCTGCC AGGGAACAAG
601 TCCCCACACC GGGACCCTGC ACCCCGAGGA CCAGCTCGCT TCCTGCCACT ACCAGGCCTG
661 CCCCCCGCAC TCCCGGAGCC ACCCGGAATC CTGGCCCCCC AGCCCCCCGA TGTGGGCTCC
721 TCGGACCCTC TGAGCATGGT GGGACCTTCC CAGGGCCGAA GCCCCAGCTA CGCTTCCTGA
781 AGCCAGAGGC TGTTTACTAT GACATCTCCT CTTTATTTAT TAGGTTATTT ATCTTATTTA
841 TTTTTTTATT TTTCTTACTT GAGATAATAA AGAGTTCCAG AGGAAAAAAA AAAAAAAAAA
901 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA
FGF21 amino acid sequence (NP_061986) (SEQ ID NO: 33)
1 MDSDETGFEH SGLWVSVLAG LLLGACQAHP IPDSSPLLQF GGQVRQRYLY TDDAQQTEAH
61 LEIREDGTVG GAADQSPESL LQLKALKPGV IQILGVKTSR FLCQRPDGAL YGSLHFDPEA
121 CSFRELLLED GYNVYQSEAH GLPLHLPGNK SPHRDPAPRG PARFLPLPGL PPALPEPPGI
181 LAPQPPDVGS SDPLSMVGPS QGRSPSYAS
FGF23 nucleic acid sequence (NM_020638) (SEQ ID NO: 34)
Protein coding region 147-902
1 cggcaaaaag gagggaatcc agtctaggat cctcacacca gctacttgca agggagaagg
61 aaaaggccag taaggcctgg gccaggagag tcccgacagg agtgtcaggt ttcaatctca
121 gcaccagcca ctcagagcag ggcacgatgt tgggggcccg cctcaggctc tgggtctgtg
181 ccttgtgcag cgtctgcagc atgagcgtcc tcagagccta tcccaatgcc tccccactgc
241 tcggctccag ctggggtggc ctgatccacc tgtacacagc cacagccagg aacagctacc
301 acctgcagat ccacaagaat ggccatgtgg atggcgcacc ccatcagacc atctacagtg
361 ccctgatgat cagatcagag gatgctggct ttgtggtgat tacaggtgtg atgagcagaa
94
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
421 gatacctctg catggatttc agaggcaaca tttttggatc acactatttc gacccggaga
481 actgcaggtt ccaacaccag acgctggaaa acgggtacga cgtctaccac tctcctcagt
541 atcacttcct ggtcagtctg ggccgggcga agagagcctt cctgccaggc atgaacccac
601 ccccgtactc ccagttcctg tcccggagga acgagatccc cctaattcac ttcaacaccc
661 ccataccacg gcggcacacc cggagcgccg aggacgactc ggagcgggac cccctgaacg
721 tgctgaagcc ccgggcccgg atgaccccgg ccccggcctc ctgttcacag gagctcccga
781 gcgccgagga caacagcccg atggccagtg acccattagg ggtggtcagg ggcggtcgag
841 tgaacacgca cgctggggga acgggcccgg aaggctgccg ccccttcgcc aagttcatct
901 agggtcgctg gaagggcacc ctctttaacc catccctcag caaacgcagc tcttcccaag
961 gaccaggtcc cttgacgttc cgaggatggg aaaggtgaca ggggcatgta tggaatttgc
1021 tgcttctctg gggtcccttc cacaggaggt cctgtgagaa ccaacctttg aggcccaagt
1081 catggggttt caccgccttc ctcactccat atagaacacc tttcccaata ggaaacccca
1141 acaggtaaac tagaaatttc cccttcatga aggtagagag aaggggtctc tcccaacata
1201 tttctcttcc ttgtgcctct cctctttatc acttttaagc ataaaaaaaa aaaaaaaaaa
1261 aaaaaaaaaa aaaagcagtg ggttcctgag ctcaagactt tgaaggtgta gggaagagga
1321 aatcggagat cccagaagct tctccactgc cctatgcatt tatgttagat gccccgatcc
1381 cactggcatt tgagtgtgca aaccttgaca ttaacagctg aatggggcaa gttgatgaaa
1441 acactacttt caagccttcg ttcttccttg agcatctctg gggaagagct gtcaaaagac
1501 tggtggtagg ctggtgaaaa cttgacagct agacttgatg cttgctgaaa tgaggcagga
1561 atcataatag aaaactcagc ctccctacag ggtgagcacc ttctgtctcg ctgtctccct
1621 ctgtgcagcc acagccagag ggcccagaat ggccccactc tgttcccaag cagttcatga
1681 tacagcctca ccttttggcc ccatctctgg tttttgaaaa tttggtctaa ggaataaata
1741 gcttttacac tggctcacga aaatctgccc tgctagaatt tgcttttcaa aatggaaata
1801 aattccaact ctcctaagag gcatttaatt aaggctctac ttccaggttg agtaggaatc
1861 cattctgaac aaactacaaa aatgtgactg ggaagggggc tttgagagac tgggactgct
1921 ctgggttagg ttttctgtgg actgaaaaat cgtgtccttt tctctaaatg aagtggcatc
1981 aaggactcag ggggaaagaa atcaggggac atgttataga agttatgaaa agacaaccac
2041 atggtcaggc tcttgtctgt ggtctctagg gctctgcagc agcagtggct cttcgattag
2101 ttaaaactct cctaggctga cacatctggg tctcaatccc cttggaaatt cttggtgcat
2161 taaatgaagc cttaccccat tactgcggtt cttcctgtaa gggggctcca ttttcctccc
2221 tctctttaaa tgaccaccta aaggacagta tattaacaag caaagtcgat tcaacaacag
2281 cttcttccca gtcacttttt tttttctcac tgccatcaca tactaacctt atactttgat
2341 ctattctttt tggttatgag agaaatgttg ggcaactgtt tttacctgat ggttttaagc
2401 tgaacttgaa ggactggttc ctattctgaa acagtaaaac tatgtataat agtatatagc
2461 catgcatggc aaatatttta atatttctgt tttcatttcc tgttggaaat attatcctgc
2521 ataatagcta ttggaggctc ctcagtgaaa gatcccaaaa ggattttggt ggaaaactag
2581 ttgtaatctc acaaactcaa cactaccatc aggggttttc tttatggcaa agccaaaata
2641 gctcctacaa tttcttatat ccctcgtcat gtggcagtat ttatttattt atttggaagt
2701 ttgcctatcc ttctatattt atagatattt ataaaaatgt aacccctttt tcctttcttc
2761 tgtttaaaat aaaaataaaa tttatctcag cttctgttag cttatcctct ttgtagtact
2821 acttaaaagc atgtcggaat ataagaataa aaaggattat gggaggggaa cattagggaa
2881 atccagagaa ggcaaaattg aaaaaaagat tttagaattt taaaattttc aaagatttct
2941 tccattcata aggagactca atgattttaa ttgatctaga cagaattatt taagttttat
3001 caatattgga tttctggt
FGF23 amino acid sequence (NP_065689) (SEQ ID NO: 35)
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS YHLQIHKNGH
61 VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG NIFGSHYFDP ENCRFQHQTL
121 ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN PPPYSQFLSR RNEIPLIHFN TPIPRRHTRS
181 AEDDSERDPL NVLKPRARMT PAPASCSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG
241 PEGCRPFAKF I
FGF23 (R179Q) amino acid sequence (SEQ ID NO: 36)
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS YHLQIHKNGH
61 VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG NIFGSHYFDP ENCRFQHQTL
121 ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN PPPYSQFLSR RNEIPLIHFN TPIPRRHTQS
181 AEDDSERDPL NVLKPRARMT PAPASCSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG
241 PEGCRPFAKF I
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
Human beta-Klotho domain 1 (b-KL-D1) amino acid sequence (SEQ ID NO: 37)
77 ydt fpknffwgig tgalqvegsw kkdgkgpsiw dhfihthlkn
121 vsstngssds yiflekdlsa ldfigvsfyq fsiswprlfp dgivtvanak glqyystlld
181 alvlrniepi vtlyhwdlpl alqekyggwk ndtiidifnd yatycfqmfg drvkywitih
241 npylvawhgy gtgmhapgek gnlaavytvg hnlikahskv whnynthfrp hqkgwlsitl
301 gshwiepnrs entmdifkcq qsmvsvlgwf anpihgdgdy pegmrkklfs vlpifseaek
361 hemrgtadff afsfgpnnfk plntmakmgq nvslnlreal nwikleynnp riliaengwf
421 tdsrvktedt taiymmknfl sqvlqairld eirvfgytaw slldgfewqd aytirrglfy
481 vdfnskqker kpkssahyyk qiirengf
Human beta-Klotho domain 2 (b-KL-D2) amino acid sequence (SEQ ID NO: 38)
571 trpaqctdfv nikkqlemla
rmkvthyrfa
601 ldwasvlptg nlsavnrqal ryyrcvvseg lklgisamvt lyypthahlg
lpepllhadg
661 wlnpstaeaf qayaglcfqe lgdlvklwit inepnrlsdi ynrsgndtyg
aahnllvaha
721 lawrlydrqf rpsqrgavsl slhadwaepa npyadshwra aerflqfeia
wfaeplfktg
781 dypaamreyi askhrrglss salprlteae rrllkgtvdf calnhfttrf
vmheqlagsr
841 ydsdrdiqfl qditrlsspt rlavipwgvr kllrwvrrny gdmdiyitas
giddqaledd
901 rlrkyylgky lqevlkayli dkvrikgyya fklaeekskp rfgfftsdfk
akssiqfynk
961 vissrgf
Beta-Klotho extracellular domain (without signal peptide) amino acid sequence
(SEQ ID NO: 39)
52 gfsgdgrai
61 wsknpnftpv nesqlflydt fpknffwgig tgalqvegsw kkdgkgpsiw dhfihthlkn
121 vsstngssds yiflekdlsa ldfigvsfyq fsiswprlfp dgivtvanak glqyystlld
181 alvlrniepi vtlyhwdlpl alqekyggwk ndtiidifnd yatycfqmfg drvkywitih
241 npylvawhgy gtgmhapgek gnlaavytvg hnlikahskv whnynthfrp hqkgwlsitl
301 gshwiepnrs entmdifkcq qsmvsvlgwf anpihgdgdy pegmrkklfs vlpifseaek
361 hemrgtadff afsfgpnnfk plntmakmgq nvslnlreal nwikleynnp riliaengwf
421 tdsrvktedt taiymmknfl sqvlqairld eirvfgytaw slldgfewqd aytirrglfy
481 vdfnskqker kpkssahyyk qiirengfsl kestpdvqgq fpcdfswgvt esvlkpesva
541 sspqfsdphl yvwnatgnrl lhrvegvrlk trpaqctdfv nikkqlemla rmkvthyrfa
601 ldwasvlptg nlsavnrqal ryyrcvvseg lklgisamvt lyypthahlg lpepllhadg
661 wlnpstaeaf qayaglcfqe lgdlvklwit inepnrlsdi ynrsgndtyg aahnllvaha
721 lawrlydrqf rpsqrgavsl slhadwaepa npyadshwra aerflqfeia wfaeplfktg
781 dypaamreyi askhrrglss salprlteae rrllkgtvdf calnhfttrf vmheqlagsr
841 ydsdrdigf1 qditrlsspt rlavipwgvr kllrwvrrny gdmdiyitas giddqaledd
901 rlrkyylgky lqevlkayli dkvrikgyya fklaeekskp rfgfftsdfk akssiqfynk
961 vissrgfpfe nsssrcsqtq entectvclf lvqkkpl
sKlotho without signal peptide - FGF23 amino acid sequence (without signal
peptide) (SEQ ID NO: 40)
EPGDGAQ TWARFSRPPA
51 PEAAGLFQGT FPDGFLWAVG SAAYQTEGGW QQHGKGASIW DTFTHHPLAP
101 PGDSRNASLP LGAPSPLQPA TGDVASDSYN NVFRDTEALR ELGVTHYRFS
151 ISWARVLPNG SAGVPNREGL RYYRRLLERL RELGVQPVVT LYHWDLPQRL
96
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
201 QDAYGGWANR ALADHFRDYA ELCFRHFGGQ VKYWITIDNP YVVAWHGYAT
251 GRLAPGIRGS PRLGYLVAHN LLLAHAKVWH LYNTSFRPTQ GGQVSIALSS
301 HWINPRRMTD HSIKECQKSL DFVLGWFAKP VFIDGDYPES MKNNLSSILP
351 DFTESEKKFI KGTADFFALC FGPTLSFQLL DPHMKFRQLE SPNLRQLLSW
401 IDLEFNHPQI FIVENGWFVS GTTKRDDAKY MYYLKKFIME TLKAIKLDGV
451 DVIGYTAWSL MDGFEWHRGY SIRRGLFYVD FLSQDKMLLP KSSALFYQKL
501 IEKNGFPPLP ENQPLEGTFP CDFAWGVVDN YIQVDTTLSQ FTDLNVYLWD
551 VHHSKRLIKV DGVVTKKRKS YCVDFAAIQP QIALLQEMHV THFRFSLDWA
601 LILPLGNQSQ VNHTILQYYR CMASELVRVN ITPVVALWQP MAPNQGLPRL
651 LARQGAWENP YTALAFAEYA RLCFQELGHH VKLWITMNEP YTRNMTYSAG
701 HNLLKAHALA WHVYNEKFRH AQNGKISIAL QADWIEPACP FSQKDKEVAE
751 RVLEFDIGWL AEPIFGSGDY PWVMRDWLNQ RNNFLLPYFT EDEKKLIQGT
801 FDFLALSHYT TILVDSEKED PIKYNDYLEV QEMTDITWLN SPSQVAVVPW
851 GLRKVLNWLK FKYGDLPMYI ISNGIDDGLH AEDDQLRVYY MQNYINEALK
901 AHILDGINLC GYFAYSFNDR TAPRFGLYRY AADQFEPKAS MKHYRKIIDS
951 NGFPGPETLE RFCPEEFTVC TECSFFHTRK SLGSGGGGSG GGGSGGGGSL
1001 KYPNASPLLG SSWGGLIHLY TATARNSYHL QIHKNGHVDG APHQTIYSAL
1051 MIRSEDAGFV VITGVMSRRY LCMDFRGNIF GSHYFDPENC RFQHQTLENG
1101 YDVYHSPQYH FLVSLGRAKR AFLPGMNPPP YSQFLSRRNE IPLIHFNTPI
1151 PRRHTRSAED DSERDPLNVL KPRARMTPAP ASCSQELPSA EDNSPMASDP
1201 LGVVRGGRVN THAGGTGPEG CRPFAKFI*
sKlotho without signal peptide -FGF23 (R179Q) (without signal peptide) amino
acid
sequence (SEQ ID NO: 41)
EPGDGAQ TWARFSRPPA
51 PEAAGLFQGT FPDGFLWAVG SAAYQTEGGW QQHGKGASIW DTFTHHPLAP
101 PGDSRNASLP LGAPSPLQPA TGDVASDSYN NVFRDTEALR ELGVTHYRFS
151 ISWARVLPNG SAGVPNREGL RYYRRLLERL RELGVQPVVT LYHWDLPQRL
201 QDAYGGWANR ALADHFRDYA ELCFRHFGGQ VKYWITIDNP YVVAWHGYAT
251 GRLAPGIRGS PRLGYLVAHN LLLAHAKVWH LYNTSFRPTQ GGQVSIALSS
301 HWINPRRMTD HSIKECQKSL DFVLGWFAKP VFIDGDYPES MKNNLSSILP
351 DFTESEKKFI KGTADFFALC FGPTLSFQLL DPHMKFRQLE SPNLRQLLSW
401 IDLEFNHPQI FIVENGWFVS GTTKRDDAKY MYYLKKFIME TLKAIKLDGV
451 DVIGYTAWSL MDGFEWHRGY SIRRGLFYVD FLSQDKMLLP KSSALFYQKL
501 IEKNGFPPLP ENQPLEGTFP CDFAWGVVDN YIQVDTTLSQ FTDLNVYLWD
551 VHHSKRLIKV DGVVTKKRKS YCVDFAAIQP QIALLQEMHV THFRFSLDWA
601 LILPLGNQSQ VNHTILQYYR CMASELVRVN ITPVVALWQP MAPNQGLPRL
651 LARQGAWENP YTALAFAEYA RLCFQELGHH VKLWITMNEP YTRNMTYSAG
701 HNLLKAHALA WHVYNEKFRH AQNGKISIAL QADWIEPACP FSQKDKEVAE
751 RVLEFDIGWL AEPIFGSGDY PWVMRDWLNQ RNNFLLPYFT EDEKKLIQGT
801 FDFLALSHYT TILVDSEKED PIKYNDYLEV QEMTDITWLN SPSQVAVVPW
851 GLRKVLNWLK FKYGDLPMYI ISNGIDDGLH AEDDQLRVYY MQNYINEALK
901 AHILDGINLC GYFAYSFNDR TAPRFGLYRY AADQFEPKAS MKHYRKIIDS
951 NGFPGPETLE RFCPEEFTVC TECSFFHTRK SLGSGGGGSG GGGSGGGGSL
1001 KYPNASPLLG SSWGGLIHLY TATARNSYHL QIHKNGHVDG APHQTIYSAL
1051 MIRSEDAGFV VITGVMSRRY LCMDFRGNIF GSHYFDPENC RFQHQTLENG
1101 YDVYHSPQYH FLVSLGRAKR AFLPGMNPPP YSQFLSRRNE IPLIHFNTPI
1151 PRRHTQSAED DSERDPLNVL KPRARMTPAP ASCSQELPSA EDNSPMASDP
1201 LGVVRGGRVN THAGGTGPEG CRPFAKFI*
FGF23 without signal peptide (SEQ ID NO: 42)
YPNASP LLGSSWGGLI HLYTATARNS YHLQIHKNGH
61 VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG NIFGSHYFDP ENCRFQHQTL
121 ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN PPPYSQFLSR RNEIPLIHFN TPIPRRHTRS
181 AEDDSERDPL NVLKPRARMT PAPASCSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG
241 PEGCRPFAKF I
97
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
FGF23(R179Q) without signal peptide (SEQ ID NO: 43)
YPNASP LLGSSWGGLI HLYTATARNS YHLQIHKNGH
61 VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG NIFGSHYFDP ENCRFQHQTL
121 ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN PPPYSQFLSR RNEIPLIHFN TPIPRRHTQS
181 AEDDSERDPL NVLKPRARMT PAPASCSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG
241 PEGCRPFAKF I
sKlotho with Klotho signal peptide (SEQ ID NO: 44)
1 MPASAPPRRP RPPPPSLSLL LVLLGLGGRR LRAEPGDGAQ TWARFSRPPA
51 PEAAGLFQGT FPDGFLWAVG SAAYQTEGGW QQHGKGASIW DTFTHHPLAP
101 PGDSRNASLP LGAPSPLQPA TGDVASDSYN NVFRDTEALR ELGVTHYRFS
151 ISWARVLPNG SAGVPNREGL RYYRRLLERL RELGVQPVVT LYHWDLPQRL
201 QDAYGGWANR ALADHFRDYA ELCFRHFGGQ VKYWITIDNP YVVAWHGYAT
251 GRLAPGIRGS PRLGYLVAHN LLLAHAKVWH LYNTSFRPTQ GGQVSIALSS
301 HWINPRRMTD HSIKECQKSL DFVLGWFAKP VFIDGDYPES MKNNLSSILP
351 DFTESEKKFI KGTADFFALC FGPTLSFQLL DPHMKFRQLE SPNLRQLLSW
401 IDLEFNHPQI FIVENGWFVS GTTKRDDAKY MYYLKKFIME TLKAIKLDGV
451 DVIGYTAWSL MDGFEWHRGY SIRRGLFYVD FLSQDKMLLP KSSALFYQKL
501 IEKNGFPPLP ENQPLEGTFP CDFAWGVVDN YIQVDTTLSQ FTDLNVYLWD
551 VHHSKRLIKV DGVVTKKRKS YCVDFAAIQP QIALLQEMHV THFRFSLDWA
601 LILPLGNQSQ VNHTILQYYR CMASELVRVN ITPVVALWQP MAPNQGLPRL
651 LARQGAWENP YTALAFAEYA RLCFQELGHH VKLWITMNEP YTRNMTYSAG
701 HNLLKAHALA WHVYNEKFRH AQNGKISIAL QADWIEPACP FSQKDKEVAE
751 RVLEFDIGWL AEPIFGSGDY PWVMRDWLNQ RNNFLLPYFT EDEKKLIQGT
801 FDFLALSHYT TILVDSEKED PIKYNDYLEV QEMTDITWLN SPSQVAVVPW
851 GLRKVLNWLK FKYGDLPMYI ISNGIDDGLH AEDDQLRVYY MQNYINEALK
901 AHILDGINLC GYFAYSFNDR TAPRFGLYRY AADQFEPKAS MKHYRKIIDS
951 NGFPGPETLE RFCPEEFTVC TECSFFHTRK SL
sKlotho with IgG Signal peptide (SEQ ID NO: 45)
1 MSVLTQVLAL LLLWLTGLGG RRLRAEPGDG AQTWARFSRP PAPEAAGLFQ
51 GTFPDGFLWA VGSAAYQTEG GWQQHGKGAS IWDTFTHHPL APPGDSRNAS
101 LPLGAPSPLQ PATGDVASDS YNNVFRDTEA LRELGVTHYR FSISWARVLP
151 NGSAGVPNRE GLRYYRRLLE RLRELGVQPV VTLYHWDLPQ RLQDAYGGWA
201 NRALADHFRD YAELCFRHFG GQVKYWITID NPYVVAWHGY ATGRLAPGIR
251 GSPRLGYLVA HNLLLAHAKV WHLYNTSFRP TQGGQVSIAL SSHWINPRRM
301 TDHSIKECQK SLDFVLGWFA KPVFIDGDYP ESMKNNLSSI LPDFTESEKK
351 FIKGTADFFA LCFGPTLSFQ LLDPHMKFRQ LESPNLRQLL SWIDLEFNHP
401 QIFIVENGWF VSGTTKRDDA KYMYYLKKFI METLKAIKLD GVDVIGYTAW
451 SLMDGFEWHR GYSIRRGLFY VDFLSQDKML LPKSSALFYQ KLIEKNGFPP
501 LPENQPLEGT FPCDFAWGVV DNYIQVDTTL SQFTDLNVYL WDVHHSKRLI
551 KVDGVVTKKR KSYCVDFAAI QPQIALLQEM HVTHFRFSLD WALILPLGNQ
601 SQVNHTILQY YRCMASELVR VNITPVVALW QPMAPNQGLP RLLARQGAWE
651 NPYTALAFAE YARLCFQELG HHVKLWITMN EPYTRNMTYS AGHNLLKAHA
701 LAWHVYNEKF RHAQNGKISI ALQADWIEPA CPFSQKDKEV AERVLEFDIG
751 WLAEPIFGSG DYPWVMRDWL NQRNNFLLPY FTEDEKKLIQ GTFDFLALSH
801 YTTILVDSEK EDPIKYNDYL EVQEMTDITW LNSPSQVAVV PWGLRKVLNW
851 LKFKYGDLPM YIISNGIDDG LHAEDDQLRV YYMQNYINEA LKAHILDGIN
901 LCGYFAYSFN DRTAPRFGLY RYAADQFEPK ASMKHYRKII DSNGFPGPET
951 LERFCPEEFT VCTECSFFHT RKSL*
98
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
sKlotho-FGF23-FcLALA vl (SEQ ID NO: 46)
1 ATGCCCGCCA GCGCCCCGCC GCGCCGCCCG CGGCCGCCGC CGCCGTCGCT
GTCGCTGCTG
61 CTGGTGCTGC TGGGCCTGGG CGGCCGCCGC CTGCGTGCGG AGCCGGGCGA
CGGCGCGCAG
121 ACCTGGGCCC GTTTCTCGCG GCCTCCTGCC CCCGAGGCCG CGGGCCTCTT
CCAGGGCACC
181 TTCCCCGACG GCTTCCTCTG GGCCGTGGGC AGCGCCGCCT ACCAGACCGA
GGGCGGCTGG
241 CAGCAGCACG GCAAGGGTGC GTCCATCTGG GATACGTTCA CCCACCACCC
CCTGGCACCC
301 CCGGGAGACT CCCGGAACGC CAGTCTGCCG TTGGGCGCCC CGTCGCCGCT
GCAGCCCGCC
361 ACCGGGGACG TAGCCAGCGA CAGCTACAAC AACGTCTTCC GCGACACGGA
GGCGCTGCGC
421 GAGCTCGGGG TCACTCACTA CCGCTTCTCC ATCTCGTGGG CGCGAGTGCT
CCCCAATGGC
481 AGCGCGGGCG TCCCCAACCG CGAGGGGCTG CGCTACTACC GGCGCCTGCT
GGAGCGGCTG
541 CGGGAGCTGG GCGTGCAGCC CGTGGTCACC CTGTACCACT GGGACCTGCC
CCAGCGCCTG
601 CAGGACGCCT ACGGCGGCTG GGCCAACCGC GCCCTGGCCG ACCACTTCAG
GGATTACGCG
661 GAGCTCTGCT TCCGCCACTT CGGCGGTCAG GTCAAGTACT GGATCACCAT
CGACAACCCC
721 TACGTGGTGG CCTGGCACGG CTACGCCACC GGGCGCCTGG CCCCCGGCAT
CCGGGGCAGC
781 CCGCGGCTCG GGTACCTGGT GGCGCACAAC CTCCTCCTGG CTCATGCCAA
AGTCTGGCAT
841 CTCTACAATA CTTCTTTCCG TCCCACTCAG GGAGGTCAGG TGTCCATTGC
CCTAAGCTCT
901 CACTGGATCA ATCCTCGAAG AATGACCGAC CACAGCATCA AAGAATGTCA
AAAATCTCTG
961 GACTTTGTAC TAGGTTGGTT TGCCAAACCC GTATTTATTG ATGGTGACTA
TCCCGAGAGC
1021 ATGAAGAATA ACCTTTCATC TATTCTGCCT GATTTTACTG AATCTGAGAA
AAAGTTCATC
1081 AAAGGAACTG CTGACTTTTT TGCTCTTTGC TTTGGACCCA CCTTGAGTTT
TCAACTTTTG
1141 GACCCTCACA TGAAGTTCCG CCAATTGGAA TCTCCCAACC TGAGGCAACT
GCTTTCCTGG
1201 ATTGACCTTG AATTTAACCA TCCTCAAATA TTTATTGTGG AAAATGGCTG
GTTTGTCTCA
1261 GGGACCACCA AGAGAGATGA TGCCAAATAT ATGTATTACC TCAAAAAGTT
CATCATGGAA
1321 ACCTTAAAAG CCATCAAGCT GGATGGGGTG GATGTCATCG GGTATACCGC
ATGGTCCCTC
1381 ATGGATGGTT TCGAGTGGCA CAGAGGTTAC AGCATCAGGC GTGGACTCTT
CTATGTTGAC
1441 TTTCTAAGCC AGGACAAGAT GTTGTTGCCA AAGTCTTCAG CCTTGTTCTA
CCAAAAGCTG
1501 ATAAAGAAAA ATGGCTTCCC TCCTTTACCT GAAAATCAGC CCCTAGAAGG
GACATTTCCC
1561 TGTGACTTTG CTTGGGGAGT TGTTGACAAC TACATTCAAG TAGATACCAC
TCTGTCTCAG
1621 TTTACCGACC TGAATGTTTA CCTGTGGGAT GTCCACCACA GTAAAAGGCT
TATTAAAGTG
99
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
1681 GATGGGGTTG TGACCAAGAA GAGGAAATCC TACTGTGTTG ACTTTGCTGC
CATCCAGCCC
1741 CAGATCGCTT TACTCCAGGA AATGCACGTT ACACATTTTC GCTTCTCCCT
GGACTGGGCC
1801 CTGATTCTCC CTCTGGGTAA CCAGTCCCAG GTGAACCACA CCATCCTGCA
GTACTATCGC
1861 TGCATGGCCA GCGAGCTTGT CCGTGTCAAC ATCACCCCAG TGGTGGCCCT
GTGGCAGCCT
1921 ATGGCCCCGA ACCAAGGACT GCCGCGCCTC CTGGCCAGGC AGGGCGCCTG
GGAGAACCCC
1981 TACACTGCCC TGGCCTTTGC AGAGTATGCC CGACTGTGCT TTCAAGAGCT
CGGCCATCAC
2041 GTCAAGCTTT GGATAACGAT GAATGAGCCG TATACAAGGA ATATGACATA
CAGTGCTGGC
2101 CACAACCTTC TGAAGGCCCA TGCCCTGGCT TGGCATGTGT ACAATGAAAA
GTTTAGGCAT
2161 GCTCAGAATG GGAAAATATC CATAGCCTTG CAGGCTGATT GGATAGAACC
TGCCTGCCCT
2221 TTCTCCCAAA AGGACAAAGA GGTGGCCGAG AGAGTTTTGG AATTTGACAT
TGGCTGGCTG
2281 GCTGAGCCCA TTTTCGGCTC TGGAGATTAT CCATGGGTGA TGAGGGACTG
GCTGAACCAA
2341 AGAAACAATT TTCTTCTTCC TTATTTCACT GAAGATGAAA AAAAGCTAAT
CCAGGGTACC
2401 TTTGACTTTT TGGCTTTAAG CCATTATACC ACCATCCTTG TAGACTCAGA
AAAAGAAGAT
2461 CCAATAAAAT ACAATGATTA CCTAGAAGTG CAAGAAATGA CCGACATCAC
GTGGCTCAAC
2521 TCCCCCAGTC AGGTGGCGGT AGTGCCCTGG GGGTTGCGCA AAGTGCTGAA
CTGGCTGAAG
2581 TTCAAGTACG GAGACCTCCC CATGTACATA ATATCCAACG GAATCGATGA
CGGGCTGCAT
2641 GCTGAGGACG ACCAGCTGAG GGTGTATTAT ATGCAGAATT ACATAAACGA
AGCTCTCAAA
2701 GCCCACATAC TGGATGGTAT CAATCTTTGC GGATACTTTG CTTATTCGTT
TAACGACCGC
2761 ACAGCTCCGA GGTTTGGCCT CTATCGTTAT GCTGCAGATC AGTTTGAGCC
CAAGGCATCC
2821 ATGAAACATT ACAGGAAAAT TATTGACAGC AATGGTTTCC CGGGCCCAGA
AACTCTGGAA
2881 AGATTTTGTC CAGAAGAATT CACCGTGTGT ACTGAGTGCA GTTTTTTTCA
CACCCGAAAG
2941 TCTTTAGGAT CCGGAGGTGG AGGTTCAGGA GGTGGAGGTT CAGGAGGTGG
AGGTTCACTT
3001 AAGTATCCCA ATGCCTCCCC ACTGCTCGGC TCCAGCTGGG GTGGCCTGAT
CCACCTGTAC
3061 ACAGCCACAG CCAGGAACAG CTACCACCTG CAGATCCACA AGAATGGCCA
TGTGGATGGC
3121 GCACCCCATC AGACCATCTA CAGTGCCCTG ATGATCAGAT CAGAGGATGC
TGGCTTTGTG
3181 GTGATTACAG GTGTGATGAG CAGAAGATAC CTCTGCATGG ATTTCAGAGG
CAACATTTTT
3241 GGATCACACT ATTTCGACCC GGAGAACTGC AGGTTCCAAC ACCAGACGCT
GGAAAACGGG
3301 TACGACGTCT ACCACTCTCC TCAGTATCAC TTCCTGGTCA GTCTGGGCCG
GGCGAAGAGA
3361 GCCTTCCTGC CAGGCATGAA CCCACCCCCG TACTCCCAGT TCCTGTCCCG
GAGGAACGAG
3421 ATCCCCCTAA TTCACTTCAA CACCCCCATA CCACGGCGGC ACACCCAGAG
CGCCGAGGAC
3481 GACTCGGAGC GGGACCCCCT GAACGTGCTG AAGCCCCGGG CCCGGATGAC
CCCGGCCCCG
100
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
3541 GCCTCCTGTT CACAGGAGCT CCCGAGCGCC GAGGACAACA GCCCGATGGC
CAGTGACCCA
3601 TTAGGGGTGG TCAGGGGCGG TCGAGTGAAC ACGCACGCTG GGGGAACGGG
CCCGGAAGGC
3661 TGCCGCCCCT TCGCCAAGTT CATCGGAGGT GGAGGTTCAA AAACCCACAC
GTGTCCTCCT
3721 TGTCCTGCCC CAGAAGCAGC AGGTGGTCCA TCAGTTTTTC TTTTCCCTCC
CAAACCCAAG
3781 GATACGCTGA TGATCTCTCG CACGCCTGAG GTGACATGCG TCGTAGTAGA
CGTGAGCCAC
3841 GAAGATCCCG AGGTGAAGTT CAATTGGTAT GTGGACGGAG TAGAAGTGCA
TAACGCGAAA
3901 ACTAAGCCGC GCGAGGAACA ATATAACAGT ACTTACAGGG TGGTATCCGT
GCTCACAGTC
3961 CTGCACCAGG ACTGGCTGAA CGGTAAGGAA TACAAGTGCA AAGTAAGCAA
CAAGGCACTT
4021 CCCGCGCCTA TTGAGAAAAC AATCTCCAAG GCGAAGGGAC AACCAAGAGA
ACCTCAGGTT
4081 TACACTCTCC CGCCTTCCAG GGAAGAGATG ACCAAAAATC AAGTTTCCCT
GACTTGCCTC
4141 GTCAAAGGAT TCTACCCTTC CGACATTGCT GTTGAATGGG AAAGCAATGG
ACAACCAGAG
4201 AACAACTACA AGACAACACC CCCGGTGCTG GATAGTGACG GATCTTTCTT
TCTCTACTCA
4261 AAGCTGACCG TGGATAAGTC CAGGTGGCAG CAGGGAAACG TGTTTTCCTG
CTCTGTCATG
4321 CATGAAGCGC TGCATAATCA CTATACCCAG AAGTCTCTGA GCTTGAGCCC
AGGCAAGTAA
sKlotho-FGF23-FcLALA vl (SEQ ID NO: 47)
1 MPASAPPRRP RPPPPSLSLL LVLLGLGGRR LRAEPGDGAQ TWARFSRPPA
51 PEAAGLFQGT FPDGFLWAVG SAAYQTEGGW QQHGKGASIW DTFTHHPLAP
101 PGDSRNASLP LGAPSPLQPA TGDVASDSYN NVFRDTEALR ELGVTHYRFS
151 ISWARVLPNG SAGVPNREGL RYYRRLLERL RELGVQPVVT LYHWDLPQRL
201 QDAYGGWANR ALADHFRDYA ELCFRHFGGQ VKYWITIDNP YVVAWHGYAT
251 GRLAPGIRGS PRLGYLVAHN LLLAHAKVWH LYNTSFRPTQ GGQVSIALSS
301 HWINPRRMTD HSIKECQKSL DFVLGWFAKP VFIDGDYPES MKNNLSSILP
351 DFTESEKKFI KGTADFFALC FGPTLSFQLL DPHMKFRQLE SPNLRQLLSW
401 IDLEFNHPQI FIVENGWFVS GTTKRDDAKY MYYLKKFIME TLKAIKLDGV
451 DVIGYTAWSL MDGFEWHRGY SIRRGLFYVD FLSQDKMLLP KSSALFYQKL
501 IEKNGFPPLP ENQPLEGTFP CDFAWGVVDN YIQVDTTLSQ FTDLNVYLWD
551 VHHSKRLIKV DGVVTKKRKS YCVDFAAIQP QIALLQEMHV THFRFSLDWA
601 LILPLGNQSQ VNHTILQYYR CMASELVRVN ITPVVALWQP MAPNQGLPRL
651 LARQGAWENP YTALAFAEYA RLCFQELGHH VKLWITMNEP YTRNMTYSAG
701 HNLLKAHALA WHVYNEKFRH AQNGKISIAL QADWIEPACP FSQKDKEVAE
751 RVLEFDIGWL AEPIFGSGDY PWVMRDWLNQ RNNFLLPYFT EDEKKLIQGT
801 FDFLALSHYT TILVDSEKED PIKYNDYLEV QEMTDITWLN SPSQVAVVPW
851 GLRKVLNWLK FKYGDLPMYI ISNGIDDGLH AEDDQLRVYY MQNYINEALK
901 AHILDGINLC GYFAYSFNDR TAPRFGLYRY AADQFEPKAS MKHYRKIIDS
951 NGFPGPETLE RFCPEEFTVC TECSFFHTRK SLGSGGGGSG GGGSGGGGSL
1001 KYPNASPLLG SSWGGLIHLY TATARNSYHL QIHKNGHVDG APHQTIYSAL
1051 MIRSEDAGFV VITGVMSRRY LCMDFRGNIF GSHYFDPENC RFQHQTLENG
1101 YDVYHSPQYH FLVSLGRAKR AFLPGMNPPP YSQFLSRRNE IPLIHFNTPI
1151 PRRHTQSAED DSERDPLNVL KPRARMTPAP ASCSQELPSA EDNSPMASDP
1201 LGVVRGGRVN THAGGTGPEG CRPFAKFIGG GGSKTHTCPP CPAPEAAGGP
1251 SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK
1301 TKPREEQYNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK
1351 AKGQPREPQV YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE
1401 NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ
101
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
1451 KSLSLSPGK*
sKlotho-FGF23-FcLALA v2 (SEQ ID NO: 48)
1 ATGCCCGCCA GCGCCCCGCC GCGCCGCCCG CGGCCGCCGC CGCCGTCGCT
GTCGCTGCTG
61 CTGGTGCTGC TGGGCCTGGG CGGCCGCCGC CTGCGTGCGG AGCCGGGCGA
CGGCGCGCAG
121 ACCTGGGCCC GTTTCTCGCG GCCTCCTGCC CCCGAGGCCG CGGGCCTCTT
CCAGGGCACC
181 TTCCCCGACG GCTTCCTCTG GGCCGTGGGC AGCGCCGCCT ACCAGACCGA
GGGCGGCTGG
241 CAGCAGCACG GCAAGGGTGC GTCCATCTGG GATACGTTCA CCCACCACCC
CCTGGCACCC
301 CCGGGAGACT CCCGGAACGC CAGTCTGCCG TTGGGCGCCC CGTCGCCGCT
GCAGCCCGCC
361 ACCGGGGACG TAGCCAGCGA CAGCTACAAC AACGTCTTCC GCGACACGGA
GGCGCTGCGC
421 GAGCTCGGGG TCACTCACTA CCGCTTCTCC ATCTCGTGGG CGCGAGTGCT
CCCCAATGGC
481 AGCGCGGGCG TCCCCAACCG CGAGGGGCTG CGCTACTACC GGCGCCTGCT
GGAGCGGCTG
541 CGGGAGCTGG GCGTGCAGCC CGTGGTCACC CTGTACCACT GGGACCTGCC
CCAGCGCCTG
601 CAGGACGCCT ACGGCGGCTG GGCCAACCGC GCCCTGGCCG ACCACTTCAG
GGATTACGCG
661 GAGCTCTGCT TCCGCCACTT CGGCGGTCAG GTCAAGTACT GGATCACCAT
CGACAACCCC
721 TACGTGGTGG CCTGGCACGG CTACGCCACC GGGCGCCTGG CCCCCGGCAT
CCGGGGCAGC
781 CCGCGGCTCG GGTACCTGGT GGCGCACAAC CTCCTCCTGG CTCATGCCAA
AGTCTGGCAT
841 CTCTACAATA CTTCTTTCCG TCCCACTCAG GGAGGTCAGG TGTCCATTGC
CCTAAGCTCT
901 CACTGGATCA ATCCTCGAAG AATGACCGAC CACAGCATCA AAGAATGTCA
AAAATCTCTG
961 GACTTTGTAC TAGGTTGGTT TGCCAAACCC GTATTTATTG ATGGTGACTA
TCCCGAGAGC
1021 ATGAAGAATA ACCTTTCATC TATTCTGCCT GATTTTACTG AATCTGAGAA
AAAGTTCATC
1081 AAAGGAACTG CTGACTTTTT TGCTCTTTGC TTTGGACCCA CCTTGAGTTT
TCAACTTTTG
1141 GACCCTCACA TGAAGTTCCG CCAATTGGAA TCTCCCAACC TGAGGCAACT
GCTTTCCTGG
1201 ATTGACCTTG AATTTAACCA TCCTCAAATA TTTATTGTGG AAAATGGCTG
GTTTGTCTCA
1261 GGGACCACCA AGAGAGATGA TGCCAAATAT ATGTATTACC TCAAAAAGTT
CATCATGGAA
1321 ACCTTAAAAG CCATCAAGCT GGATGGGGTG GATGTCATCG GGTATACCGC
ATGGTCCCTC
1381 ATGGATGGTT TCGAGTGGCA CAGAGGTTAC AGCATCAGGC GTGGACTCTT
CTATGTTGAC
1441 TTTCTAAGCC AGGACAAGAT GTTGTTGCCA AAGTCTTCAG CCTTGTTCTA
CCAAAAGCTG
1501 ATAAAGAAAA ATGGCTTCCC TCCTTTACCT GAAAATCAGC CCCTAGAAGG
GACATTTCCC
1561 TGTGACTTTG CTTGGGGAGT TGTTGACAAC TACATTCAAG TAGATACCAC
TCTGTCTCAG
1621 TTTACCGACC TGAATGTTTA CCTGTGGGAT GTCCACCACA GTAAAAGGCT
TATTAAAGTG
102
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
1681 GATGGGGTTG TGACCAAGAA GAGGAAATCC TACTGTGTTG ACTTTGCTGC
CATCCAGCCC
1741 CAGATCGCTT TACTCCAGGA AATGCACGTT ACACATTTTC GCTTCTCCCT
GGACTGGGCC
1801 CTGATTCTCC CTCTGGGTAA CCAGTCCCAG GTGAACCACA CCATCCTGCA
GTACTATCGC
1861 TGCATGGCCA GCGAGCTTGT CCGTGTCAAC ATCACCCCAG TGGTGGCCCT
GTGGCAGCCT
1921 ATGGCCCCGA ACCAAGGACT GCCGCGCCTC CTGGCCAGGC AGGGCGCCTG
GGAGAACCCC
1981 TACACTGCCC TGGCCTTTGC AGAGTATGCC CGACTGTGCT TTCAAGAGCT
CGGCCATCAC
2041 GTCAAGCTTT GGATAACGAT GAATGAGCCG TATACAAGGA ATATGACATA
CAGTGCTGGC
2101 CACAACCTTC TGAAGGCCCA TGCCCTGGCT TGGCATGTGT ACAATGAAAA
GTTTAGGCAT
2161 GCTCAGAATG GGAAAATATC CATAGCCTTG CAGGCTGATT GGATAGAACC
TGCCTGCCCT
2221 TTCTCCCAAA AGGACAAAGA GGTGGCCGAG AGAGTTTTGG AATTTGACAT
TGGCTGGCTG
2281 GCTGAGCCCA TTTTCGGCTC TGGAGATTAT CCATGGGTGA TGAGGGACTG
GCTGAACCAA
2341 AGAAACAATT TTCTTCTTCC TTATTTCACT GAAGATGAAA AAAAGCTAAT
CCAGGGTACC
2401 TTTGACTTTT TGGCTTTAAG CCATTATACC ACCATCCTTG TAGACTCAGA
AAAAGAAGAT
2461 CCAATAAAAT ACAATGATTA CCTAGAAGTG CAAGAAATGA CCGACATCAC
GTGGCTCAAC
2521 TCCCCCAGTC AGGTGGCGGT AGTGCCCTGG GGGTTGCGCA AAGTGCTGAA
CTGGCTGAAG
2581 TTCAAGTACG GAGACCTCCC CATGTACATA ATATCCAACG GAATCGATGA
CGGGCTGCAT
2641 GCTGAGGACG ACCAGCTGAG GGTGTATTAT ATGCAGAATT ACATAAACGA
AGCTCTCAAA
2701 GCCCACATAC TGGATGGTAT CAATCTTTGC GGATACTTTG CTTATTCGTT
TAACGACCGC
2761 ACAGCTCCGA GGTTTGGCCT CTATCGTTAT GCTGCAGATC AGTTTGAGCC
CAAGGCATCC
2821 ATGAAACATT ACAGGAAAAT TATTGACAGC AATGGTTTCC CGGGCCCAGA
AACTCTGGAA
2881 AGATTTTGTC CAGAAGAATT CACCGTGTGT ACTGAGTGCA GTTTTTTTCA
CACCCGAAAG
2941 TCTTTAGGAT CCGGAGGTGG AGGTTCAGGA GGTGGAGGTT CAGGAGGTGG
AGGTTCACTT
3001 AAGTATCCCA ATGCCTCCCC ACTGCTCGGC TCCAGCTGGG GTGGCCTGAT
CCACCTGTAC
3061 ACAGCCACAG CCAGGAACAG CTACCACCTG CAGATCCACA AGAATGGCCA
TGTGGATGGC
3121 GCACCCCATC AGACCATCTA CAGTGCCCTG ATGATCAGAT CAGAGGATGC
TGGCTTTGTG
3181 GTGATTACAG GTGTGATGAG CAGAAGATAC CTCTGCATGG ATTTCAGAGG
CAACATTTTT
3241 GGATCACACT ATTTCGACCC GGAGAACTGC AGGTTCCAAC ACCAGACGCT
GGAAAACGGG
3301 TACGACGTCT ACCACTCTCC TCAGTATCAC TTCCTGGTCA GTCTGGGCCG
GGCGAAGAGA
3361 GCCTTCCTGC CAGGCATGAA CCCACCCCCG TACTCCCAGT TCCTGTCCCG
GAGGAACGAG
3421 ATCCCCCTAA TTCACTTCAA CACCCCCATA CCACGGCGGC ACACCCAGAG
CGCCGAGGAC
3481 GACTCGGAGC GGGACCCCCT GAACGTGCTG AAGCCCCGGG CCCGGATGAC
CCCGGCCCCG
103
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
3541 GCCTCCTGTT CACAGGAGCT CCCGAGCGCC GAGGACAACA GCCCGATGGC
CAGTGACCCA
3601 TTAGGGGTGG TCAGGGGCGG TCGAGTGAAC ACGCACGCTG GGGGAACGGG
CCCGGAAGGC
3661 TGCCGCCCCT TCGCCAAGTT CATCGGAGGT GGAGGTTCAG CCCCAGAAGC
AGCAGGTGGT
3721 CCATCAGTTT TTCTTTTCCC TCCCAAACCC AAGGATACGC TGATGATCTC
TCGCACGCCT
3781 GAGGTGACAT GCGTCGTAGT AGACGTGAGC CACGAAGATC CCGAGGTGAA
GTTCAATTGG
3841 TATGTGGACG GAGTAGAAGT GCATAACGCG AAAACTAAGC CGCGCGAGGA
ACAATATAAC
3901 AGTACTTACA GGGTGGTATC CGTGCTCACA GTCCTGCACC AGGACTGGCT
GAACGGTAAG
3961 GAATACAAGT GCAAAGTAAG CAACAAGGCA CTTCCCGCGC CTATTGAGAA
AACAATCTCC
4021 AAGGCGAAGG GACAACCAAG AGAACCTCAG GTTTACACTC TCCCGCCTTC
CAGGGAAGAG
4081 ATGACCAAAA ATCAAGTTTC CCTGACTTGC CTCGTCAAAG GATTCTACCC
TTCCGACATT
4141 GCTGTTGAAT GGGAAAGCAA TGGACAACCA GAGAACAACT ACAAGACAAC
ACCCCCGGTG
4201 CTGGATAGTG ACGGATCTTT CTTTCTCTAC TCAAAGCTGA CCGTGGATAA
GTCCAGGTGG
4261 CAGCAGGGAA ACGTGTTTTC CTGCTCTGTC ATGCATGAAG CGCTGCATAA
TCACTATACC
4321 CAGAAGTCTC TGAGCTTGAG CCCAGGCAAG TAA
sKlotho-FGF23-FcLALA v2 (SEQ ID NO: 49)
1 MPASAPPRRP RPPPPSLSLL LVLLGLGGRR LRAEPGDGAQ TWARFSRPPA
51 PEAAGLFQGT FPDGFLWAVG SAAYQTEGGW QQHGKGASIW DTFTHHPLAP
101 PGDSRNASLP LGAPSPLQPA TGDVASDSYN NVFRDTEALR ELGVTHYRFS
151 ISWARVLPNG SAGVPNREGL RYYRRLLERL RELGVQPVVT LYHWDLPQRL
201 QDAYGGWANR ALADHFRDYA ELCFRHFGGQ VKYWITIDNP YVVAWHGYAT
251 GRLAPGIRGS PRLGYLVAHN LLLAHAKVWH LYNTSFRPTQ GGQVSIALSS
301 HWINPRRMTD HSIKECQKSL DFVLGWFAKP VFIDGDYPES MKNNLSSILP
351 DFTESEKKFI KGTADFFALC FGPTLSFQLL DPHMKFRQLE SPNLRQLLSW
401 IDLEFNHPQI FIVENGWFVS GTTKRDDAKY MYYLKKFIME TLKAIKLDGV
451 DVIGYTAWSL MDGFEWHRGY SIRRGLFYVD FLSQDKMLLP KSSALFYQKL
501 IEKNGFPPLP ENQPLEGTFP CDFAWGVVDN YIQVDTTLSQ FTDLNVYLWD
551 VHHSKRLIKV DGVVTKKRKS YCVDFAAIQP QIALLQEMHV THFRFSLDWA
601 LILPLGNQSQ VNHTILQYYR CMASELVRVN ITPVVALWQP MAPNQGLPRL
651 LARQGAWENP YTALAFAEYA RLCFQELGHH VKLWITMNEP YTRNMTYSAG
701 HNLLKAHALA WHVYNEKFRH AQNGKISIAL QADWIEPACP FSQKDKEVAE
751 RVLEFDIGWL AEPIFGSGDY PWVMRDWLNQ RNNFLLPYFT EDEKKLIQGT
801 FDFLALSHYT TILVDSEKED PIKYNDYLEV QEMTDITWLN SPSQVAVVPW
851 GLRKVLNWLK FKYGDLPMYI ISNGIDDGLH AEDDQLRVYY MQNYINEALK
901 AHILDGINLC GYFAYSFNDR TAPRFGLYRY AADQFEPKAS MKHYRKIIDS
951 NGFPGPETLE RFCPEEFTVC TECSFFHTRK SLGSGGGGSG GGGSGGGGSL
1001 KYPNASPLLG SSWGGLIHLY TATARNSYHL QIHKNGHVDG APHQTIYSAL
1051 MIRSEDAGFV VITGVMSRRY LCMDFRGNIF GSHYFDPENC RFQHQTLENG
1101 YDVYHSPQYH FLVSLGRAKR AFLPGMNPPP YSQFLSRRNE IPLIHFNTPI
1151 PRRHTQSAED DSERDPLNVL KPRARMTPAP ASCSQELPSA EDNSPMASDP
1201 LGVVRGGRVN THAGGTGPEG CRPFAKFIGG GGSAPEAAGG PSVFLFPPKP
1251 KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
1301 STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ
1351 VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV
1401 LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
1451
104
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
FGF23-FcLALA vl (SEQ ID NO: 50)
1 ATGTTGGGGG CCCGCCTCAG GCTCTGGGTC TGTGCCTTGT GCAGCGTCTG
CAGCATGAGC
61 GTCCTCAGAG CCTATCCCAA TGCCTCCCCA CTGCTCGGCT CCAGCTGGGG
TGGCCTGATC
121 CACCTGTACA CAGCCACAGC CAGGAACAGC TACCACCTGC AGATCCACAA
GAATGGCCAT
181 GTGGATGGCG CACCCCATCA GACCATCTAC AGTGCCCTGA TGATCAGATC
AGAGGATGCT
241 GGCTTTGTGG TGATTACAGG TGTGATGAGC AGAAGATACC TCTGCATGGA
TTTCAGAGGC
301 AACATTTTTG GATCACACTA TTTCGACCCG GAGAACTGCA GGTTCCAACA
CCAGACGCTG
361 GAAAACGGGT ACGACGTCTA CCACTCTCCT CAGTATCACT TCCTGGTCAG
TCTGGGCCGG
421 GCGAAGAGAG CCTTCCTGCC AGGCATGAAC CCACCCCCGT ACTCCCAGTT
CCTGTCCCGG
481 AGGAACGAGA TCCCCCTAAT TCACTTCAAC ACCCCCATAC CACGGCGGCA
CACCCAGAGC
541 GCCGAGGACG ACTCGGAGCG GGACCCCCTG AACGTGCTGA AGCCCCGGGC
CCGGATGACC
601 CCGGCCCCGG CCTCCTGTTC ACAGGAGCTC CCGAGCGCCG AGGACAACAG
CCCGATGGCC
661 AGTGACCCAT TAGGGGTGGT CAGGGGCGGT CGAGTGAACA CGCACGCTGG
GGGAACGGGC
721 CCGGAAGGCT GCCGCCCCTT CGCCAAGTTC ATCGGAGGTG GAGGTTCAAA
AACCCACACG
781 TGTCCTCCTT GTCCTGCCCC AGAAGCAGCA GGTGGTCCAT CAGTTTTTCT
TTTCCCTCCC
841 AAACCAAACG ATACGCTGAT GATCTCTCGC ACGCCTGAGG TGACATGCGT
CGTAGTAGAC
901 GTGAGCCACG AAGATCCCGA GGTGAAGTTC AATTGGTATG TGGACGGAGT
AGAAGTGCAT
961 AACGCGAAAA CTAAGCCGCG CGAGGAACAA TATAACAGTA CTTACAGGGT
GGTATCCGTG
1021 CTCACAGTCC TGCACCAGGA CTGGCTGAAC GGTAAGGAAT ACAAGTGCAA
AGTAAGCAAC
1081 AAGGCACTTC CCGCGCCTAT TGAGAAAACA ATCTCCAAGG CGAAGGGACA
ACCAAGAGAA
1141 CCTCAGGTTT ACACTCTCCC GCCTTCCAGG GAAGAGATGA CCAAAAATCA
AGTTTCCCTG
1201 ACTTGCCTCG TCAAAGGATT CTACCCTTCC GACATTGCTG TTGAATGGGA
AAGCAATGGA
1261 CAACCAGAGA ACAACTACAA GACAACACCC CCGGTGCTGG ATAGTGACGG
ATCTTTCTTT
1321 CTCTACTCAA AGCTGACCGT GGATAAGTCC AGGTGGCAGC AGGGAAACGT
GTTTTCCTGC
1381 TCTGTCATGC ATGAAGCGCT GCATAATCAC TATACCCAGA AGTCTCTGAG
CTTGAGCCCA
1441 GGCAAGTAA
FGF23(R179Q)-FcLALAvl (SEQ ID NO: 51)
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS
51 YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG
101 NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN
105
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
151 PPPYSQFLSR RNEIPLIHFN TPIPRRHTQS AEDDSERDPL NVLKPRARMT
201 PAPASCSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGCRPFAKF
251 IGGGGSKTHT CPPCPAPEAA GGPSVFLFPP KPKDTLMISR TPEVTCVVVD
301 VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN
351 GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR EEMTKNQVSL
401 TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS
451 RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK*
FGF23-FcLALA v2 (SEQ ID NO: 52)
1 ATGTTGGGGG CCCGCCTCAG GCTCTGGGTC TGTGCCTTGT GCAGCGTCTG
CAGCATGAGC
61 GTCCTCAGAG CCTATCCCAA TGCCTCCCCA CTGCTCGGCT CCAGCTGGGG
TGGCCTGATC
121 CACCTGTACA CAGCCACAGC CAGGAACAGC TACCACCTGC AGATCCACAA
GAATGGCCAT
181 GTGGATGGCG CACCCCATCA GACCATCTAC AGTGCCCTGA TGATCAGATC
AGAGGATGCT
241 GGCTTTGTGG TGATTACAGG TGTGATGAGC AGAAGATACC TCTGCATGGA
TTTCAGAGGC
301 AACATTTTTG GATCACACTA TTTCGACCCG GAGAACTGCA GGTTCCAACA
CCAGACGCTG
361 GAAAACGGGT ACGACGTCTA CCACTCTCCT CAGTATCACT TCCTGGTCAG
TCTGGGCCGG
421 GCGAAGAGAG CCTTCCTGCC AGGCATGAAC CCACCCCCGT ACTCCCAGTT
CCTGTCCCGG
481 AGGAACGAGA TCCCCCTAAT TCACTTCAAC ACCCCCATAC CACGGCGGCA
CACCCAGAGC
541 GCCGAGGACG ACTCGGAGCG GGACCCCCTG AACGTGCTGA AGCCCCGGGC
CCGGATGACC
601 CCGGCCCCGG CCTCCTGTTC ACAGGAGCTC CCGAGCGCCG AGGACAACAG
CCCGATGGCC
661 AGTGACCCAT TAGGGGTGGT CAGGGGCGGT CGAGTGAACA CGCACGCTGG
GGGAACGGGC
721 CCGGAAGGCT GCCGCCCCTT CGCCAAGTTC ATCGGAGGTG GAGGTTCAGC
CCCAGAAGCA
781 GCAGGTGGTC CATCAGTTTT TCTTTTCCCT CCCAAACCCA AGGATACGCT
GATGATCTCT
841 CGCACGCCTG AGGTGACATG CGTCGTAGTA GACGTGAGCC ACGAAGATCC
CGAGGTGAAG
901 TTCAATTGGT ATGTGGACGG AGTAGAAGTG CATAACGCGA AAACTAAGCC
GCGCGAGGAA
961 CAATATAACA GTACTTACAG GGTGGTATCC GTGCTCACAG TCCTGCACCA
GGACTGGCTG
1021 AACGGTAAGG AATACAAGTG CAAAGTAAGC AACAAGGCAC TTCCCGCGCC
TATTGAGAAA
1081 ACAATCTCCA AGGCGAAGGG ACAACCAAGA GAACCTCAGG TTTACACTCT
CCCGCCTTCC
1141 AGGGAAGAGA TGACCAAAAA TCAAGTTTCC CTGACTTGCC TCGTCAAAGG
ATTCTACCCT
1201 TCCGACATTG CTGTTGAATG GGAAAGCAAT GGACAACCAG AGAACAACTA
CAAGACAACA
1261 CCCCCGGTGC TGGATAGTGA CGGATCTTTC TTTCTCTACT CAAAGCTGAC
CGTGGATAAG
1321 TCCAGGTGGC AGCAGGGAAA CGTGTTTTCC TGCTCTGTCA TGCATGAAGC
GCTGCATAAT
1381 CACTATACCC AGAAGTCTCT GAGCTTGAGC CCAGGCAAGT AA
FGF23(R179Q)-FcLALAv2 (SEQ ID NO: 53)
106
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS
51 YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG
101 NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN
151 PPPYSQFLSR RNEIPLIHFN TPIPRRHTQS AEDDSERDPL NVLKPRARMT
201 PAPASCSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGCRPFAKF
251 IGGGGSAPEA AGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK
301 FNWYVDGVEV HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS
351 NKALPAPIEK TISKAKGQPR EPQVYTLPPS REEMTKNQVS LTCLVKGFYP
401 SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS
451 CSVMHEALHN HYTQKSLSLS PGK*
107
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
54067A
Amino acid sequence of sKlotho-FGF23 (R1156Q, C1183S) (SEQ ID NO: 54)
sKlotho: as [amino acid] 1-982; Linkerl: as 983-1001; FGF23: as 1002-1228
1 MPASAPPRRP RPPPPSLSLL LVLLGLGGRR LRAEPGDGAQ TWARFSRPPA
51 PEAAGLFQGT FPDGFLWAVG SAAYQTEGGW QQHGKGASIW DTFTHHPLAP
101 PGDSRNASLP LGAPSPLQPA TGDVASDSYN NVFRDTEALR ELGVTHYRFS
151 ISWARVLPNG SAGVPNREGL RYYRRLLERL RELGVQPVVT LYHWDLPQRL
201 QDAYGGWANR ALADHFRDYA ELCFRHFGGQ VKYWITIDNP YVVAWHGYAT
251 GRLAPGIRGS PRLGYLVAHN LLLAHAKVWH LYNTSFRPTQ GGQVSIALSS
301 HWINPRRMTD HSIKECQKSL DFVLGWFAKP VFIDGDYPES MKNNLSSILP
351 DFTESEKKFI KGTADFFALC FGPTLSFQLL DPHMKFRQLE SPNLRQLLSW
401 IDLEFNHPQI FIVENGWFVS GTTKRDDAKY MYYLKKFIME TLKAIKLDGV
451 DVIGYTAWSL MDGFEWHRGY SIRRGLFYVD FLSQDKMLLP KSSALFYQKL
501 IEKNGFPPLP ENQPLEGTFP CDFAWGVVDN YIQVDTTLSQ FTDLNVYLWD
551 VHHSKRLIKV DGVVTKKRKS YCVDFAAIQP QIALLQEMHV THFRFSLDWA
601 LILPLGNQSQ VNHTILQYYR CMASELVRVN ITPVVALWQP MAPNQGLPRL
651 LARQGAWENP YTALAFAEYA RLCFQELGHH VKLWITMNEP YTRNMTYSAG
701 HNLLKAHALA WHVYNEKFRH AQNGKISIAL QADWIEPACP FSQKDKEVAE
751 RVLEFDIGWL AEPIFGSGDY PWVMRDWLNQ RNNFLLPYFT EDEKKLIQGT
801 FDFLALSHYT TILVDSEKED PIKYNDYLEV QEMTDITWLN SPSQVAVVPW
851 GLRKVLNWLK FKYGDLPMYI ISNGIDDGLH AEDDQLRVYY MQNYINEALK
901 AHILDGINLC GYFAYSFNDR TAPRFGLYRY AADQFEPKAS MKHYRKIIDS
951 NGFPGPETLE RFCPEEFTVC TECSFFHTRK SLGSGGGGSG GGGSGGGGSL
1001 KYPNASPLLG SSWGGLIHLY TATARNSYHL QIHKNGHVDG APHQTIYSAL
1051 MIRSEDAGFV VITGVMSRRY LCMDFRGNIF GSHYFDPENC RFQHQTLENG
1101 YDVYHSPQYH FLVSLGRAKR AFLPGMNPPP YSQFLSRRNE IPLIHFNTPI
1151 PRRHTQSAED DSERDPLNVL KPRARMTPAP ASSSQELPSA EDNSPMASDP
1201 LGVVRGGRVN THAGGTGPEG CRPFAKFI*
Amino acid sequence of sKlotho-FGF23 (R1156Q, C1221S) (SEQ ID NO: 55)
sKlotho: 1-982; Linkerl: 983-1001; FGF23: 1002-1228;
1 MPASAPPRRP RPPPPSLSLL LVLLGLGGRR LRAEPGDGAQ TWARFSRPPA
51 PEAAGLFQGT FPDGFLWAVG SAAYQTEGGW QQHGKGASIW DTFTHHPLAP
101 PGDSRNASLP LGAPSPLQPA TGDVASDSYN NVFRDTEALR ELGVTHYRFS
151 ISWARVLPNG SAGVPNREGL RYYRRLLERL RELGVQPVVT LYHWDLPQRL
201 QDAYGGWANR ALADHFRDYA ELCFRHFGGQ VKYWITIDNP YVVAWHGYAT
251 GRLAPGIRGS PRLGYLVAHN LLLAHAKVWH LYNTSFRPTQ GGQVSIALSS
301 HWINPRRMTD HSIKECQKSL DFVLGWFAKP VFIDGDYPES MKNNLSSILP
351 DFTESEKKFI KGTADFFALC FGPTLSFQLL DPHMKFRQLE SPNLRQLLSW
401 IDLEFNHPQI FIVENGWFVS GTTKRDDAKY MYYLKKFIME TLKAIKLDGV
451 DVIGYTAWSL MDGFEWHRGY SIRRGLFYVD FLSQDKMLLP KSSALFYQKL
501 IEKNGFPPLP ENQPLEGTFP CDFAWGVVDN YIQVDTTLSQ FTDLNVYLWD
551 VHHSKRLIKV DGVVTKKRKS YCVDFAAIQP QIALLQEMHV THFRFSLDWA
601 LILPLGNQSQ VNHTILQYYR CMASELVRVN ITPVVALWQP MAPNQGLPRL
651 LARQGAWENP YTALAFAEYA RLCFQELGHH VKLWITMNEP YTRNMTYSAG
701 HNLLKAHALA WHVYNEKFRH AQNGKISIAL QADWIEPACP FSQKDKEVAE
751 RVLEFDIGWL AEPIFGSGDY PWVMRDWLNQ RNNFLLPYFT EDEKKLIQGT
801 FDFLALSHYT TILVDSEKED PIKYNDYLEV QEMTDITWLN SPSQVAVVPW
851 GLRKVLNWLK FKYGDLPMYI ISNGIDDGLH AEDDQLRVYY MQNYINEALK
901 AHILDGINLC GYFAYSFNDR TAPRFGLYRY AADQFEPKAS MKHYRKIIDS
951 NGFPGPETLE RFCPEEFTVC TECSFFHTRK SLGSGGGGSG GGGSGGGGSL
1001 KYPNASPLLG SSWGGLIHLY TATARNSYHL QIHKNGHVDG APHQTIYSAL
1051 MIRSEDAGFV VITGVMSRRY LCMDFRGNIF GSHYFDPENC RFQHQTLENG
108
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
54067A
1101 YDVYHSPQYH FLVSLGRAKR AFLPGMNPPP YSQFLSRRNE IPLIHFNTPI
1151 PRRHTQSAED DSERDPLNVL KPRARMTPAP ASCSQELPSA EDNSPMASDP
1201 LGVVRGGRVN THAGGTGPEG SRPFAKFI*
Amino acid sequence of sKlotho-FGF23 (R1156Q, Q1133A) (SEQ ID NO: 56)
sKlotho: 1-982; Linkerl: 983-1001; FGF23: 1002-1228
1 MPASAPPRRP RPPPPSLSLL LVLLGLGGRR LRAEPGDGAQ TWARFSRPPA
51 PEAAGLFQGT FPDGFLWAVG SAAYQTEGGW QQHGKGASIW DTFTHHPLAP
101 PGDSRNASLP LGAPSPLQPA TGDVASDSYN NVFRDTEALR ELGVTHYRFS
151 ISWARVLPNG SAGVPNREGL RYYRRLLERL RELGVQPVVT LYHWDLPQRL
201 QDAYGGWANR ALADHFRDYA ELCFRHFGGQ VKYWITIDNP YVVAWHGYAT
251 GRLAPGIRGS PRLGYLVAHN LLLAHAKVWH LYNTSFRPTQ GGQVSIALSS
301 HWINPRRMTD HSIKECQKSL DFVLGWFAKP VFIDGDYPES MKNNLSSILP
351 DFTESEKKFI KGTADFFALC FGPTLSFQLL DPHMKFRQLE SPNLRQLLSW
401 IDLEFNHPQI FIVENGWFVS GTTKRDDAKY MYYLKKFIME TLKAIKLDGV
451 DVIGYTAWSL MDGFEWHRGY SIRRGLFYVD FLSQDKMLLP KSSALFYQKL
501 IEKNGFPPLP ENQPLEGTFP CDFAWGVVDN YIQVDTTLSQ FTDLNVYLWD
551 VHHSKRLIKV DGVVTKKRKS YCVDFAAIQP QIALLQEMHV THFRFSLDWA
601 LILPLGNQSQ VNHTILQYYR CMASELVRVN ITPVVALWQP MAPNQGLPRL
651 LARQGAWENP YTALAFAEYA RLCFQELGHH VKLWITMNEP YTRNMTYSAG
701 HNLLKAHALA WHVYNEKFRH AQNGKISIAL QADWIEPACP FSQKDKEVAE
751 RVLEFDIGWL AEPIFGSGDY PWVMRDWLNQ RNNFLLPYFT EDEKKLIQGT
801 FDFLALSHYT TILVDSEKED PIKYNDYLEV QEMTDITWLN SPSQVAVVPW
851 GLRKVLNWLK FKYGDLPMYI ISNGIDDGLH AEDDQLRVYY MQNYINEALK
901 AHILDGINLC GYFAYSFNDR TAPRFGLYRY AADQFEPKAS MKHYRKIIDS
951 NGFPGPETLE RFCPEEFTVC TECSFFHTRK SLGSGGGGSG GGGSGGGGSL
1001 KYPNASPLLG SSWGGLIHLY TATARNSYHL QIHKNGHVDG APHQTIYSAL
1051 MIRSEDAGFV VITGVMSRRY LCMDFRGNIF GSHYFDPENC RFQHQTLENG
1101 YDVYHSPQYH FLVSLGRAKR AFLPGMNPPP YSAFLSRRNE IPLIHFNTPI
1151 PRRHTQSAED DSERDPLNVL KPRARMTPAP ASCSQELPSA EDNSPMASDP
1201 LGVVRGGRVN THAGGTGPEG CRPFAKFI*
Amino acid sequence of sKlotho-FGF23 (R1156Q, C1183S, C1221S) (SEQ ID NO: 57)
sKlotho: 1-982; Linkerl: 983-1001; FGF23: 1002-1228
1 MPASAPPRRP RPPPPSLSLL LVLLGLGGRR LRAEPGDGAQ TWARFSRPPA
51 PEAAGLFQGT FPDGFLWAVG SAAYQTEGGW QQHGKGASIW DTFTHHPLAP
101 PGDSRNASLP LGAPSPLQPA TGDVASDSYN NVFRDTEALR ELGVTHYRFS
151 ISWARVLPNG SAGVPNREGL RYYRRLLERL RELGVQPVVT LYHWDLPQRL
201 QDAYGGWANR ALADHFRDYA ELCFRHFGGQ VKYWITIDNP YVVAWHGYAT
251 GRLAPGIRGS PRLGYLVAHN LLLAHAKVWH LYNTSFRPTQ GGQVSIALSS
301 HWINPRRMTD HSIKECQKSL DFVLGWFAKP VFIDGDYPES MKNNLSSILP
351 DFTESEKKFI KGTADFFALC FGPTLSFQLL DPHMKFRQLE SPNLRQLLSW
401 IDLEFNHPQI FIVENGWFVS GTTKRDDAKY MYYLKKFIME TLKAIKLDGV
451 DVIGYTAWSL MDGFEWHRGY SIRRGLFYVD FLSQDKMLLP KSSALFYQKL
501 IEKNGFPPLP ENQPLEGTFP CDFAWGVVDN YIQVDTTLSQ FTDLNVYLWD
551 VHHSKRLIKV DGVVTKKRKS YCVDFAAIQP QIALLQEMHV THFRFSLDWA
601 LILPLGNQSQ VNHTILQYYR CMASELVRVN ITPVVALWQP MAPNQGLPRL
651 LARQGAWENP YTALAFAEYA RLCFQELGHH VKLWITMNEP YTRNMTYSAG
701 HNLLKAHALA WHVYNEKFRH AQNGKISIAL QADWIEPACP FSQKDKEVAE
751 RVLEFDIGWL AEPIFGSGDY PWVMRDWLNQ RNNFLLPYFT EDEKKLIQGT
801 FDFLALSHYT TILVDSEKED PIKYNDYLEV QEMTDITWLN SPSQVAVVPW
851 GLRKVLNWLK FKYGDLPMYI ISNGIDDGLH AEDDQLRVYY MQNYINEALK
901 AHILDGINLC GYFAYSFNDR TAPRFGLYRY AADQFEPKAS MKHYRKIIDS
951 NGFPGPETLE RFCPEEFTVC TECSFFHTRK SLGSGGGGSG GGGSGGGGSL
109
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
54067A
1001 KYPNASPLLG SSWGGLIHLY TATARNSYHL QIHKNGHVDG APHQTIYSAL
1051 MIRSEDAGFV VITGVMSRRY LCMDFRGNIF GSHYFDPENC RFQHQTLENG
1101 YDVYHSPQYH FLVSLGRAKR AFLPGMNPPP YSQFLSRRNE IPLIHFNTPI
1151 PRRHTQSAED DSERDPLNVL KPRARMTPAP ASSSQELPSA EDNSPMASDP
1201 LGWRGGRVN THAGGTGPEG SRPFAKFI*
Amino acid sequence of sKlotho-FGF23 (R1156Q, C1183S, C1221S, Q1133A) (SEQ ID
NO: 58)
sKlotho: 1-982; Linkerl: 983-1001; FGF23: 1002-1228
1 MPASAPPRRP RPPPPSLSLL LVLLGLGGRR LRAEPGDGAQ TWARFSRPPA
51 PEAAGLFQGT FPDGFLWAVG SAAYQTEGGW QQHGKGASIW DTFTHHPLAP
101 PGDSRNASLP LGAPSPLQPA TGDVASDSYN NVFRDTEALR ELGVTHYRFS
151 ISWARVLPNG SAGVPNREGL RYYRRLLERL RELGVQPVVT LYHWDLPQRL
201 QDAYGGWANR ALADHFRDYA ELCFRHFGGQ VKYWITIDNP YVVAWHGYAT
251 GRLAPGIRGS PRLGYLVAHN LLLAHAKVWH LYNTSFRPTQ GGQVSIALSS
301 HWINPRRMTD HSIKECQKSL DFVLGWFAKP VFIDGDYPES MKNNLSSILP
351 DFTESEKKFI KGTADFFALC FGPTLSFQLL DPHMKFRQLE SPNLRQLLSW
401 IDLEFNHPQI FIVENGWFVS GTTKRDDAKY MYYLKKFIME TLKAIKLDGV
451 DVIGYTAWSL MDGFEWHRGY SIRRGLFYVD FLSQDKMLLP KSSALFYQKL
501 IEKNGFPPLP ENQPLEGTFP CDFAWGVVDN YIQVDTTLSQ FTDLNVYLWD
551 VHHSKRLIKV DGVVTKKRKS YCVDFAAIQP QIALLQEMHV THFRFSLDWA
601 LILPLGNQSQ VNHTILQYYR CMASELVRVN ITPVVALWQP MAPNQGLPRL
651 LARQGAWENP YTALAFAEYA RLCFQELGHH VKLWITMNEP YTRNMTYSAG
701 HNLLKAHALA WHVYNEKFRH AQNGKISIAL QADWIEPACP FSQKDKEVAE
751 RVLEFDIGWL AEPIFGSGDY PWVMRDWLNQ RNNFLLPYFT EDEKKLIQGT
801 FDFLALSHYT TILVDSEKED PIKYNDYLEV QEMTDITWLN SPSQVAVVPW
851 GLRKVLNWLK FKYGDLPMYI ISNGIDDGLH AEDDQLRVYY MQNYINEALK
901 AHILDGINLC GYFAYSFNDR TAPRFGLYRY AADQFEPKAS MKHYRKIIDS
951 NGFPGPETLE RFCPEEFTVC TECSFFHTRK SLGSGGGGSG GGGSGGGGSL
1001 KYPNASPLLG SSWGGLIHLY TATARNSYHL QIHKNGHVDG APHQTIYSAL
1051 MIRSEDAGFV VITGVMSRRY LCMDFRGNIF GSHYFDPENC RFQHQTLENG
1101 YDVYHSPQYH FLVSLGRAKR AFLPGMNPPP YSAFLSRRNE IPLIHFNTPI
1151 PRRHTQSAED DSERDPLNVL KPRARMTPAP ASSSQELPSA EDNSPMASDP
1201 LGVVRGGRVN THAGGTGPEG SRPFAKFI*
Amino acid sequence of FGF23(R179Q; C206S)-FcLALAv1 (SEQ ID NO: 59)
FGF23: 1-251; Linker: 252-256; FcLALA: 257-482
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS
51 YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG
101 NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN
151 PPPYSQFLSR RNEIPLIHFN TPIPRRHTQS AEDDSERDPL NVLKPRARMT
201 PAPASSSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGCRPFAKF
251 IGGGGSKTHT CPPCPAPEAA GGPSVFLFPP KPKDTLMISR TPEVTCVVVD
301 VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN
351 GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR EEMTKNQVSL
401 TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS
451 RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK*
110
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
54067A
Amino acid sequence of FGF23(R179Q, C244S)-FcLALAv1 (SEQ ID NO: 60)
FGF23: 1-251; Linker: 252-256; FcLALA: 257-482
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS
51 YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG
101 NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN
151 PPPYSQFLSR RNEIPLIHFN TPIPRRHTQS AEDDSERDPL NVLKPRARMT
201 PAPASCSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGSRPFAKF
251 IGGGGSKTHT CPPCPAPEAA GGPSVFLFPP KPKDTLMISR TPEVTCVVVD
301 VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN
351 GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR EEMTKNQVSL
401 TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS
451 RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK*
Amino acid sequence of FGF23(R179Q, Q156A)-FcLALAv1 (SEQ ID NO: 61)
FGF23: 1-251; Linker: 252-256; FcLALA: 257-482
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS
51 YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG
101 NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN
151 PPPYSAFLSR RNEIPLIHFN TPIPRRHTQS AEDDSERDPL NVLKPRARMT
201 PAPASCSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGSRPFAKF
251 IGGGGSKTHT CPPCPAPEAA GGPSVFLFPP KPKDTLMISR TPEVTCVVVD
301 VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN
351 GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR EEMTKNQVSL
401 TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS
451 RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK*
Amino acid sequence of FGF23(R179Q, C206S, C244S)-FcLALAv1 (SEQ ID NO: 62)
FGF23: 1-251; Linker: 252-256; FcLALA: 257-482
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS
51 YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG
101 NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN
151 PPPYSQFLSR RNEIPLIHFN TPIPRRHTQS AEDDSERDPL NVLKPRARMT
201 PAPASSSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGSRPFAKF
251 IGGGGSKTHT CPPCPAPEAA GGPSVFLFPP KPKDTLMISR TPEVTCVVVD
301 VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN
351 GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR EEMTKNQVSL
401 TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS
451 RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK*
111
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
54067A
Amino acid sequence of FGF23(R179Q, C206S, C244S, Q156A)-FcLALAv1 (SEQ ID
NO: 63)
FGF23: 1-251; Linker: 252-256; FcLALA: 257-482
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS
51 YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG
101 NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN
151 PPPYSAFLSR RNEIPLIHFN TPIPRRHTQS AEDDSERDPL NVLKPRARMT
201 PAPASSSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGSRPFAKF
251 IGGGGSKTHT CPPCPAPEAA GGPSVFLFPP KPKDTLMISR TPEVTCVVVD
301 VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN
351 GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR EEMTKNQVSL
401 TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS
451 RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK*
Amino acid sequence of FGF23(R179Q, C206S)-FcLALAv2 (SEQ ID NO: 64)
FGF23: 1-251; Linker: 252-256; FcLALA: 257-473
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS
51 YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG
101 NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN
151 PPPYSQFLSR RNEIPLIHFN TPIPRRHTQS AEDDSERDPL NVLKPRARMT
201 PAPASSSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGCRPFAKF
251 IGGGGSAPEA AGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK
301 FNWYVDGVEV HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS
351 NKALPAPIEK TISKAKGQPR EPQVYTLPPS REEMTKNQVS LTCLVKGFYP
401 SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS
451 CSVMHEALHN HYTQKSLSLS PGK*
Amino acid sequence of FGF23(R179Q,C244S)-FcLALAv2 (SEQ ID NO: 65)
FGF23: 1-251; Linker: 252-256; FcLALA: 257-473
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS
51 YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG
101 NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN
151 PPPYSQFLSR RNEIPLIHFN TPIPRRHTQS AEDDSERDPL NVLKPRARMT
201 PAPASCSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGSRPFAKF
251 IGGGGSAPEA AGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK
301 FNWYVDGVEV HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS
351 NKALPAPIEK TISKAKGQPR EPQVYTLPPS REEMTKNQVS LTCLVKGFYP
401 SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS
112
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
54067A
451 CSVMHEALHN HYTQKSLSLS PGK*
Amino acid sequence of FGF23(R179Q,Q156A)-FcLALAv2 (SEQ ID NO: 66)
FGF23: 1-251; Linker: 252-256; FcLALA: 257-473
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS
51 YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG
101 NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN
151 PPPYSAFLSR RNEIPLIHFN TPIPRRHTQS AEDDSERDPL NVLKPRARMT
201 PAPASCSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGCRPFAKF
251 IGGGGSAPEA AGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK
301 FNWYVDGVEV HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS
351 NKALPAPIEK TISKAKGQPR EPQVYTLPPS REEMTKNQVS LTCLVKGFYP
401 SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS
451 CSVMHEALHN HYTQKSLSLS PGK*
Amino acid sequence of FGF23(R179Q, C206S, C244S)-FcLALAv2 (SEQ ID NO: 67)
FGF23: 1-251; Linker: 252-256; FcLALA: 257-473
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS
51 YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG
101 NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN
151 PPPYSQFLSR RNEIPLIHFN TPIPRRHTQS AEDDSERDPL NVLKPRARMT
201 PAPASSSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGSRPFAKF
251 IGGGGSAPEA AGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK
301 FNWYVDGVEV HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS
351 NKALPAPIEK TISKAKGQPR EPQVYTLPPS REEMTKNQVS LTCLVKGFYP
401 SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS
451 CSVMHEALHN HYTQKSLSLS PGK*
Amino acid sequence of FGF23(R179Q, C206S, C244S, Q156A)-FcLALAv2 (SEQ ID
NO: 68)
FGF23: 1-251; Linker: 252-256; FcLALA: 257-473
1 MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS
51 YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG
101 NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN
151 PPPYSAFLSR RNEIPLIHFN TPIPRRHTQS AEDDSERDPL NVLKPRARMT
201 PAPASSSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGSRPFAKF
251 IGGGGSAPEA AGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK
301 FNWYVDGVEV HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS
351 NKALPAPIEK TISKAKGQPR EPQVYTLPPS REEMTKNQVS LTCLVKGFYP
401 SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS
113
CA 02787285 2012-07-17
WO 2011/092234 PCT/EP2011/051112
54067A
451 CSVMHEALHN HYTQKSLSLS PGK*
114
